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ABSTRACT
Gene expression of human immunodeficiency virus type-1 (HIV-1), which
causes Acquired Immunodeficiency Syndrome (AIDS), is regulated at the
transcriptional level where negative factors can block elongation that is
overcome by HIV Tat protein and P-TEFb. P-TEFb, a positive elongation
transcription factor with two subunits , CDK9 and Cyclin T1 (CycT1), catalyzes
Tat-dependent phosphorylation of Ser-5 in the Pol II C-terminal domain (CTD),
allowing production of longer mRNAs. Ser-5 phosphorylation enables the CTD to
recruit mammalian mRNA capping enzyme (Mce1) and stimulate its
guanylyltransferase activity. This dissertation demonstrates that stable binding of
Mce1 and cap methyltransferase to template-engaged Pol II depends on CTD
phosphorylation , but not on nascent RNA. Capping and methylation doesn
occur until nascent pre-mRNA become 19-22 nucleotides long. A second and
novel pathway for recruiting and activating Mce1 involved direct physical
interaction between the CTD, Tat and Mce1. Tat stimulated the
guanylyltransferase and triphosphatase activities of Mce1 , thereby enhancing the
otherwise low efficiency of cotranscriptional capping of HIV mRNA. These
findings imply that multiple mechanisms exist for coupling transcription
elongation and mRNA processing at a checkpoint critical to HIV gene expression.
To elucidate P-TEFb' s function in human (HeLa) cells , RNA interference
(RNAi) was used to degrade mRNA for hCycT1 or CDK9. Down-regulation of P-
TEFb expression by RNAi can be achieved without causing major toxic or lethal
effects and can control Tat transactivation and HIV replication in host cells. High-
density oligonucleotide arrays were used to determine the effect of P-TEFb
knockdown on global gene expression. Of 44 928 human genes analyzed , 25
were down-regulated and known or likely to be involved in cell proliferation and
differentiation. These results provide new insight into P-TEFb function , its potent
role in early embryonic development and strong evidence that P- TEFb is a new
target for developing AIDS and cancer therapies.
To fulfill the promise of RNAi for treating infectious and human genetic
diseases , structural and functional mechanisms underlying RNAi in human cells
were studied. The status of the 5' hydroxyl terminus of the antisense strand of
short interfering RNA (siRNA) duplexes determined RNAi activity, while a 3'
terminus block was tolerated in vivo. A perfect A-form helix in siRNA was not
required for RNAi , but was required for antisense-target RNA duplexes.
Strikingly, crosslinking siRNA duplexes with psoralen did not completely block
RNAi , indicating that complete unwinding of the siRNA helix is not necessary for
RNAi in vivo. These results suggest that RNA amplification by RNA-dependent
RNA polymerase is not essential for RNAi in human cells.
V11
TABLE OF CONTENTS
Page No.
Title page............................................................................................................ . . . i
Approval page......................................... ....... n........""""'''''''''''''''''''''''''''''''''''''' .
Dedication... ... ... ... ... ... 
... ... ... ... ... ... ... ... ... ... ... ... ... ." .. . ... . .. ... ... ... . .. 
. .. ... .., .. iij
Acknowledgement...........
;. .  . . .... . . ..... . .... ....... .. .. .. , . . . 
........... iv
Contributions........................................................................................... ...."....... . 
Abstract.................................................................................... .. 
... . .. . . 
. . .... .. .. .. . . vi
Tab I e of co nte nts. . 
.. .. . .. .. .. .  .  .  . ..  .  .  .   .   .   . .. . .   .  . .  .  .  .   .  . . . . . .. . . . . . . . . . . . . . . . . . . . . . . . . . .. 
. vii i
List of figures........................................................ .............................................. ix
List of abbreviations. ...... .................... .... 
 
........................................................ xii
Chapter I: I ntrod uction.................... ........... .. 
.   . .  ..   . . ........ . . . .
Chapter II: HIV-1 Tat protein interacts with mammalian capping enzyme
and stimulates capping of TAR RNA........................................ ...
Chapter III: Tat stimulates cotranscriptional capping of HIV mRNA.............. ..
Chapter IV: Human transcription elongation factor (CDK9/CyclinT1):
A new therapeutic target for AIDS and cancer?......................... 122
Chapter V: RNA interference in human cells: Basic structural and
functional features of small interfering RNA.................. ......... . 170
Reference............................................ ............... ............................................219
Appendix........................................................ .................... 
. . . .
244
Curriculum vitae..................................................... .......................................... .265
V11
LIST OF FIGURES
Page No.
Chapter I: Introduction
Figure 1 Functional domains of HIV- 1 Tat protein and secondary
structure of wild-type TAR RNA......................... ..........................
Figure 2 Acquisition of the 5 terminal m7GpppN cap through a
series of three enzymatic reactions........... ... ............. ................ .
Chapter II: HIV- 1 Tat protein interacts with mammalian capping enzyme
and stimulates capping of TAR RNA
Figure 1 Tat interacts directly with Mce1 in vitro.......... 
...... "'''''''''''''''''' ....
Figure 2 The C-terminal segment of Tat containing the RNA binding
domain is sufficientfor interaction with Mce1............................
Figure 3 Tat enhances guanylylation of Mce1.......................................... .
Figure 4 Tat enhances the RNA triphosphatase activity of full-length
Mce1 but not the isolated triphosphatase domain......... ........... ..
Figure 5 The RNA triphosphatase domain of mammalian capping
enzyme can bind to TaL......... ...... 
""'''''''''''''''''''''''''''''''' ' ....
Figure 6 Tat enhances RNA cap formation............. """""""
""'"'' ''  .
Figure 7 Tat enhances capping of TAR RNA.......................................... 72
Figure 8 Emerging connections between CTD phosphorylation
capping, and transcription elongation.......... 
" "  "" " 
... ..... 74
Chapter II: Tat stimulates cotranscriptional capping of HIV mRNA
Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Mammalian capping enzyme is not a component of PICs but
can associate with TECs on the H IV-1 transcription unit.......... 1 08
HIV-1 mRNA capping during transcription elongation............. .. 11 0
Mce1 binding to Pol" transcription complexes requires
CTD phosphorylation but does not require nascent RNA...... .. .. 112
Dissociation of Mce1 from the transcription complex during
elongation is stimulated by a factor in nuclear extract.. ... 
...... .. .
114
Hcm1 associates with transcription elongation complexes
and methylates the 5' Cap of nascent RNAs............................ 116
Figure 6 Tat stimulates cotranscriptional capping by Mce1..... 
....... ..
118
Figure 7 Interaction of Tat and Mce1 in vivo........................ 
.....  ..  .
120
Chapter IV: Human transcription elongation factor (CDK9/CyclinT1):
Figure 1
Figure 2
Figure 3
new therapeutic target for AIDS and cancer?
Specific down-regulation of P-TEFb expression by RNAi........... 156
Kinetics of hCycT1 and CDK9 knockdown by siRNA... ....... .... . 159
TEFb down-regulation can be achieved without causing
major toxic and lethal effect in HeLa cells................ ............. .. 161
Figure 4 hCycT1 and CDK9 duplex siRNAs inhibit HIV-1 Tat
transactivation in Magi cells...... ... ... ... ... 
.. . ... . .. . .. . .. .   .  ..  .   
163
Figure 5 Small interfering RNAs targeting Cyclin T1 or CDK9
Figure 6
modulate H IV-1 infectivity................................................... 166
Genomewide analysis of gene expression in P- TEFb
Chapter 
Figure 1
knockdown HeLa cells........... ...... 
.................."................... .
168
RNA interference in human cells: Basic structural and
functional features of small interfering RNA
Dual fluorescence reporter assay system for RNAi
analysis in HeLa cells...................................... 
.. .. ...  ..
200
Figure 2 Analysis of specific RNAi activities by western blotting............. 202
Figure 3 Expression of GFP in HeLa cells treated with antisense or
double-stranded siRNA targeting GFP...... ... ... 
.   .  ..  ..
204
Figure 4 Modification of GFP siRNA duplexes... ... ...... 
. ..  .. ,   .
206
Figure 5
Figure 6
Figure 7
Figure 8
Figure 9
Fluorescence images showing RNA interference effects in
living HeLa cells transfected with modified siRNA duplexes.... ...208
Quantitative analysis of RNAi effects in HeLa cells transfected
with modified siRNAs....... ... ... ... 
.. .. .. .  .  .  . .   .     .  .
21 0
Isolation of 5' end phosphorylated and 3' end biotinylated
siRNA from HeLa cells........... 
.... , "" """" "'"
212
RNA interference activities of covalently photocrosslinked
duplex RNA in HeLa cells........ ... 
. . . . .  
214
Isolation of psoralen-crosslinked siRNA from human cells........ .217
AIDS
gal
CDK7
CDK9
CTD
CTR
CycT1
ORB
DSIF
GFP
GTF
Hcm1
HIV-
HMT
LTR
Magi
Mce1
NELF
PAGE
LIST OF ABBREVIATIONS
Acquired Immunodeficiency Syndrome
antisense strand
galactosidase
cyclin dependent kinase 7
cyclin dependent kinase 9
carboxy-terminal domain
terminal repeat
Cyclin T1
5 , d ichloro- D-ribofuranosylbenzimidazole
double-stranded
DRB sensitivity- inducting factor
green fluorescent protein
general transcription factor
human mRNA cap methyltransferase
Human immunodeficiency virus type-
hydroxymethyl- , 5' , 8-trimethylpsoralen
Long terminal repeat
multinucleate activation of galactosidase indicator cells
mammalian capping enzyme 
mismatch
amino modification
negative elongation factor
nucleotide
polyacrylamide gel electrophoresis
Xll
PIC
Pmn
TEFb
PTGS
RDRP
RFP
RISC
RNAi
RNA Pol II
RNA PolliA
RNA PolliO
RT-PCR
SDS
siRNA
TAK
TAR
Tat
TEC
TFIIH
TRM
pre- initiation complex
Puromycin
positive transcriptional elongation factor b
post transcriptional gene silencing
RNA-dependent RNA polymerase
red fluorescent protein
RNA- induced silencing complex
RNA interference
RNA Polymerase II
unphosphorylated RNA Polymerase II
phosphorylated RNA Polymerase II
reverse transcriptase-polymerase chain reaction
sodium-dodecyl sulfate
small interfering RNA
sense strand
Tat-associated kinase
trans-activation responsive
trans-activator of transcription
transcription elongation complex
transcription factor II 
Tat-TAR RNA recognition motif
Xll
CHAPTER I
INTRODUCTION
Part I. Transcriptional Regulation of HIV-1 Gene Expression
1. Human immunodeficiency virus type-
Human immunodeficiency virus type- 1 (HIV-1), the etiological agent for
Acquired Immunodeficiency Syndrome (AIDS) (7 , 69 , 132), is a member of the
primate lineages of the lentivirus family of retroviruses. HIV- 1 contains two
identical copies of a linear single-stranded RNA genome of -9.2 kb (63 , 109).
The virion 
,RNA genome is converted into a linear double-strand (ds) DNA by
viral reverse transcriptase in infected cells and then integrated into the host
genome as proviral DNA. This ds DNA genome encodes nine open reading
frames (63 236). Three of them are polyproteins named gag, pol and env , which
are subsequently proteolyzed into individual proteins. Gag and env encode the
structural proteins that build up the core and the envelope of the virion. Gag
(group specific antigen) precursor protein is cleaved into MA (matrix), CA
(capsid), NC (nucleocapsid) and p6. Env (envelope) precursor protein is cleaved
into SU (surface or gp120) and TM (transmembrane or gp41). Pol (Polymerase)
comprises three proteins , PR (protease), RT (reverse transcriptase), and 
(integrase) and possesses essential enzymatic activities. Net, vpu, vif and vpr
genes encode accessory proteins that are dispensable for viral growth in tissue
culture cells but appear to help virus infectivity and replication in vivo (63). Tat
and rev are two regulatory genes that can act in trans to control HIV-1 gene
expression and up-regulate virus replication through transactivating proteins (43
, 114).
2. Tat (I.rans- ctivator of Iranscription) and TAR (Irans- cting
esponsive) RNA
Tat , the HIV- trans-activator of transcription , is a small nuclear protein
encoded by two separate exons. Tat is essential for virus replication and is
conserved in all primate lentiviruses (107). Naturally occurring HIV- 1 Tat
comprises 101 amino acids (107). However, an 86-amino acids version of Tat
which arose from the 01-amino acid form as a consequence of laboratory tissue
culture passage , is commonly used for research and completely reflects
biological functions for full- length Tat. (163). The extreme C-terminus of native
Tat is apparently not needed for ex vivo propagation of HIV- , although these
amino acids remain conserved by viruses that replicate in vivo (183).
Tat protein is composed of several functional regions (Figure 1A)(183).
The first 72 amino acids encoded by the first exon are both necessary and
sufficient for TAR RNA binding (see below) and transcriptional activation. The
acidic N-terminal region has a periodic arrangement of acidic, polar, and
hydrophobic residues consistent with an amphipathic a-helix. A cysteine rich
region (amino acids 22 to 37) contains seven cysteine residues. Individual
mutations in six of the seven cysteines abolish Tat function. The "core" sequence
of Tat (amino acids 37 to 48) contains hydrophobic amino acids and is essential
for trans-activation and specific high affinity binding of TAR RNA. The basic
RNA-binding region (amino acids 48 to 59), adjacent to the core domain
contains six arginines and two Iysines. This domain has TAR RNA-binding
properties and mediates nuclear localization of Tat protein. A glutamine-rich
region at the carboxyl-terminus of the first exon contains several regularly spaced
glutamines. The second exon encodes a 14-amino-acid C-terminal sequence
that is not required for trans-activation but does contain an RGD (arginine-
glycine-aspartate) motif (amino aicds 78-80), which is used as a cell adhesion
signal for binding to cellular integrins (18). Based on mutational analysis , Tat also
can be divided into two functional domains. The first domain is the activation
domain (amino acid 1 to 47) that mediates interaction with other cellular proteins
required for Tat transactivation (204). The second functional domain , containing
a basic region , is required for RNA binding as well as nuclear localization
activities of Tat (52).
As a potent activator of HIV-1 long terminal repeat (L TR) region-specific
transcription , Tat protein acts by binding to a nascent RNA element named TAR
(trans-acting responsive element) (14 , 203). TAR RNA is a 59-base stem-bulge-
loop structure located at the 5' ends of all nascent HIV- 1 transcripts (14). TAR
RNA was originally localized to nucleotide +1 to +80 within the viral L TR (193).
Subsequent deletion studies have established that the region from +19 to +42
incorporates the minimal domain that is both necessary and sufficient to support
Tat transactivation in vivo (72 , 106 , 183 , 203). The functional domain of TAR
HNA contains a six-nucleotide loop and a three-nucleotide pyrimidine bulge that
separate two helical stem regions (Figure 1 B). Key elements required for TAR
RNA recognition by Tat have been defined by various approaches , such as
mutagenesis , chemical probing, and peptide binding studies (183). It has been
demonstrated that Tat interacts with U23 in the trinucleotide bulge domain. C24
and U25 function as spacers because they can be substituted by other
nucleotides or linkers (33 , 222). In addition to the trinucleotide bulge region , two
base-pairs (bp) above and below the bulge also contribute significantly to Tat
binding (33 , 251). By using a site-specific photocrosslinking, Tat has been shown
to interact with U23 , U38 , and U40 in the major groove of TAR RNA (246 , 247).
The loop region of TAR RNA is necessary for efficient transactivation , but not
required for Tat binding. Recently, a cellular loop-binding protein has been
identified and is required for Tat transactivation (252).
3. RNA polymerase II transcription complex
Transcription, copying the sequence of DNA template into a
complementary RNA transcript by the enzyme RNA polymerase , is the first step
of the central dogma. RNA polymerase , the enzyme that catalyzes DNA
transcription , is a complex molecule containing many polypeptide chains. In
eukaryotic cells there are three distinct RNA polymerase enzymes , designated
RNA polymerases I , II and III , The three eukaryotic RNA polymerase were
initially distinguished by their chromatographic property differences during
purification and by their sensitivity to a-amanitin. Sensitivity of RNA polymerase
to a-amanitin indicates that each RNA polymerase is responsible for the
transcription of a subclass of nuclear genes. Among them , RNA polymerase II
(RNA Pol II) mediates the synthesis of the mature and functional messenger
RNA (mRNA) that serves as a message for translation into protein.
Synthesis of mRNA by eukaryotic RNA Pol II can be divided into at least
four major steps , i.e. preinitiation or the assembly of transcription complexes on a
promoter, initiation , elongation , and termination and dissociation of Pol II from the
DNA template (39 , 60). In addition to RNA Pol II , a universal set of proteins
called general transcription factors (GTFs), including, TFIIA , TFIIB , TFIID , TFIIE
TFIIF and TFIIH , assemble at the core promoter of a gene and form the pre-
initiation complex (PIC)(168). Following PIC formation , DNA melting, initiation
and promoter clearance take place rapidly in an energy-dependent manner
(192). TFIIH plays a major role and may be the source of ATP dependence to
facilitate these events. The helicase activity of TFIIH melts the ds DNA template
through hydrolysis of the 
'Y bond of ATP (or dATP) at about 10 bp region , just
upstream of the transcription start site , to form an activated PIC. The kinase
activity of TFIIH can phosphorylate the RNA polymerase II to facilitate promoter
clearance and leads transcription complex into the elongation stage (142 , 223).
RNA pol II and the GTFs are sufficient to mediate basal level transcription.
However , highly ordered , gene-specific transcription requires the cooperative
action of many cellular proteins and is tightly regulated by transcription regulators
at many levels (240).
4. CTD ( arboxY-Ierminal omain) of RNA polymerase II
RNA Pol II is a large multisubunit enzyme complex. The largest subunit of
RNA Pol II from eukaryoties contains a unique feature at its C-terminus , the so
called CTD (carboxy-terminal domain) (45). Neither eukaryotic RNA polymerase
, III nor prokaryotic RNA polymerase contains a region resembling the CTD. In
eukaryotic cells , the CTD of RNA Pol II is composed of tandem repeats (52 in
vertebrates and 26 in budding yeast) of a heptapeptide with the conserved
consensus motif Tyr-Ser-Pro-Thr-Ser-Pro-Ser (YSPTSPS)(45). Each cycle of
transcription involves the dynamic phosphorylation and dephosphorylation of the
CTD on the serine residues 2 and 5 (Ser-2 and Ser-5) of each repeated unit. A
large number of CTD kinases including TFIIH , cdc2 , CTK1 and CDK9 , have been
implicated in the phosphorylation of the CTD at multiple sites in vitro and cause a
characteristic mobility shift in SDS-polyacrylamide gel electrophoresis (PAGE)
(12). A phosphatase responsible for dephosphorylation of the CTD has been
discovered (12 , 23 , 24). RNA Pol II with an unphosphorylated CTD is designated
RNA PolliA and polymerase with a highly phosphorylated CTD is designated
RNA PolliO. RNA PolliA is efficiently recruited to promoters during assembly of
a preinitiation complex '(110 , 141) whereas RNA PolliO is associated with the
elongation complex (46). The CTD of RNA Pol II is required for transcriptional
activation or repression and for controlling mRNA synthesis and maturation
events , such as capping, splicing and cleavage/polyadenylation (53 , 92 , 93 , 152
153 , 270). The CTD functions as a platform for the recruitment and assembly of
factors involved in pre-mRNA processing (13 , 182).
5. Transcriptional elongation regulators
After successful initiation of RNA synthesis , the RNA pol II transcription
complex enters the elongation stage. Transcriptional elongation by RNA Pol II is
controlled by a number of trans-acting factors called transcription elongation
factors (39 , 40). During mRNA synthesis , RNA Pol II frequently encounters
blocks to elongation; a primary cause of pause or arrest is thought to be the
secondary structure formed by nascent transcripts. Transcription factors such as
TFIIF , elongatin , ELL and TFIIS interact with RNA Pol II and thereby prevent it
from pausing or reactivating from arrest (185 207).
Recently, proteins involved in regulation of transcriptional elongation were
discovered during studies aimed at understanding the mechanism of transcription
inhibition by a nucleoside analog, 5 dichloro- 1-p-D-ribofuranosylbenzimidazole
(DRB). DRB was originally discovered as an inhibitor of hnRNA and mRNA
synthesis in HeLa cells (103 , 202 , 231 232). Treatment of mammalian cells with
DRB is lethal , but its initial effect is a dramatic reduction of mRNA (202). DRB
treatment has caused the production of shortened transcripts from a variety of
genes , suggesting that RNA pol II elongation was affected (232). However, DRB
had no effect on promoter- independent RNA pol II transcription and 
transcription reconstituted by purified general transcription factors and RNA pol II
(32 , 119). These studies suggested that cellular proteins other than RNA Pol II
and general transcription factors confer ORB sensitivity on elongation. The recent
discovery of this class of transcription elongation factors , which include DRB-
sensitivity inducing factor (DSIF), negative elongation factor (NELF), and positive
transcription elongation factor (P-TEFb), has shed new light on the control of
RNA Pol II elongation (40 , 181 243 262).
1. P-TEFb (J;ositive-Iranscriptional Iongation factor 
P- TEFb , the first and only known component of positive transcription
factor, was originally identified and purified from Drosophila melanogaster Kc cell
nuclear extract (147). P-TEFb is a factor required for the production of long
transcripts by Pol II in vitro and is required for the bypass of an early block to
elongation (147). P-TEFb consists of two subunits: the catalytic subunit cyclic-
dependent kinase CDK9 (previously named PITALRE) (76) and the regulatory
subunit Cyclin T1 (76 , 175 , 176 , 252). CDK9 is a cdc2-related serine/threonine
kinase (48 , 73) and can form a complex with several cyclin partners in human
cells: CyclinT1 , Cyclin T2a , Cyclin T2b , and Cyclin K (66 , 176). In HeLa cells
roughly 80% of CDK9 binds with Cyclin T1 and 10% with Cyclin T2a and Cyclin
T2b (176). The assembly of P-TEFb involves the sequential interactions of
Hsp70 and Hsp90/Cdc37 with CDK9. These two chaperone complexes
CDK9/Hsp70 and CDK9/Hsp90/Cdc37 , are important and essential precursors
for the generation of the mature and active CDK9/CyclinT1 complex (167).
CDK9 and its Cyclin T partners are expressed in a wide variety of tissues
, 49). In situ immunohistology and immunofluorescence studies of mouse
embryos have indicated that murine CDK9/PITALRE protein appears to be
expressed predominantly in tissues that are terminally differentiated , such as
developing brain and dorsal root ganglia , areas of skeletal muscle, cardic
muscle , and the lining of the developing intestinal epithelium (6). Analysis of the
expression pattern of murine CDK9/PITALRE protein in adult mouse tissues by
immunoblottng indicates that murine CDK9/PITALRE expression is ubiquitous
although steady-state protein levels are markedly higher in the brain , liver , lung,
spleen and kidney. Kinase activity of CDK9/PITALRE kinase has also been
detected in the same adult tissues and was highest in mouse brain , liver, spleen
and lung. Only minimal kinase activity was found in the heart , muscle , and
kidney. The expression pattern of CycT1 in adult human tissues was investigated
by immunohistochemistry (49). Tissues of mesenchymal origin , such as
cardiovascular and connective tissues , skeletal muscle cells , myocardial cells
adipocytes , chondrocytes and endothial cells , blood and lymphoid tissues
showed high immunoreactivity. Astrocytes , oligodendroglial and microglial cells
of brain tissue also showed high expression levels of Cyclin T1 , while endocrine
and reproductive systems showed low Cyclin T1 expression.
""'.._..
Although P-TEFb is not involved in the cell cycle , it has been suggested
that P-TEFb may serve as a multifunctional cyclin-dependent kinase , which
regulates various cellular events (216). It has also been proposed that the P-
TEFb complex is required for global gene expression during embryonic
development of Caenorhabditis elegans (208). Knockdown of CDK9 or CycT1
genes by siRNA in C. elegans embryos inhibits transcription of embryonic genes.
It has been demonstrated that P-TEFb is a Tat-associated-kinase-complex
(TAK) and that the effect of Tat on transcription elongation depends on P-TEFb
(265 , 277). Studies of the general transcription elongation inhibitor , DRB , have
shown that it inhibits P-TEFb protein kinase activity, thereby blocking a step in
transcription elongation where P-TEFb is required. Pol II CTD and the Spt5
subunit of the DSIF complex have been identified as substrates for P-TEFb
activity and will be discussed later. Depletion of P- TEFb from HeLa nuclear
extracts greatly reduces the ability of RNA pol II to produce full-length transcripts
and eliminates the ORB sensitivity of nuclear extracts (144 , 146 , 147 , 175 , 277).
Moreover, in addition to ORB , P-TEFb is strongly inhibited by flavopiridol (L86-
8275 , HMR1275), a cyclin-dependent kinase (CDK) inhibitor being tested in
clinical trials as a potential anti-cancer drug (117 , 205). However, flavopiridol's
target and the mechanism for its antiproliferative effects are unknown. Recent
evidence indicates that flavopiridol inactivates P-TEFb and inhibits HIV-
transcription (25 , 26).
2. DSIF ( RB ,!ensitivity-lnducing factor) and NELF (negative ongation
factor)
DSIF and NELF are two negative transcription elongation factors (N- TEF)
that can impede RNA Pol II elongation (242 , 261). DSIF was primarily identified
for its ability to repress transcription in the presence of ORB (242). DSIF is a
heterodimer comprising mammalian homologues of Saccharomyces cerevisiae
Spt5 and Spt4 transcription factors. Spt4 possesses a putative zinc finger domain
and most likely interacts with Spt5 through mainly hydrophobic interactions (261).
Spt5 has several distinct domains including four KOW repeats and two C-
terminal elements , CTR1 (
-1erminal Iepeat 1) and CTR2 (103 , 261). KOW
domains , which are also found in Escherichia coli RNA polymerase-binding
protein NusG , playa role in binding to RNA Pol II and affecting transcriptional
termination and anti-termination (134). The CTR domains possess multiple
amino acid repeats that are rich in serine and threonine residues , a similar
composition to the C-terminal domain of RNA Pol II , which may provide
phosphorylation sites for cellular kinases (103 , 218).
Immunodepletion of DSIF p160 (hSpt5) from HeLa cell nuclear extract
results in DRB- insensitive transcription and adding back DSIF restores DRB-
sensitivity (242). Recent studies have shown that Spt4 and Spt5 function during
early transcription elongation process , which is regulated by P-TEFb (242 , 243).
Immunodepletion of DSIF and P-TEFb restored transcription to normal levels
and addition of recombinant DSIF was able to repress transcription in a dose-
. . '
'r:
. .. .
dependent manner (243). These results indicated that DSIF plays a role as a
negative regulator in transcription in the absence of P-TEFb (243). However, In
yeast , Spt4 , Spt5 , and Spt6 appear to have a positive effect on transcription
elongation through the modulation of chromatin structure (80 , 224 , 225). Results
from studies of Drosophila polytene chromosomes have shown that Spt5 and
Spt6 co- localize with phdsphorylated RNA Pol II and Cyclin T1 at a large number
of transcriptionally active sites (3 , 112). These findings provide support for the
closely related role of Spt5 and Spt6 in active transcription elongation in vivo.
Purified NELF is composed of five polypeptides , A to E (66 , 61 , 59 , 58
and 46 kDa , respectively) (261). NELF- , the largest subunit of NELF , is
encoded by Wolf-Hirschhorn syndrome (WHSC) 2 gene. A sequence analysis
showed limit homology (27% identity) between the N-terminal half of NELF-
AIHSC2 and hepatitis delta antigen (HDAg), the only protein encoded by
hepatitis delta virus (HDV) (260). NELF-E is the smallest subunit containing
repeats of the dipeptide arg-asp (RD repeats), an RNA recognition motif (RRM),
and a leucine zipper at the C-terminal end. RD is a putative RNA-binding protein
with unknown function (261). NELF and DSIF function to cooperatively repress
transcriptional elongation by RNA Pol II (261).
Unlike P-TEFb , neither DSIF nor NELF has protein kinase activity,
suggesting that they are not direct targets of ORB. The connection between ORB
and these three elongation factors was revealed by the finding that only active P-
TEFb can counteract the negative effects of DSIF and NELF in a transcription
extract (278). Immunodepletion and in vitro transcription studies suggest that the
main mechanism for P- TEFb control of RNA pol II transcription elongation in vitro
is to alleviate the inhibition effect of DSIF and NELF by phosphorylating the CTD
of RNA Pol" (263) and also the Spt5 subunit of DSIF (178 , 243). Furthermore
recent studies have demonstrated a chromatin-specific elongation factor , FACT
which removes the negative regulation of transcription imposed by DSIF and
NELF in cooperation with P-TEFb (241).
6. Coupling of transcription elongation and mRNA capping
mRNA processing plays an important role in the expression of eukaryotic
genes and is specifically targeted to transcripts made by RNA Pol II. Placing a
mammalian Pol II transcription unit under the control of a Pol III promoter results
in a failure to cap, splice , or polyadenylate transcripts (211). How is pre-mRNA
identity" established? Accumulated evidence indicates that the unique Pol II
CTD appears to occupy a central position as a platform for interacting with
macromolecular assemblies that regulate mRNA synthesis and processing (53
, 93, 152, 153 , 270). However, the CTD is more than a passive scaffold;
indeed , binding to the CTD can regulate the activity of protein partners (13).
Acquisition of the 5' terminal m7GpppN cap is the first modification event
in mRNA biogenesis and capping facilitates downstream transactions such as
splicing, polyadenylation , transport and translation. RNA capping is essential for
cell growth i. e. mutations of the triphosphatase , guanylyltransferase , or
methyltransferase components of the capping apparatus that abrogate their
catalytic activity are lethal in vivo (65 , 94 , 145 , 161 200 , 201 , 214 , 245).
Capping entails a series of three enzymatic reactions: (i) RNA
triphosphatase (RTP) removes the phosphate from the 5 triphosphate end of the
nascent mRNA to form a diphosphate terminus; (ii) RNA guanylyltransferase
(RGT) transfers GMP from GTP to the diphosphate RNA terminus to form
GpppRNA; and (iii) RNA (guanine-7)-methyltransferase (MT) adds a methyl
group to the N7 position of the cap guanine (213). The yeast S. cerevisiae
encodes three proteins , each possessing one activity (213) while the mammalian
capping apparatus consists of two components: a bifunctional triphosphatase-
guanylyltransferase (mammalian capping enzyme , Mce1) and a separate cap
methyltransferase (Hcm1) (94 , 177 , 195 269).
Capping occurs shortly after transcription initiation when the 5' -end of the
nascent RNA chain is extruded from the RNA-binding pocket of the elongating
RNA polymerase (41 , 81 , 184). Capping of cellular RNAs in vivo is specific to
transcripts synthesized by RNA polymerase II (Pol II) (79 , 139). It has been
suggested that this specific targeting is achieved through direct physical
interaction of one or more components of the capping apparatus with the
phosphorylated CTD of the largest subunit of Pol II (30 , 31 , 93 , 94 , 152 , 177
269). In the budding yeast S. cerevisiae the guanylyltransferase (Ceg1) and
methyltransferase (Abd 1) bind directly to the phosphorylated CTD (31 , 152). The
mammalian capping enzyme, Mce1 binds to the phosphorylated CTD but not to
. .
'1.
':-
an unphosphorylated CTD (93 , 94 , 152 , 269). Binding to CTD phosphorylated at
Ser-5 of the YSPTSPS heptad stimulates the guanylyltransferase activity of
Mce1 (93 , 253). Recruitment of the capping apparatus to the yeast Pol 
elongation complex in vivo requires the action of the TFIIH-associated CTD
kinase Kin28 (equivalent to CDK7 in mammals), which phosphorylates Ser-5 of
the CTD (128 191 199).
There is a fascinating link between capping and transcription elongation
which may serve as a checkpoint to ensure that Pol II commits to productive
elongation only after transcript has been capped. For example , it was reported
that hSpt5 , the human homolog of yeast elongation factor Spt5 , which also plays
a role in Tat transactivation of HIV-1 gene expression at the level of transcription
elongation (123 , 256) interacts directly with the mammalian capping enzyme and
stimulates its guanylyltransferase activity (253).
What happens after the cap has been added? In vivo crosslinking
experiments In budding yeast showed that the complex of RNA triphosphatase
and guanylyltransferase is released early, in a step coupled with removal of Ser-
5 phosphorylation by the CTD phosphatase Fcp1 (199) or another phosphatase
(29). Methyltransferase remains associated with Pol II even at the 3' end of the
gene , indicating that the methyltransferase may travel with Pol II for the whole
length of the gene or it could be bound and released in a dynamic equilibrium
throughout elongation of the RNA chain (199). At present, no evidences in
mammalian systems has shown whether cellular capping enzymes remain
associated with the elongation RNA polymerase after the cap structure has been
formed or whether they are jettisoned to make room for other processing
assemblies.
7. Regulation of HIV-1 gene expression
In theory, each of transcription steps , Le , preinitiation , initiation , elongation
and termination (39 , 60) can be regulated , resulting in either overall stimulation or
repression of transcription. While it is widely accepted that the preinitiation step
plays a criticial role in transcriptional regulation , over the past several years
increasing attention has focused on the role of the elongation step. A number of
genes including c-myc , c-fos, c-myb , hsp70 and HIV long terminal repeat (L TR)
region , are potentially regulated at the elongation stage of transcription (109
129 , 194 , 268). Among them , the mechanism of HIV-1 gene expression is one
elegant example of transcription elongation control.
As described above , RNA synthesis from HIV proviral DNA is mediated by
host RNA polymerase II (RNA Pol II). Shortly after the initation of transcription
RNA Pol II is subjected to both negative and positive control by the transcription
regulators listed above. In the absence of HIV-1 Tat, the initiated transcripts
prematurely terminate within 100 nucleotides (nt) of the start site. In the presence
of Tat, elongation is very effective , and hyperphosphorylation of the CTD of RNA
Pol II has been suggested as the molecular event underlying Tat transactivation
(108 , 113). In addition to the binding of Tat with TAR RNA , other cellular factors
are also involved in the stimulation of RNA pol II elongation processivity by Tat. A
gene located at human chromosome 12 encodes a species-specific cofactor for
Tat (1). A cellular protein kinase complex called TAK (Iat- ssociated ,!inase) was
identified that specifically binds to the activation domain of Tat and can
phosphorylate the CTD of RNA Pol II (90 , 91). The kinase component of TAK
was then shown to be identical to a previously identified cdc2-related kinase
named PITALRE. PITALRE has also been identified as the kinase component of
an essential multiprotein complex , P- TEFb , which is involved in transcription
elongation in Drosophila and mammals (175 , 277). Furthermore , PITALRE
kinase was identified during an in vitro screening of drug inhibitors of Tat activity
(144). Moreover, Cyclin T was independently cloned as a Tat-associated protein
(252) .
The detailed interactions of Tat , TAR , and P-TEFb have been studied very
well (181 , 183). Although CDK9 can form a complex with various cyclin partners
it is clear that CDK9/Cyclin T1 is the only target of Tat. Human Cyclin T2a , Cyclin
T2b as well as Cyclin K do not support Tat transactivation (255). Rodent cells
can be made permissive for Tat transactivation by making them express human
Cyclin T1 or by making a single amino acid (A261 C) change in mouse Cyclin T1.
The cysteine residue at position 261 of Cyclin T1 is required for a zinc-dependent
interaction between Cyclin T1 and Tat (16 255).
Tat appears to contact residues in the carboxy-terminal boundary of
human Cyclin T1 ' s (hCycT1 's) cyclin domain that are not critical for binding of
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hCycT1 to CDK9 (16 104 255 276). The hCycT1 sequence containing
amino acids 1-272 is sufficient to form complexes with Tat-TAR , CDK9 , and to
activate transcription by Tat (16 , 68, 71 , 104 , 255 , 276). The sequence and
structural determinants for high affinity hCycT1-Tat-TAR RNA ternary complex
formation have been identified (188). Human Cyclin T1 residues 250-262
represent the Tat-TAR RNA recognition motif (TRM)(71) and have been shown
to interact with one side of the TAR RNA loop and enhance interaction of Tat
residue K50 with the other side of the loop (189). The binding of Cyclin T1 with
Tat increases the binding affinity of Tat for TAR (71 , 252 , 273). hCycT1 and Tat
binding to TAR RNA is highly cooperative , with a capacity of 85% , Hill coefficient
of 2. 7 and a dissociation constant (Ko) of 2.45 nM (188). All these results indicate
that TAR RNA provides a scaffold for two protein partners to bind and assemble
a regulatory switch in HIV replication.
Besides P-TEFb-Tat-TAR complex , Pol II CTD , Spt5 , and Tat are also
intimately connected to regulation of HIV gene expression (reviewed in 181).
Human Spt5 and its binding partner hSpt4 comprise the transcription elongation
regulatory factor DSIF (DRB sensitivity- inducing factor). DSIF binds to Pol II and
in concert with NELF (negative elongation factor), represses elongation at
promoter-proximal positions in the transcription unit. Escape from the repressive
effect of DSIF/NELF requires the action of P-TEFb , a DRB-sensitive protein
kinase that phosphorylates both the Pol II CTD and the Spt5 subunit of DSIF.
The interactions of these regulatory factors with Pol II at discrete functional
stages of transcription from the HIV-1 L TR promoter in vitro have been analyzed
(178 , 179). P-TEFb is a component of the Pol II preinitiation complex (PIC) and
travels with the transcription elongation complex (TEC) along the H 
transcription unit (179). In contrast , DSIF and NELF are not present in the PIC
but associate with the TEC at promoter proximal positions and then travel with
the TECs down the template (178). It has been demonstrated that the kinase
activity of P- TEFb is able to phosphorylate a number of cellular proteins
including the CTD of RNA Pol" and Spt5 in vitro (101 , 103 , 179 , 256 , 275 , 276).
Furthermore , P-TEFb functions to counteract negative elongation factors DSIF as
well as NELF (261). Although DSIF was discovered as a negative elongation
factor , Spt5 , the subunit of DSIF , was identified independently as a factor
involved in HIV- 1 Tat transactivation and functions as a positive elongation factor
(123 256). Taken together, the regulation of HIV-1 gene expression requires not
only Tat-TAR- TEFb interaction , but also the interactions between RNA Pol 
transcription complexes and the positive as well as negative transcriptional
elongation factors.
How does capping fit into the scheme of HIV transcription regulation? At
present , little is known about the dynamics of the interactions of mammalian
capping and methylating enzymes with mammalian Pol" during the transcription
cycle or about the efficiency and timing of the cap guanylylation and methylation
steps. It has been proposed that Tat expression would result in a marked
increase in the steady state level of the mRNA and stimulated the translation of
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mRNAs synthesized from the HIV transcription unit (44). Since Tat
transactivation and capping are both correlated with CTD phosphorylation at an
early stage of transcription elongation , it is conceivable that Tat may interact
physically or functionally with mammalian capping enzyme. Spt5- induced arrest
at promoter-proximal sites in the HIV transcription unit might ensure a temporal
window for recruitment of the capping enzymes and stimulate modification of the
S' end of the HIV pre-mRNA.
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Figure 1. (A) Functional domains of HIV-1 Tat protein. (B) Secondary
structure of wild-type TAR RNA. Wild-type TAR-RNA spans the minimal
sequences that are required for Tat trans-activation.
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Figure 2. Acquisition of the 5 terminal m7GpppN cap through a series 
three enzymatic reactions. Capping entails a series of three enzymatic
reactions: (i) RNA triphosphatase (RTP) removes the phosphate from the S'
triphosphate end of the nascent mRNAto form a diphosphate terminus; (ii) RNA
guanylyltransferase (RGT) transfers GMP from GTP to the diphosphate RNA
terminus to form GpppRNA; and (iii) RNA (guanine-7)-methyltransferase (MT)
adds a methyl group to the N7 position of the cap guanine.
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Part II. Structural and Functional Study of RNA Interference
1. RNA interference is broadly distributed in nature
RNAi interference (RNAi) is the process whereby ds RNA induces the
sequence-specific degradation of homologous mRNA. Fire and associates first
reported on RNA interference when they demonstrated potent and specific
genetic interference upon injecting dsRNA into C. elegans (62). However, the
underlying phenomenon, known as posttranscriptional gene silencing
phenomena (PTGS), had initially been described in transgenic plants (as PTGS
or cosuppression) and Neurospora crassa (as quelling) (reviewed in 84 , 206).
PTGS was observed when the introduction of all or a portion of a transgene
occasionally resulted in the loss of expression from the corresponding
endogenous gene with no disruption in gene transcription. It has become clear
that dsRNA- induced silencing phenomena are present in evolutionarily diverse
organisms , e. , nematodes , plants , fungi , and trypanosomes (8 , 37 , 84 , 122
150, 206, 215, 238, 248). Although PTGS and RNAi were identified
independently, genetic and biochemical analyses suggest a strong evolutionary
link between these multi-step pathways (8-10).
2. RNA interference pathway
The discovery of RNAi was followed by studies of its mechanism. Work in
C. elegans indicated that RNAi had at least two important steps , the first of which
probably involved the generation of a sequence-specific silencing agent (78). A
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strong candidate for this agent was a class of short RNAs originally reported by
Andrew Hamilton and David Baulcombe (82). They found that Arabidopsis plants
undergoing transgene- or virus- induced PTGS contained 21-25 nt RNAs that
were complementary to both strands of the silenced gene and that had been
processed from a long dsRNA precursor. An A TP-dependent, processive
cleavage of dsRNA into 21- to 23-nt short interfering RNAs (siRNAs) was
recapitulated in vitro using Drosophila embryo Iysates and S2 cell extracts (15
271). Accumulated evidence revealed that 21- to 23-nt RNAs were associated
with RNAi silencing in C. elegans and Drosophila (83, 171 264). Cloning and
sequencing of these native siRNA duplexes revealed a very specific structure:
21-to 23-nt dsRNAs with 2-nt 3' end overhangs (57). Cleavage of the dsRNA 
vitro and in cultured Drosophila cells requires the multidomain RNase III protein
Dicer, a member of the RNase III family of dsRNA-specific endonucleases (15).
Cleavage products containing 5' phosphate and 3' hydroxyl termini are then
incorporated into a protein complex called A-lnduced ilencing .Qomplex
(RISC) (83). ATP-dependent unwinding of the siRNA duplex generates an active
complex , RISC* (the asterisk indicates the active conformation of the complex)
(166). Guided by the antisense strand of siRNA, RISC* recognizes and cleaves
the corresponding mRNA (57 , 166).
Functional anatomy studies of synthetic siRNA in Drosophila cell Iysates
have demonstrated that each siRNA duplex cleaves its target RNA at a single
site (58). The 5' end of the guide siRNA sets the ruler for defining the position of
of'
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target RNA cleavage (58). 5' phosphorylation of the antisense strand is required
for effective RNA interference in vitro (166). Mutation studies have shown that a
single mutation within the center of a siRNA duplex discriminates between
mismatched targets (58). However , none of these phenomena have been
demonstrated in vivo especially in mammalian systems.
A particularly fascinating aspect of RNAi is its extraordinary efficiency.
Conversion of the long trigger dsRNA into many 21- to 23-nt siRNA fragments
would , itself, provide some degree of amplification. Another plausible explanation
for the potency of interference is that the RISC* is a multiple-turnover enzyme
(98), which can catalytically perform the targeting and cleavage activity.
3. Enzymes of RNA interference
Several groups are actively pursuing the identification and characterization
of enzymes in RNAi and cosuppression. In C. elegans initial mutant screens
have generated -80 candidates, of which five have been specifically identified:
RDE- , RDE- , RDE- , RDE-4 and Mut-7 (78 , 121 , 122 , 226). Selection of
mutations after cosuppression in Arabidopsis have identified homologs of the
genes coding for the enzymes in C. elegans (47 , 59 , 160).
DCR- (the gene coding for Dicer) comprises an ATP-dependent RNA
helicase domain , a Piwi/Argonaute/Zwille (PAZ) domain , a tandem RNase III
domain , and a dsRNA-binding-domain. Deletion of the Dcr- in worms abrogates
RNAi and leads to misregulation of developmental timing (77 , 120). Dicer is
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required for cleavage of the dsRNA in vitro and in cultured Drosophila cells to
produce siRNAs with characteristic structure of 5' phosphate and 3' OH termini
with 2-nt overhangs. The presence of two RNase III domains suggests that Dicer
might cleave dsRNA as a monomer. The dsRNA-binding domain could position
the enzyme on the substrate , and the two catalytic domains could hydrolyze
bonds in both strands of the dsRNAs.
The involvement of RNA-dependent RNA polymerase (RdRP) in the
amplification process has recently been postulated since genetic screening has
identified the gene for RdRP as a requirement for gene silencing in plants , fungi
and worms (36 , 47 , 160 , 215). A random degradative PCR model has been
suggested (136 , 164 , 215), in which siRNA serves as the primer for the RdRP
reaction. The siRNA-primed RdRP converts target mRNA into dsRNA , which can
serve as Dicer substrates , initiating the RdRP chain reaction. Certain structural
features of siRNA , including the 3' hydroxyl group and 5' phosphate group, are
critical for the RdRP reaction and RNA ligation (136 , 215). Although RdRP
activity has been reported in Drosophila embryo Iysates (136), a homolog of
RdRP has not been identified in available mammalian genomic sequences.
Rde- which is important for RNAi in C. elegans is a member of a large
Piwi/STlNG/Argonaute/Zwile/eIF2C family. There are 23 related genes in C.
elegans (226), four family members in Drosophila and several in humans.
Arabidopsis encodes eight genes related to rde- 1. Mutation in two of these
genes ago- and zll/pnh results in developmental defects. Recently, EIF2C has
been identified as the major component of RISC complex isolated from HeLa
cytolasma extract by biotinylated double stranded RNA pull down assay (148).
Rde- encodes a dsRNA binding protein required for RNAi (227). The
stable interaction between RDE-4 and dsRNA requires rde- (+) activity in vivo.
RDE-4 protein also interacts in vivo with DCR- 1 proteins and with a conserved
DexH- box helicase that is required for RNAi in C. elegans (227). RNA sequences
bound to RDE-4 were restricted to regions found within the trigger dsRNA
suggesting that RDE-4 functions during the initial steps of RNAi to recognize
foreign dsRNA and to present this dsRNA to DCR-1 for processing (227).
Mut- , the putative C. elegans exonuclease , acts downstream in the RNAi
pathway, as well as in repressing transposition of mobile genetic elements (59).
Its homolog in Neurospora QDE- , which belongs to the RecQ DNAIRNA
helicase family (38), is essential for the post transcriptional gene silencing
phenomenon , quelling. However, WRN , BLM and RecQ1 are not involoved in
dsRNA- induced sequence-specific mRNA degradation in mammals , suggesting
potential differences with the mammalian RNAi pathway (220).
4. dsRNA- induced gene silencing in somatic mammalian cells
Tuschl and colleagues (55) have demonstrated that RNAi can be induced
in numerous mammalian cell lines by introducing synthetic 21-nt siRNAs. By
virtue of their small size , these siRNAs avoid provoking an interferon response
that activates the protein kinase PKR (219). The principal method used to
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introduce the small siRNAs was by co-transfection (using lipofectamine) with
plasmids expressing marker genes or control sequences. The 21- to 23-nt
dsRNAs consisted of chemically synthesized and annealed single-stranded
sense and antisense RNAs with 2-nt 3' overhangs. Several somatic mammalian
cell lines were tested , including murine , non-human primate and human-derived
cells. All theses cell lines showed evidence for sequence-specific inhibition of the
target gene when the appropriate small dsRNA was transfected. Ability of dsRNA
to down-regulate the expression of an endogenously expressed protein has been
investigated as well. dsRNAs corresponding to the nuclear envelope protein
lamin AIC induced -90% reduction in protein levels 40-45 hous after initiation of
transfection (55). More and more researchers are seizing siRNA technology to
elucidate mammalian gene function , and the types of genes that are being
knocked down vary widely, from structural to catalytic proteins (155).
5. Delivery vectors for siRNA
Synthetic siRNAs can be delivered into cells by cationic liposome
(lipofectamine) transfection as described above. However , these exogenously
added siRNAs have only a short-term silencing effect (4-5 days) (55). Several
strategies using recombinant DNA constructs to express siRNA duplexes within
cells have been explored to see if they might allow long-term target gene
suppression. Mammalian Pol III promoter system (U6 small nuclear RNA
(snRNA) promoter) has been reported to be capable of expressing functional ds
siRNAs (131 , 157 , 172 , 221 , 267). Transcriptional termination by RNA Pol III
occurs at runs of four consecutive T residues in the DNA template , providing a
mechanism to end a siRNA transcript at a sepecific sequence. The siRNA
corresponds to the sequence of the target gene (21 mer), and 5' 3' and 3'
orientations can be expressed in the same or separate constructs. Hairpin
siRNAs , driven by U6 snRNA promoter and expressed in cultured cells , can
inhibit expression of their target genes (131 , 157 , 172 , 221 , 267). Constructs
containing siRNA sequences under the control of the T7 promoter can also be
made into functional siRNAs when cotransfected into cells with a vector
expressing T7 RNA polymerase (105). It has been shown that animal cells
express a range of -22-nt noncoding RNAs termed micro RNA (miRNAs), which
can regulate gene expression at posttranscriptional or translational levels during
embryonic development. One common feature of miRNAs is that they are all
excised from a -70-nt precursor RNA stem-loop, probably by Dicer. By
substituting the stem sequences of the miRNA precursor with a designed miRNA
sequence , a vector under control of the RNA Pol II promoter can be constructed
and can be used to produce siRNAs that initiate RNAi against specific mRNA
targets in mammalian cells (272). When expressed by DNA vectors containing
polymerase III promoters , micro-RNA designed hairpin are also active on
silencing gene expression (154). Viral-mediated delivery mechanism can result in
specific silencing of targeted genes through expression of siRNA. Recombinant
adenoviruses harboring siRNA under RNA Pol II promoter transcription control
have been generated. Infection of HeLa cells by these recombinant adenoviruses
diminishes endogenous target gene expression. This recombinant adenovirus
vector delivery strategy holds promise in therapeutic applications , since such
vectors reduce the expression of genes targeted by the siRNAs injected into
transgenic mice. (258).
6. RNAi in reverse genetics and its potential as a therapeutic approach
Reverse genetics is a genetic analysis that proceeds from genotype to
phenotype by gene-manipulation techniques. The ability of siRNA technology to
knock down the expression of any given gene promises to revolutionize reverse
genetic approaches. In C. elegans the direct injection of dsRNA has been used
to establish or confirm the function of numerous genes and to assign phenotypic
effects to many genes that had previously been identified only as computer-
predicted open reading frames (64 , 75). The direct injection of dsRNA into
Drosophila embryos has been used to study the function of several genes
expressed during development (198) Reports using small dsRNA-triggered RNAi
in human cells to determine gene function have recently been published (56
155).
PTGS has been suggested to protect plant tissues from viral infection
(249). Initial studies to test the potential application of synthetic siRNAs to inhibit
virus infection in vertebrates have been promising (155). Decreased mRNA
expression by the respiratory syncytial virus (RSV), a negative-strand virus and
the causative agent of a severe respiratory disease , has been successfully
demonstrated by using RNAi technology (17). siRNA-mediated silencing of HIV
has also been seen in cultured cell lines and in human primary T cells (22 , 35
, 105 , 131 , 165). These studies show that siRNAs can inhibit viral replication at
several stages of infection. Infection can also be blocked by targeting either viral
genes (tat, rev, net, vit, p24) or host genes encoding CD4 and CCR5 receptors
that are involved in the viral life cycle. siRNA can also confer resistance to
poliovirus (74).
Recent data indicate that the in vivo delivery of siRNAs in mice is possible.
RNase III prepared siRNA , delivered by electroporation into postimplantation
mouse embryos , efficiently silenced reporter gene expression in different regions
of the neural tube or other cavities of the mouse embryo (21). Rapid injection of a
siRNA-containing physiological solution into the tail vein of a postnatal mice
inhibited reporter transgene expression (133 , 151). This RNAi effect depended
on the siRNA dose and persisted for -4 days after siRNA delivery (133). The
therapeutic potential of this technique has been demonstrated by effective
targeting of a sequence from hepatitis C virus (151). siRNA expressed from viral
vectors in transgenic mice specifically reduce neuronal levels of polyglutamine
protein with a corresponding decrease in disease protein aggregation , which is
the cause of at least nine inherited neurodegenerative diseases , providing
therapy for dominantly human diseases (258).
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It is certain that the ability of siRNAs to silence specific genes , either when
transfected directly as siRNAs or generated from DNA vectors , will make RNAi
technology a powerful method in functional studies of human genes. However, to
fulfil the promise of using RNAi technology as a therapeutic approach to treating
infectious disease and human genetic diseases , structural and functional studies
are needed to elucidate the basic mechanism underlying RNA interference in
human cells.
CHAPTER II
HIV-1 TAT PROTEIN INTERACTS WITH MAMMALIAN CAPPING
ENZYME AND STIMULATES CAPPING OF TAR RNA
ABSTRACT
HIV gene expression is subject to a transcriptional checkpoint , whereby
negative transcription elongation factors induce an elongation block that is
overcome by HIV Tat protein in conjunction with P-TEFb. P-TEFb is a cyclin-
dependent kinase that catalyzes Tat-dependent phosphorylation of Ser-5 of the
Pol II C-terminal domain (CTD). Ser-5 phosphorylation confers on the CTD the
ability to recruit the mammalian mRNA capping enzyme (Mce1) and stimulate its
guanylyltransferase activity. Here we show that Tat spearheads a second and
novel pathway of capping enzyme recruitment and activation via a direct physical
interaction between the C-terminal domain of Tat and Mce1. Tat stimulates the
guanylyltransferase and triphosphatase activities of Mce1 and thereby enhances
the otherwise low efficiency of cap formation on a TAR stem- loop RNA. Our
findings suggest that multiple mechanisms exist for coupling transcription
elongation and mRNA processing.
INTRODUCTION
mRNA processing plays an important role in the expression of eukaryotic
genes , and the earliest modification event is the formation of the 5' terminal
m7GpppN cap. Capping entails a series of three enzymatic reactions: (i) RNA
triphosphatase removes the phosphate from the 5 triphosphate end of the
nascent mRNA to form a diphosphate terminus; (ii) RNA guanylyltransferase
transfers GMP from GTP to the diphosphate RNA terminus to form GpppRNA;
and (iii) RNA (guanine-7)-methyltransferase adds a methyl group to the N7
position of the cap guanine (213). RNA capping is essential for cell growth
mutations of the triphosphatase, guanylyltransferase, or methyltransferase
components of the capping apparatus that abrogate their catalytic activity are
lethal in vivo (65 , 94 , 145 , 201 , 214 , 245). The m7G cap facilitates translation
initiation (161). Failure to cap pre-mRNAs results in their accelerated decay
through the agency of a 5 exoribonuclease (200).
Capping occurs shortly after transcription initiation when the 5 -end of the
nascent RNA chain is extruded from the RNA-binding pocket of the elongating
RNA polymerase (41 , 184). Capping of cellular RNAs in vivo is specific to
transcripts synthesized by RNA polymerase II (Pol II) (79 , 139). It has been
suggested that this specific targeting is achieved through direct physical
interaction of one or more components of the capping apparatus with the
phosphorylated CTD of the largest subunit of Pol II (30 , 31 , 93 , 94 , 152 , 177
269).
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. r The CTD is unique to Pol II and consists of a tandemly repeated
heptapeptide motif with the consensus sequence YSPTSPS that is differentially
phosphorylated during the transcription cycle (46). Phosphorylation of the CTD
correlates with the release of preinitiation complexes from the promoter and
recruitment of the capping enzyme to the transcription elongation complex. In the
budding yeast Saccharomyces cere visiae , the guanylyltransferase (Ceg1) and
methyltransferase (Abd 1) bind directly to the phosphorylated CTD (31 , 152). The
mammalian capping enzyme , Mce1 , a bifunctional 597-amino acid polypeptide
with both RNA triphosphatase and guanylyltransferase activities , binds to the
phosphorylated CTD but not to an unphosphorylated CTD (93 , 94 , 152 , 269).
Binding to CTD phosphorylated at Ser-5 of the YSPTSPS heptad stimulates the
guanylyltransferase activity of Mce1 (93 , 253). Although interaction between Pol
II and capping enzymes offers an elegant explanation of the specific targeting of
capping enzyme to nascent pre-mRNAs , it is conceivable that other factors are
also involved in linking capping to transcription. For example , it was reported that
hSpt5 , the human homolog of yeast elongation factor Spt5 , interacts directly with
the mammalian capping enzyme and stimulates its guanylyltransferase activity
(253). hSpt5 also plays a role in Tat transactivation of HIV- 1 gene expression at
the level of transcription elongation (123 , 256).
HIV-1 Tat is a small RNA-binding protein required for efficient transcription
of HIV genes. Tat binds specifically to a structured RNA element, TAR, located at
the 5 -end of the nascent HIV transcript. Tat contains two important functional
.. .
domains: an arginine-rich region that mediates the binding of Tat to TAR RNA
and an activation domain that mediates interactions with cellular factors. Tat
functions through TAR to control an early step in transcription elongation that is
sensitive to protein kinase inhibitors and requires the Pol II CTD (108). Tat
increases the processivity of RNA polymerase complexes that would otherwise
prematurely terminate. This function of Tat is predicated on its ability to enhance
the activity of a positive transcription elongation factor, P-TEFb (181).
Components of the P-TEFb complex required for its activity include a
catalytic protein kinase subunit Cdk9 (previously known as PITALRE) (144 , 277)
and regulatory subunits cyclin T1 , cyclin T2a , or cyclin T2b , which associate with
Cdk9 and increase its kinase activity (176 , 252 , 277). Cyclin T1 interacts directly
with the activation domain of Tat. When the proteins are bound to TAR RNA, Tat
interacts with the bulge region , whereas cyclin T1 binds to the loop segment
(252). Phosphorylation of the Poll! CTD by P-TEFb kinase is stimulated by Tat
and leads to the formation of processive transcription elongation complexes.
Because Tat transactivation and capping are both correlated with CTD
phosphorylation at an early stage of transcription elongation , it is conceivable
that Tat may interact physically or functionally with mammalian capping enzyme.
Here , we show a direct association between Tat and Mce1 in vitro. We find that
Tat stimulates mRNA capping in vitro by enhancing the triphosphatase and
guanylyltransferase activities of Mce1. Moreover, Tat stimulates the capping of
TAR mRNA, which is not guanylylated efficiently by Mce1 , presumably because
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the 5' terminus is encompassed within a stable RNA hairpin. We suggest a
model whereby Tat stimulation of TAR mRNA capping contributes to the
activation of HIV gene expression.
MATERIALS AND METHODS
Expression and purification of recombinant wild-type and mutant
Tat. Recombinant wild-type HIV-1 Tat , hemagglutinin (HA)-tagged Tat, and Tat
deletion mutants were expressed in Escherichia coli as glutathione S-transferase
(GST) fusion proteins. These fusion proteins consisted of an N-terminal GST
moiety followed by a thrombin cleavage site and variable C-terminal polypeptides
segments comprising wild-type Tat-(1-86) with or without HA tag; Tat2/36 (a
deletion from amino acids 2-36 in the transactivation domain); Tat48 (a deletion
of amino acids 49-86 including the RNA binding domain). Recombinant fusion
proteins were purified to apparent homogeneity from bacterial Iysates by
glutathione-Sepharose affinity chromatography. Briefly, Iysates were mixed with
a 1 ml slurry of glutathione-Sepharose beads (Amersham Pharmacia Biotech) for
1 hat 4 oc. The beads were then poured into a column and washed with 20 ml of
PBS (136 mM NaCI , 2.6 mM KCI , 10 mM Na HP04 , 1.76 mM KH2P04 , pH 7.4)
containing 1% Triton X- 100 , 1 mM EDTA, and 50 J.g/ml phenylmethylsulfonyl
fluoride. The immobilized GST-Tat beads were used in protein binding assays
described below. Alternatively, the Tat proteins were recovered from glutathione-
Sepharose beads by thrombin cleavage according to previously described
procedures (187). The eluted Tat proteins were stored in buffer containing 50
mM Tris-HCI , pH 8. , 150 mM NaCI , 5 mM DTT, and 2. 5 mM CaCb at 80 o
Recombinant capping enzymes. Full-length mouse capping enzyme
Mce1 , the N-terminal RNA triphosphatase domain Mce1-(1-210), and the C-
terminal RNA guanylyltransferase domain Mce1-(211-597) were produced in
bacteria as N-terminal His-tagged fusions and purified as described (94).
In vitro assay of the binding of GST.Tat to mammalian capping
enzyme. Reaction mixtures containing 3-5 /-g of the wild-type or mutant (2/36
48) GST.Tat proteins bound to glutathione-Sepharose beads and 1 /-g of the
wild-type or mutant Mce1 proteins in 300 /-l of binding buffer (20 mM Tris-HCI , pH
, 1 % Triton X-100 , 0.5% Nonidet P- , 5 mM DTT, 0.2 mM ZnCI2 , 0. 1 %
bovine serum albumin) supplemented with a protease inhibitor mixture (Roche
Molecular Biochemicals) were incubated at 4 C for 2 h. The beads were washed
four times in 600 /-l of washing buffer (30 mM Tris-HCI , pH 8. , 150 mM NaCI , 2
mM CaCb, 5 mM DTT) and then resuspended in 200 /-l of washing buffer and
split into two equal aliquots. One of the aliquots was treated with 10 units of
thrombin (Amersham Pharmacia Biotech) for 10 min at room temperature.
Thrombin digestion was then quenched by adding 20 /-g of phenylmethylsulfonyl
fluoride. The second aliquot was not treated with thrombin. The beads were then
separated from the supernatant by centrifugation. The supernatant fractions were
resolved by SDS-PAGE. The protein contents of the gel were transferred to a
polyvinylidene difluoride membrane that was then immunoblotted with rabbit
antiserum raised against the guanylyltransferase domain Mce1-(211-597).
Immune complexes were detected by using an ECL Western blotting kit
according to the instructions of the vendor (Amersham Pharmacia Biotech).
In vitro assay of the binding of HA.Tat to the triphosphatase and
guanylyltransferase domains of mammalian capping enzyme. 40 Jlg of His-
tagged Mce1-(1-210) or Mce1-(211-597)was adsorbed to 100 JlI of Ni2+-agarose
beads (Qiagen) during a 1-h incubation at 4 C in 500 JlI of Ni2+-binding buffer A
(50 mM Tris-HCI , pH 8. , 50 mM NaCI 10% glycerol) supplemented with
protease inhibitor mixture. The beads were washed four times with 1 ml of
binding buffer A and resuspended in 250 JlI of binding buffer A. The beads were
then incubated for 1 h at 4 C with 2 Jlg of purified HA-tagged Tat protein in
binding buffer A. The beads were washed six times with 1 ml of binding buffer A
and the bound proteins were then stripped from the beads by boiling in 25 JlI of
SDS-PAGE loading buffer (50 mM Tris-HCI , pH 6. 12% glycerol , 4% SDS , 100
mM DTT , and 0. 01 % Coomassie Blue G-250). Polypeptides were resolved on
8% polyacrylamide gels. The gel contents were transferred to a polyvinylidene
difluoride membrane , and Tat protein was detected by immunoblotting with a
biotin-conjugated antibody against the HA tag. The blot was developed using a
chemiluminescence kit.
Guanylyltransferase assay. Guanylyltransferase activity of capping
enzyme was assayed by the formation of the covalent enzyme-GMP
intermediate. Reaction mixtures (20 JlI) containing 50 mM Tris-HCI , pH 8. , 5 mM
DTT , 5 mM MgCb, 1.25 JlM eZp)GTP , and capping enzyme and Tat proteins as
specified were incubated for 15 min at 37 oC. The reaction was halted by addition
of SDS to 1 % final concentration. The reaction mixtures were analyzed by SDS-
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PAGE. Capping enzyme- PJGMP complexes were visualized by
autoradiography and quantified by scanning the gel with a phosphorimager.
RNA triphosphatase assay. RNA triphosphatase activity was assayed by
liberation of pi from e PJGTP- labeled poly(A) RNA synthesized by T7 RNA
polymerase transcription. The template strand encoded the sequence for poly(A)
RNA starting with G at position +1. In vitro transcription reactions were carried
out as described previously (97) in the presence of e pJGTP. 5' GTP-terminated
29-mer poly(A) was purified on a 15% polyacrylamide , 7 M urea denaturing gel.
RNA triphosphatase reaction mixtures (10 Ill) containing 50 mM Tris-HCI , pH 8.
5 mM DTT, 10 pmol of 5' GTP-terminated poly(A), and capping enzyme and Tat
proteins as specified were incubated for 15 min at 37 oC. The reaction was halted
by addition of 1 III of 88% formic acid. Aliquots of the mixtures were applied to a
polyethyleneimine-cellulose TLC plate , which was developed with 0.75 M
potassium phosphate (pH 4. 3). The release of pi was quantified by scanning
the TLC plate with a phosphorimager.
RNA capping assay. Triphosphate-terminated 17-mer RNA with no
apparent secondary structure and TAR RNA containing a bulge and loop region
(see Figure 7A) were prepared by in vitro 17 polymerase transcription and then
purified by electrophoresis through a 20% polyacrylamide , 7 M urea gel as
described previously (97). (32PJGMP was incorporated at internal positions in the
RNAs by including (32PJGTP in the transcription reactions. Capping reaction
mixtures (20 Ill) containing 50 mM Tris-HCI , pH 8. , 5 mM DTT , 50 11M GTP , 2.
mM MgCb 10 pmol of RNA , 20 units of RNase inhibitor (Promega), and capping
J m
enzyme and Tat proteins as specified were incubated for 15 min at 37 OC. The
reaction was quenched by adding 200 /-1 of stop solution (0. 3 M Tris-HCI , pH 7.
3 M sodium acetate , 0. 5% SDS , 2 mM EDTA). The mixtures were extracted
with phenol/chloroform/isoamyl alcohol (25:24:1) and then with chloroform. RNAs
were recovered by ethanol precipitation and then analyzed by electrophoresis
through a 15% polyacrylamide gel containing 7 M urea in Tris-Borate-EDTA.
Labeled RNA products were visualized by autoradiography. The internally
labeled capped RNA product migrated more slowly than the uncapped substrate
RNA. The extent of capping was quantitated by scanning the gel with a
phosphorimager.
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RESUL TS
Tat directly interacts with mammalian capping enzyme in vitro.
To test for interaction between Tat and mammalian capping enzyme , a
purified GST-Tat fusion protein was linked to glutathione-Sepharose beads , and
the beads were incubated with purified recombinant full- length Mce1. After
washing the beads with buffer to remove unbound protein , the bound Mce1 was
recovered from the beads by treatment with thrombin , which cleaved the
GSTTat fusion protein between the GST and Tat domains (Figure 1A). Released
Mce1 was detected in the supernatant fraction by immunoblotting with antiserum
raised against the C-terminal guanylyltransferase domain (Figure 1 B , lane 3).
Mce1 was not detected in the supernatant when the thrombin cleavage step was
omitted (Figure 1 B , lane 2). Alanine mutations of the active site cysteine of the
RNA triphosphatase domain of Mce1 (C126A) or the active site lysine of the
guanylyltransferase domain of Mce1 (K294A) that abrogate the triphosphatase
and guanylyltransferase activities , respectively, did not interfere with the binding
of Mce1 to immobilized Tat (Figure 1 B , lanes 6 and 9). These results indicate
that mammalian capping enzyme can interact directly with Tat in vitro
independent of the competence of Mce1 to catalyze phosphoryl or nucleotidyl
transfer.
The C-terminal segment of Tat containing the RNA binding domain suffices
for binding to mammalian capping enzyme.
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Tat protein can be divided into two major functional domains (Figure 2A).
The transactivation domain (amino acids 1-48) is required for recruitment of
cyclin T1 by Tat to the HIV-1 long terminal repeat (L TR) promoter (252). The C-
terminal domain (amino acids 49-86) includes a basic region and is required for
both RNA binding and nuclear localization of Tat (52). Two truncated versions of
Tat, Tat2/36 and Tat48 , which are deleted in the transactivation domain and RNA
binding domain , respectively, were expressed as GST fusion proteins and tested
for binding to the guanylyltransferase domain of mammalian capping enzyme
Mce1-211-597). The guanylyltransferase bound to beads containing immobilized
wild-type Tat and Tat2/36 (Figure 2B , lanes 3 and 5), but not to Tat48 (Figure 2B
lane7). Similar results were obtained for binding of full- length Mce1 to the
truncated Tat proteins (data not shown). We conclude that the Tat segment from
amino acids 37-86 suffices for the binding of capping enzyme and that the
transactivation domain per se does not interact with capping enzyme or its
uanylyltransferase component.
Tat binding stimulates the activity of mammalian guanylyltransferase.
Are there functional consequences for the interaction of mammalian
capping enzyme with Tat? To address this question , we tested the effects of full-
length Tat and truncated Tat derivatives on the guanylyltransferase and
triphosphatase activities of Mce1. The 597-amino acid mammalian capping
enzyme consists of an N-terminal triphosphatase domain (amino acids 1-210)
and a C-terminal guanylyltransferase domain (amino acids 211-597). The
guanylyltransferase component of the enzyme catalyzes two sequential
nucleotidyl transfer reactions involving a covalent enzyme-guanylate intermediate
(212). In the first partial reaction , nucleophilic attack on the phosphate of GTP by
enzyme results in liberation of pyrophosphate and formation of a covalent adduct
in which GMP is linked via a phosphoamide bond to the -amino group of a Lys-
294 (94 , 269). The nucleotide is then transferred to the 5'-end of the RNA
acceptor to form an inverted (5')-(5' ) triphosphate bridge structure , GpppN.
The extent of Mce1. P)GMP complex formation during reaction with 1.
M GTP was proportional to input protein up to 0. 15 JlM Mce1 and leveled off as
Mce1 was increased to 0. 5 Jl M (Figure 3A). In the linear range of Mce1-
dependence , -9% of the input protein molecules were labeled with (32P)GMP.
Enzyme-(32P)GMP complex formation by 0. 05 JlM Mce1 was stimulated by Tat
and Tat2/36 , but Tat48 had no effect (Figure 3B). Optimal stimulation (4- fold)
was attained at a 2:1 molar ratio of Tat to Mce1 (Figure 3C). The activity of the
autonomous guanylyltransferase domain Mce1-(211-597) was similarly
stimulated by Tat and Tat2/36 , but not Tat48 (data not shown). Tat had no
stimulatory effect on enzyme-GMP formation by purified recombinant yeast
guanylyltransferase Ceg1 (data not shown). These results indicate that Tat
interaction with Mce1 stimulates the guanylyltransferase activity of mammalian
capping enzyme and the Tat domain from amino acids 37-86 suffices for this
function.
Tat stimulates the RNA triphosphatase activity of mammalian capping
enzyme.
The RNA triphosphatase domain of mammalian capping enzyme displays
extensive amino acid sequence similarity to protein tyrosine phosphatases and
dual-specificity protein phosphatases. By analogy to the protein phosphatases , it
is proposed that mammalian RNA triphosphatase executes a two-step
phosphoryl transfer reaction involving a covalent enzyme-(cysteinyl-S)-
phosphate intermediate (94 , 228 , 253). In the first partial reaction , nucleophilic
attack by a cysteine thiolate (Cys-126 in Mce1) on the -phosphate of RNA results
in release of diphosphate-terminated RNA and formation of a phosphoenzyme.
The phosphate is then transferred from Cys-126 to water to release Pi. RNA
triphosphatase activity is assayed by the release of pi from labeled
triphosphate-terminated RNA.
Hydrolysis of 1 M e p)GTP- labeled poly(A) by Mce1 increased linearly
from 2-8 nM enzyme and was nearly quantitative at 10 nM (Figure 4A). The
titration profile of the isolated triphosphatase domain Mce1-(1-210) was more
sigmoidal , but the slope of the curve in the linear range (4- 12 nM enzyme) was
similar to that of Mce1 (Figure 4A). RNA -phosphate hydrolysis by 3 nM Mce1
was stimulated 6- fold by the inclusion of 6-18 nM Tat (Figure 4B). Note that Tat
by itself had no detectable RNA triphosphatase activity at the highest level of
input Tat used in this experiment (data not shown). The remarkable finding was
that Tat did not stimulate RNA -phosphate hydrolysis by 5 nM of the N-terminal
RNA triphosphatase domain Mce1(1-210), which catalyzed a similar level of
basal RNA hydrolysis as 3 nM Mce1 (Figure 4B).
To investigate whether Tat interacts directly with the RNA triphosphatase
domain , we established an affinity chromatography assay using His-tagged
capping enzyme domains immobilized on Ni2+-agarose beads (Figure 5A). The
beads were incubated with HA-tagged Tat. After washing the beads with buffer to
remove unbound protein , the bead-bound material was stripped from the beads
with SDS , and the presence of HA-Tat in the SDS-eluate was detected by
immunoblotting with anti-HA antibody. As shown in Figure 5B , HA-Tat was
adsorbed to beads containing the immobilized RNA triphosphatase domain
Mce1-(1-210) (lane 3), whereas only a scant amount of HA-Tat was retained on
the control Ni2+-agarose beads (lane 1). HA-Tat also bound to beads containing
immobilized guanylyltransferase domain Mce1-(211-597) (lane 2). This
experiment reciprocates the finding that soluble guanylyltransferase domain was
bound to immobilized Tat (Figure 2).
The results presented thus far demonstrate that Tat interacts with the
isolated RNA triphosphatase and guanylyltransferase domains of mammalian
capping enzyme. Whereas Tat-binding stimulates the guanylyltransferase activity
of Mce1 and the C-terminal domain , Tat-stimulation of the RNA triphosphatase
reaction appears to occurs only in the context of the full- length Mce1.
Tat stimulates RNA cap formation by Mce1.
The enzymatic addition of an unlabeled cap guanylate to the 5 -end of an
internally labeled RNA molecule results in a characteristic slowing of the
electrophoretic mobility of the RNA , equivalent to about a 2-nucleotide increase
in apparent chain length (51). The change in mobility upon addition of capping
enzyme has been used to detect cap formation on RNAs as long as
78 nucleotides (50). Here we studied the complete capping reaction of Mce1
using a synthetic 17 -mer triphosphate-terminated RNA substrate that was
labeled internally with (32P)GMP (Figure 6A). Incubation of 0. 5 J-M RNA substrate
with Mce1 in the presence of 50 J-M cold GTP and magnesium chloride resulted
in transfer of GMP to the 5 -end , yielding a capped species that migrated more
slowly than the input substrate RNA (Figure 6B). Formation of the capped
species was dependent on inclusion of GTP in the reaction mixture (not shown).
The extent of capping was proportional to input Mce1 and saturated at 0.4 J-M
Mce1 with about 70% of the input RNA being capped (Figure 6C). In the linear
range of enzyme-dependence , 1 pmol of RNA was capped per pmol of the Mce1.
The level of capping catalyzed by 50 nM Mce1 (1 pmol of input Mce1) was
increased 6-fold by Tat (Figure 6D). The stimulation was Tat concentration-
dependent and saturation was attained at a 4:1 molar ratio of Tat to Mce1. An
identical capping stimulation profile was observed for the deletion mutant Tat2/36
containing an intact RNA binding domain. Tat48 containing the activation domain
had no salutary effect on RNA capping (Figure 6D). The ability of Tat or its
component domains to stimulate cap formation by Mce1 correlated perfectly with
the capacity to bind to Mce1 (Figure 3).
Tat enhances TAR RNA capping.
Tat functions through TAR RNA to control an early step in transcription
elongation that depends on the Pol II CTD (43 , 108). In light of our findings that
Tat stimulates mammalian capping enzyme , we envisioned that Tat might
enhance the capping of its target TAR mRNA, which might otherwise be
inefficiently capped because the 5 -end is encompassed within a stable RNA
duplex (67). To test this hypothesis , we prepared internally labeled Non-TAR
RNA (17-mer) and TAR RNA (29-mer) substrates (Figure 7A) and tested them
for capping in the same reaction mixtures with limiting Mce1. Capping reactions
containing 75 nM Mce1 and 250 nM each of the Non-TAR and TAR substrates
were supplemented with increasing amounts of Tat protein and the labeled
products were resolved by PAGE (Fig. 78). In a competitive situation in the
absence of Tat (Figure 7B , lane 2), Mce1 favored the Non-TAR substrate (1 pmol
of cap formed) over the TAR substrate (0. 3 pmol of cap formed) (Figure 7C). Tat
enhanced capping of both Non-TAR and TAR RNA substrates at a 2:1 ratio of
Tat to Mce1 (Figure 7C). Yet, the relative Tat stimulation of capping of the TAR
RNA (5-fold) was greater than that of the Non-TAR substrate (2-fold).
DISCUSSION
Selective targeting of caps to Poll! transcripts in vivo 
is achieved , at least
in part, through direct physical interaction of the capping apparatus with the
phosphorylated CTD of Poll!. In addition to recruiting capping enzyme to the Pol
II elongation complex, the phosphorylated CTD stimulates the
guanylyltransferase activity of the mammalian capping enzyme (93). This simple
and appealing model for targeting and regulation of capping is belied by the
underlying complexity of CTD phosphorylation (and dephosphorylation) and by
mounting evidence that regulation of transcription elongation is a key facet of
cotranscriptional mRNA processing. The data presented here illuminate a new
pathway of capping enzyme recruitment and activation by the HIV Tat protein.
Our findings contribute to an emerging picture of how elongation and processing
are coupled , especially during HIV gene expression.
In mammalian cells, the timely acquisition of the cap may promote
subsequent mRNA-specific processing steps (splicing and polyadenylation) and
protect the nascent mRNA from exonucleolytic decay. A clear advantage would
accrue from a mechanism whereby capping is restricted to Pol II complexes that
are committed to productive elongation , insofar as the capping of short
transcripts that are subsequently aborted and released would generate a
population of non-coding capped RNAs that could compete with bona fide
mRNAs in cap-dependent transactions. CTD hyperphosphorylation has often
been correlated with the establishment of a stable elongation complex , but there
is little information as to the exact nature of the phosphorylation array at any
point in the transcription cycle and there is still uncertainty concerning the relative
contributions of different CTD kinases (TFIIH and P-TEFb) to the establishment
and remodeling of the CTD phosphorylation array. The timing during early
elongation of the critical CTD phosphorylation steps that permit capping enzyme
recruitment are not well defined and may even vary for different transcription
units. Although it is clear that short nascent transcripts (on the order of
30 nucleotides) can be capped , such results reflect the action of the capping
enzymes on arrested polymerase elongation complexes , where there is 
kinetic competition between ongoing elongation and capping. The RNA size
threshold for capping in this experimental setting simply reflects the steric
constraints on capping of RNA chains held within the RNA binding pocket of the
polymerase. The unimpeded rate of elongation by RNA polymerase (-20
nucleotides/s) is faster than estimates of the rates of the RNA triphosphatase
andguanylyltransferase reactions (reviewed in ref. (210)), which sets up a
situation in which RNA polymerase might "outrun" the capping enzyme. It is not
known whether capping enzyme has a narrow or wide window for action on
nascent 5' ends in vivo , i. e. whether capping enzyme would dissociate from the
elongation complex after polymerase has proceeded a certain distance down the
transcription unit.
Thus , there is advantage in imposing an elongation checkpoint to
maximize the opportunity for the capping apparatus to bind the elongation
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complex. This scenario has been studied most thoroughly for HIV transcription
where the negative elongation factor DSIF induces an elongation block that is
overcome by P- TEFb , a cyclin-dependent protein kinase that phosphorylates the
CTD (181) (Figure 8). One key function of the Tat-TAR RNA complex is to recruit
TEFb to the nascent HIV mRNA through an interaction of the cyclin T1 subunit
of P-TEFb with the activation domain of Tat. The CTD kinase function of P-TEFb
is essential for Tat-TAR stimulation of HIV transcription , whereas the CTD kinase
activity of TFIIH is apparently not critical for overriding the effects of DSIF (241
275). Indeed , although TFIIH and P-TEFb are both associated with very early
HIV elongation complexes halted at position +14 , TFIIH dissociates by the time
the polymerase moves to position +30 or +36 (prior to elaboration of the TAR site
in the nascent RNA), whereas P-TEFb remains associated with the elongation
complex at least up to position +79 when TAR is formed (179 , 275). The
presence of Tat triggers a new round of P-TEFb-catalyzed CTD phosphorylation
on elongation complexes at position +79 (275).
An exciting connection between Tat , P-TEFb , and cap formation emerges
from the recent report that Tat alters the phosphorylation site-specificity of P-
TEFb in the context of the HIV transcription complex. P-TEFb phosphorylates
Ser-2 of the CTD heptad in the absence of Tat , but it phosphorylates both Ser-
and Ser-5 when Tat is present (275). CTD phosphorylation on either Ser-2 or
Ser-5 suffices to bind mammalian capping enzyme , but CTD-stimulation of
capping activity is specific for the Ser- P04 CTD array (93). Thus , the
TatlAR/P-TEFb complex helps craft a CTD array that both recruits and activates
Mce1.
Here we have shown that Tat spearheads a second and novel pathway of
capping enzyme recruitment and activation via a direct physical interaction
between Tat and Mce1. Unlike , the Tat-P- TEFb interaction , which requires the N-
terminal transactivation domain of Tat , the binding of Tat to capping enzyme is
via the C-terminal domain that includes the TAR RNA binding site. The Tat-Mce1
interaction results in a significant stimulation of the guanylyltransferase and
triphosphatase activities of Mce1 and it thereby enhances the efficiency of cap
formation on defined RNA substrates. Tat is unique among the recently
discovered regulators of mammalian capping enzyme because as it is the only
factor that up-regulates the triphosphatase component of the bifunctional
enzyme. The effects of Ser- P04 CTD and hSpt5 on Mce1 are limited to
stimulation of the guanylyltransferase (93, 253). Tat-stimulation of Mce1
triphosphatase activity occurs in the context of the native two-domain enzyme
but not with the isolated N-terminal triphosphatase component, even though Tat
can bind to the isolated triphosphatase domain. Thus , it appears that contacts of
Tat to both domains of Mce1 are needed to elicit the increase in triphosphatase
activity. In contrast, Tat is equally capable of stimulating theguanylyltransferase
activity of the full-length Mce1 and its isolated C-terminal domain. Ser- P04
CTD can also up-regulate either Mce1 or the guanylyltransferase domain , but
hSpt5 (which is a subunit of DSIF) only affects the activity of full- length Mce1.
There are now 3 possible pathways of up-regulating HIV mRNA capping
involving factors that are known to be associated with the HIV transcription
complex: (i) direct Tat activation of Mce1; (ii) CTD-P04 activation of Mce1 , via
Tat-stimulation of the CTD kinase activity of P-TEFb; (iii) DSIF activation of Mce1
via its hSpt5 subunit (Figure 8). There is potential for cross-talk between these
pathways , insofar as P-TEFb phosphorylation of CTD clearly affects DSIF
function and P- TEFb is also capable of phosphorylating the hSpt5 subunit of
DSIF (103). Phosphorylation of hSpt5 by P-TEFb has been reported to block its
ability to elicit a transcription elongation block (103). The effects of hSpt5
phosphorylation on its interaction with the capping enzyme are unclear. The
attractive feature of the direct Tat-Mce1 activation pathway in HIV gene
expression is that it is independent of CTD phosphorylation status and provides a
means for direct and specific recruitment of Mce1 to the nascent HIV transcript
containing bound Tat.
Why might HIV go to such lengths to employ Tat to recruit and activate
Mce1? The formation of stable RNA secondary structures in which the 5' end of
the HIV transcript is encompassed within a duplex stem may limit access of the 5'
terminus to the active sites of the capping enzyme (67). Such a stem structure is
formed by nascent HIV mRNA even prior to the synthesis of the TAR sequence
and , although the secondary structure changes after TAR is formed , the 5' end
remains held within a duplex stem (170). We observed a structured TAR
substrate was capped less effectively by purified Mce1 than an RNA with no
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apparent secondary structure. Although Tat stimulated the capping of both Non-
TAR and TAR RNAs , the-fold-stimulation of the structured TAR substrate was
greater than that of the unstructured transcript. Thus regulation of capping by Tat
would have the most impact where capping is inherently weak. Finally, a Tat-
dependent enhancement of mRNA cap formation may account for the finding that
Tat stimulates the translation of mRNAs synthesized from the HIV transcription
unit (44).
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Figure 1. Tat interacts directly with Mce1 in vitro. A, experimental design to
test the interaction between Mce1 and Tat protein. Purified GST-Tat fusion
protein was linked to glutathione-Sepharose beads and incubated with purified
Mce1. After loading to the column and washing with buffer (30mM Tris-HCI , pH
, 150mM NaCI , 2mM CaCIz, 5mM DTT) , the sample was divided into two
aliquots. Bound Mce1 was released by thrombin treatment (supernatant phase
ST). Supernatant without thrombin treatment (S) shows the background. B, full-
length Mce1 (lane 1) and two active site mutants , Mce1(C126A) (lane 4) and
Mce1(K294A) (lane 7), were assayed for binding to GST-Tat. The input and
supernatant fractions were analyzed by SDS-PAGE; the wild-type and mutant
Mce1 polypeptides were detected by immunoblotting.
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Figure 2. The C-terminal segment of Tat containing the RNA binding
domain is sufficient for interaction with Mce1. A, schematic representation of
the domains of HIV-1 Tat protein and the Tat deletion mutants that were used in
this binding assay. B , purified GST-Tat , GST-Tat2/36 (transactivation domain
deletion) and GST-Tat48 (RNA binding domain deletion) were incubated with
purified Mce1-(211-597). Binding was assayed as shown in Figure 1. An
immunoblot of the input and supernatant fractions is shown.
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Figure 3. Tat enhances guanylylation of Mce1. A, guanylyltransferase activity
of purified Mce1 was assayed as described under "Experimental Procedures
Mce1.e P)GMP complex formation is plotted as a function of input Mce1. B
effect of Tat. Mce1 (1 pmol) was assayed for guanylyltransferase activity in the
presence of increasing amounts (0 , 1 , and 6 pmol) of wild-type Tat (lanes 1-
5), Tat2/36 (lanes 6- 10), and Tat48 (lanes 11- 15). The reaction products were
analyzed by SDS-PAGE, and Mce1. P)GMP complexes were detected by
autoradiography. C, Mce1.e P)GMP complex formation is plotted as a function of
the TatlMce1 ratio.
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Figure 4. Tat enhances the RNA triphosphatase activity of full-length Mce1
but not the isolated triphosphatase domain. A , RNA triphosphatase activity
was assayed as described under "Experimental Procedures. pi release 
plotted as function of input Mce1 or Mce1-(1-210). B , effect of Tat.
Triphosphatase reaction mixtures contained 30 fmol of Mce1 or 50 fmol of Mce1-
(1- 210) plus increasing concentrations of Tat. The extent of pi release from
p)GTP- labeled RNA is plotted as a function of the molar ratio of Tat to capping
enzyme.
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Figure 5. The RNA triphosphatase domain of mammalian capping enzyme
can bind to Tat. A, HA-Tat was reacted with Ni2+-agarose beads alone (1), with
beads containing His-tagged Mce1-(211-597) (2), and beads containing His-
tagged Mce1-(1-21 0) (3). The bound material was eluted with SDS and resolved
by SDS-PAGE. B, Tat protein in the input sample and the SDS eluates was
detected by immunoblotting using antibody directed against the HA tag.
Ni Beads Mcel(211-597) Mcel(1-210)
PHiS P His
+ HA-Tat HAe Tat + HA-Tat
PHiSlO P HislO-8Rl\
+SDS +SDS +SDS
Background His His
HA-Tat-+ Jlli n
Figure 6. Tat enhances RNA cap formation. A , sequence of the 17-mer
substrate RNA used in capping reactions. B , capping reactions contained
10 pmol of internally labeled 17-mer RNA and Mce1 as specified. The
radiolabeled reaction products were analyzed by PAGE. An autoradiogram of the
gel is shown. The positions of capped and uncapped RNAs are indicated on the
left. C , the extent of cap formation in (B) is plotted as a function of input enzyme.
, effect of Tat on RNA capping. In these reactions , we used 10 pmol of RNA , 1
pmol of Mce1 , and increasing concentration of various Tat proteins. Quantitative
analysis of Mce1 capping activity in the presence of various Tat sequences.
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Figure 7. Tat enhances capping of TAR RNA. A , sequence and secondary
structure of TAR RNA (29-mer) used in the RNA cap formation assay. B , capping
reaction mixtures (20 J.1) contained 50 J.M GTP , 75 nM Mce1 , 250 nM Non-TAR
and 250 nM TAR RNAs and increasing amounts of Tat (0 , 1. , 3 , 6 , and 9 pmol).
The radiolabeled reaction products were analyzed by PAGE. An autoradiogram
of the gel is shown. The positions of capped and uncapped TAR and Non-TAR
RNAs are indicated by arrows. , the extent of cap formation is plotted as a
function of the TaUMce1 molar ratio for Non-TAR RNA (right y axis) and TAR
RNA (left y axis).
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Figure 8. Emerging connections between CTD phosphorylation , capping,
and transcription elongation. See text for details.

CHAPTER III
TAT STIMULATES COTRANSCRIPTIONAL CAPPING OF
HIV MESSENGER RNA
ABSTRACT
Here we investigated how capping and methylation of HIV pre-mRNAs are
coupled to Pol \I elongation. Stable binding of the capping enzyme (Mce1) and
cap methyltransferase (Hcm1) to template-engaged Pol II depends on CTD
phosphorylation , but not on nascent RNA. Both Mce1 and Hcm1 travel with Pol II
during elongation. The capping and methylation reactions cannot occur until the
nascent pre-mRNA has attained a chain length of 19-22 nucleotides. HIV pre-
mRNAs are capped quantitatively when elongation complexes are halted at
promoter-proximal positions , but capping is much less effcient during unimpeded
Pol II elongation. Cotranscriptional capping of HIV mRNA is strongly stimulated
by Tat, and this stimulation requires the C-terminal segment of Tat that mediates
its direct binding to Mce1. Our findings implicate capping in an elongation
checkpoint critical to HIV gene expression.
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INTRODUCTION
mRNA capping occurs cotranscriptionally by a series of three enzymatic
reactions in which the 5' triphosphate terminus of the pre-mRNA is cleaved to a
diphosphate by RNA triphosphatase , then capped with GMP by RNA
guanylyltransferase , and methylated by RNA (guanine-N7) methyltransferase.
Targeting of cap formation to cellular transcripts made by RNA polymerase II (Pol
II) is achieved through physical interactions of the capping enzymes with the
phosphorylated carboxyl-terminal domain (CTD) of the largest subunit of Pol II
(31 152 173, 269). The CTD , which is composed of a tandemly repeated heptad
motif YSPTSPS, undergoes extensive serine phosphorylation and
dephosphorylation during the transcription cycle. Recruitment of the capping
apparatus to the yeast Pol II elongation complex 
in vivo requires the action of the
TFIIH-associated CTD kinase Kin28 (equivalent to Cdk7 in mammals), which
phosphorylates Ser5 of the CTD (128, 191 , 199). Other factors may also be
involved in coupling capping to Pol II transcription. For example , the Pol II
transcription elongation factor Spt5 interacts directly with the triphosphatase and
guanylyltransferase components of the capping apparatus in mammals and in
the fission yeast Schizosaccharomyces pombe 
(174 , 253). Many eukaryotic
viruses that replicate in the nucleus exploit the host's enzymes to transcribe and
cap their mRNAs. Human immunodeficiency virus (HIV) is of particular interest
because it appears to impose an additional mechanism to target the capping
enzyme to the viral transcription unit , whereby the HIV-encoded Tat protein binds
to the triphosphatase and guanylyltransferase domains of the mammalian
capping enzyme and upregulates both catalytic activities (27).
The Pol II CTD , Spt5 , and Tat are intimately connected to the regulation of
HIV gene expression (reviewed in 181). Human Spt5 and its binding partner
hSpt4 comprise the transcription elongation regulatory factor DSIF (DRB
sensitivity- inducing factor). DSIF binds to Pol II and , in concert with NELF
(negative elongation factor), represses elongation at promoter-proximal positions
in the transcription unit. Escape from the repressive effect of DSIF/NELF requires
the action of P-TEFb (positive transcription elongation factor b), a ORB-sensitive
protein kinase that phosphorylates both the Pol II CTD and the Spt5 subunit of
DSIF. P-TEFb is composed of two subunits , Cdk9 and cyclin T1 , and it binds to
the HIV Tat protein via the cyclin T1 subunit (181 , 252). In previous studies we
have analyzed the interactions of these regulatory factors with Pol II at discrete
functional stages of transcription from the HIV-1 L TR promoter in vitro. We found
that P-TEFb is a component of the Pol II preinitiation complex (PIC) and that it
travels with the transcription elongation complex (TEC) as in moves along the
HIV transcription unit (179). In contrast , DSIF and NELF are not present in the
PIC , but associate with the TEC at promoter proximal positions and then travel
with the TECs down the template (178).
How does capping fit into the scheme of HIV transcription regulation? The
mammalian capping apparatus consists of two components: a bifunctional
tri p hosp h atase-g uanylyltra nsferase (Mce1) and separate cap
methyltransferase (Hcm1) (94 , 177 , 195 269). Our finding that Tat enhances the
effciency of capping of isolated HIV mRNA by Mce1 in vitro led to the suggestion
that Spt5- induced arrest at promoter-proximal sites in the HIV transcription unit
might ensure a temporal window for recruitment of the capping enzymes and
stimulate modification of the 5' end of the HIV pre-mRNA (27).
At present , little is known about the dynamics of the interactions of
mammalian capping and methylating enzymes with mammalian Pol II during the
transcription cycle or about the efficiency and timing of the cap guanylylation and
methylation steps. To rectify these gaps in our knowledge , we monitored the
binding of Mce1 and Hcm1 to Pol II complexes arrested at discrete steps of the
initiation and elongation reactions on the HIV transcription unit. We report that
the capping enzymes are associated with TECs , but not PICs. Whereas Mce1
and Hcm1 are bound stably to TECs containing nascent .RNAs as short as 14
nucleotides , the capping and methylation reactions do not occur until the nascent
pre-mRNA has attained a chain length of 19-22 nucleotides , at which point an
-4-7 nucleotide 5' segment is extruded from Pol II. Mce1 and Hcm1 binding to
template-engaged Pol II does not require RNA synthesis , but does require CTD
phosphorylation. Both Mce1 and Hcm1 travel with Poll! during elongation down
the template and remain poised to quantitatively cap the nascent pre-mRNA
when elongation is halted. In contrast , capping of nascent HIV mRNA is much
less effcient during unimpeded Pol II elongation. Under such conditions
cotranscriptional capping of HIV mRNA is strongly stimulated by Tat , and this
stimulation of capping requires the C-terminal segment of Tat that mediates its
direct binding to Mce1. Our findings implicate cap formation as a component of a
transcription elongation checkpoint critical to HIV gene expression.
MATERIALS AND METHODS
Recombinant capping enzymes and Tat. The bifunctional mammalian
triphosphatase-guanylyltransferase Mce1 and the cap guanine N7-
methyltransferase Hcm1 were produced in E. coli as N-terminal His-tagged
fusions and purified by Ni-agarose affnity chromatography as described
previously (94 , 195). A new version of Hcm1 with an N-terminal hemagglutinin
(HA) tag and a His tag was produced and purified by the same procedure. HIV-
Tat was produced in E. coli as a glutathione S-transferase fusion and purified by
glutathione-Sepharose affinity chromatography (187).
DNA templates. The DNA templates used for preparing transcription
ternary complexes were generated by PCR amplification using the HIV- 1 L TR
promoter-containing plasmid p10SL T as a template (116) and primer pairs
corresponding to p1 OSL T plasmid sequences 5' ACCAGTTGAACCAGAGC and
CACACTGACTAAGGGT. The first primer contained a biotin at the 5' end
which was used to immobilize the DNA on beads. Gel-purified duplex PCR
products (0.25 Ilg of DNA) were adsorbed to 25 III of streptavidin-coated
magnetic beads (Dynal Inc.) by overnight incubation at 22 C in 10 mM Tris-HCI
(pH 8.0), 1 mM EDTA, and 1 M NaCI. The beads were washed with the same
buffer to remove any free DNA and then stored in 10 mM Tris-HCI , pH 8. , and 
mM EDT A.
Stepwise walking of Pol II. Stepwise transcriptions were performed as
described previously (178 , 179). Preinitiation complexes (PICs) were assembled
by incubating the immobilized DNA template (200 ng) in a volume of 25 III
containing 12 III of HeLa cell nuclear extract , 6 mM MgCI2, and 0. 5 Ilg of poly(dA-
dT) for 15 min at 30 C. PolliO complexes at the PIC stage were formed by
including 200 11M dATP during the incubation. To remove unbound materials , the
bead-bound PICs were pelleted and then washed with 25 III of buffer A (20 mM
HEPES , pH 7. , 100 mM KCI , 20% (v/v) glycerol , 0.2 mM EDTA, 0.5 mM
dithiothreitol , 0.5 mM phenylmethyl-sulfonyl fluoride , 6 mM MgCb). PIGs were
walked to template position +14U by incubation with 12. 5 mM phosphocreatine
20 11M CTP , GTP , UTP , and dATP for 5 min at room temperature. TECs stalled
at +14U were washed with 25 III of buffer B (buffer A containing 0. 05% Nonidet
40 and 0.015% Sarkosyl) and twice with 25 III of buffer C (buffer A containing
05% Nonidet P-40). The TECs were walked stepwise along the DNA template
by serial incubations with different combinations of NTPs (20 11M each). For all
experiments that required additional purified proteins (or cellular factors supplied
by nuclear extract), the TECs were incubated with the purified proteins (or
nuclear extract) at 30 C for 10 min and then washed three times with buffer C
before the next manipulation. For chase experiments , the stalled TECs were
incubated with 211M ATP , CTP , GTP , and UTP for 10 min at 30
Western blotting. For the isolation of ternary complexes on immobilized
DNA template , the PICs and TECs stalled at different steps were released by
restriction enzyme digestion at 30 C. The supernatant phase containing released
ternary complexes was resolved by 8% SDS-PAGE , and the gel contents were
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transferred to a polyvinylidene difluoride membrane (Bio-Rad), which was then
immunoblotted with antibodies raised against either the largest subunit of Pol II
or Mce1 or Hcm1. Immunoreactive polypeptides were visualized by
chemiluminescence using either an ECL kit from Amersham Pharmacia Biotech
or a BM chemiluminescence Blotting Kit from Roche Molecular Biochemicals. Pol
II antibodies were a gift of Dr. Michael Dahmus. Rabbit antibodies were raised
against the C-terminal domain of Mce1. Anti-GFP antibodies were purchased
from Clontech.
Capping of nascent RNAs in stalled transcription elongation
complexes. TECs stalled at different positions were formed by stepwise
transcription , and nascent RNAs were labeled internally by including (-32P)CTP
in the reaction mixture. TECs were incubated with 20 pmol of Mce1 at 30 C for
10 min and washed three times with 200 f.l of transcription buffer C (as described
in "Stepwise Walking of Pol II") to remove the unbound Mce1. Mce1-treated
TECs were incubated in capping reaction mixtures (20 f.l) containing 50 mM Tris-
HCI , pH 8. 5 mM DTT, 50 f.M GTP , and 2. 5 mM MgCI2 for 10 min at 30 C. The
reaction was quenched by adding 200 f.l of stop solution (0. 3 M Tris-HCI , pH 7.
3 M sodium acetate , 0.5% SDS , 2 mM EDTA). The mixtures were extracted
with phenol/chloroform/isoamyl alcohol (25:24:1) and then with chloroform. RNAs
were recovered by ethanol precipitation and then analyzed by electrophoresis
through a 15% polyacrylamide gel containing 7 M urea in Tris-borate , EDTA
buffer. Labeled RNA products were visualized with a phosphorimager.
Cap methylation of nascent RNAs in stalled transcription complexes.
Nascent unlabeled RNAs in TECs stalled at A22 were 5' 32P cap- labeled by
Mce1 in capping reaction mixtures as described above containing 1.25 J.M
p)GTP. The p cap- labeled A22 TECs were then incubated with 20 pmol of
Hcm1 for 10 min at 30 C. After removing the unbound Hcm1 , TECs were walked
to different positions , released from the beads by restriction digestion , and
incubated in a methyltransferase reaction mixture (20 J.1) containing 50 mM Tris-
HCI (pH 8. 0), 5 mM DTT , and 50 J.M AdoMet (Aldrich) for 10 min at 30 C. The
reaction was quenched by adding 200 J.1 of stop solution. RNAs were recovered
by phenol-extraction and ethanol precipitation and dissolved in nuclease S1
buffer (pH 5.5) (GIBCO-BRL). The samples were incubated with 20 U of
nuclease S1 (GIBCO-BRL) for 2 hr at 37 C. The digests were than spotted on
polyethyleneimine-cellulose TLC plates that were developed with 0.2 M
(NH4hS04' Cap dinucleotides were visualized by scanning the TLC plate with a
phosphorimager.
RNA capture assay. TECs containing CMP labeled nascent RNA
were stalled at +14U. The U14 TECs were incubated with 20 pmol of purified
Mce1 for 10 min at 30 C. The unbound proteins were removed by washing three
times with 200 J.1 of transcription buffer C. TECs were chased by the addition of 2
J.M NTPs for 90 s in the presence of 10 pmol of wild-type or mutant Tat proteins.
RNAs were recovered by phenol extraction and ethanol precipitation , then
treated with 50 pmol of purified Hcm1 for 1 hi" at 3rC. Hcm1 will only methylate
the 5' termini of RNAs that had been guanylylated during the transcription
elongation reaction. m G-capped RNAs were recovered by "Capture" affinity
chromatography, a method based on the selective binding of m GpppRNA to
immobilized cap binding protein e1F4E. The recombinant GST-eIF4E fusion
protein was expressed in bacteria (with an expression plasmid kindly provided by
Dr. J. Pelletier, McGill University), then purified and immobilized on glutathione-
Sepharose beads according to previously described procedures with minor
modifications (54 , 152). RNAs were preheated for 2 min at 95 C in 1 00 I of cap
binding buffer (17 mM Hepes , pH 7. , 85 mM NaCI , 80 M EDTA , 1 mM DTT
17% glycerol , 0.08% NP- , 1% polyvinyl alcohol , 200 g/ml calf liver tRNA) and
then cooled on ice. 6 mM DTT was added , followed by 2 U of RNase inhibitor
(Promega). The RNAs were mixed with immobilized GST-eIF4E in 300 I of cap
binding buffer for 1 hr at 4 C. The beads were washed six times with 600 I of
washing buffer (20 mM Hepes , pH 7. , 0. 1 M NaCI , 0. 1 mM EDTA , 1 mM DTT
20% glycerol , 0. 1 % NP40). The bound RNAs were eluted from the beads by
phenol extraction and recovered by ethanol precipitation and then analyzed by
12% polyacrylamidel7 M urea PAGE. Labeled RNAs were visualized by scanning
the gel with a phosphorimager.
Coimmunoprecipitation of Tat with Mce1. pEGFP-Mce1 expression
plasm ids were constructed by fusing the coding sequences for EGFP and Mce1
according to protocols provided by the pEGFP vendor (Clontech). HA-Tat-tagged
plasmids were kindly provided by Dr. Katherine Jones. In these plasmids
expression of the EGFP-Mce1 and HA-Tat proteins is driven by a CMV promoter.
The plasmids were cotransfected into HL3T1 cells with Lipofectamine (GIBCO-
BRL). After 48 hr, the cells were lysed with RIPA buffer (20 mM Tris-HCI , pH 8.
5% Nonidet P- , 1% Triton X-100 , and 150 mM KCI , 5 mM DTT). Ceillysates
(120 g of protein) were immunoprecipitated with anti-GFP or anti-Mce1
antibodies which had been adsorbed to protein G-Sepharose beads (Amersham
Pharmacia Biotech) in RIPA buffer during an overnight incubation at 4 C. The
beads were washed three times with 300 I of RIPA buffer containing 0. 015%
Sarkosyl and 1 M KCI and once with 300 I of RIPA buffer. The bead-bound
proteins were eluted with SDS , resolved by 8% SDS-PAGE , and probed by
Western blotting with anti-HA antibodies.
RESULTS
Capping enzyme is not a component of PICs formed at the HIV-1 L 
Promoter but is present in TECs
Pol II PICs were assembled on immobilized DNA templates containing the
HIV- 1 L TR promoter and then probed by Western blotting for the presence of Pol
II and Mce1. PICs were prepared by incubating the bead-bound DNA with NTP-
depleted HeLa cell nuclear extract and then released from the beads by cleaving
the template upstream of the promoter with the restriction enzyme 
BspE1 (Figure
1 B). Whereas Pol II was present in PICs , Mce1 was not , although Mce1 was
readily detected in the nuclear extract (Figure 1 C , lanes 1 and 2). Moreover
supplementation of the PIGs with purified recombinant Mce1 resulted in only
trace levels of binding of the capping enzyme to the PICs (Figure 1 C , lane 3).
To determine if and when Mce1 associates stably with the Pol 
transcription complex , we converted the PICs into elongation complexes arrested
at discrete promoter-proximal sites by provision of only three NTPs for initiation
and elongation. The 5' sequence of the HIV- 1 pre-mRNA is shown in Figure 1A.
Elongation complexes starved for ATP were stalled at template position +14U.
After stripping the bead-bound TECs with sarkosyl to prevent further initiation
events , the U14 TECs were walked to +30C. The arrested TECs were
supplemented with recombinant Mce1 and then washed with transcription buffer
to remove unbound proteins. The TECs were released from the beads by
cleavage with Pvull and then probed by Western blotting for Pol II and Mce1.
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Capping enzyme was detected in the U14 and C30 TECs after incubation with
purified Mce1 ( Figure 1 C , lanes 5 and 7). There was no Mce1 present in TECs
that had not been supplemented ( Figure 1C , lanes 4 and 6). The PICs and TECs
contained similar amounts of the Pol II large subunit.
Nascent HIV- 1 Ttranscripts as short as 22 nucleotides are capped in vitro
by Mce1
To determine when nascent HIV transcripts acquire their caps , we
arrested TECs at templates positions +14U , +22A , +30C , and +46U , washed
them to remove nucleotides , supplemented them with Mce1 , and washed again
to remove unbound Mce1. These TECs were then incubated with GTP , the
substrate for the guanylyltransferase component of Mce1. The addition of an
unlabeled cap guanylate to the 5' end of an internally labeled RNA molecule
results in a characteristic slowing of the electrophoretic mobility of the RNA
equivalent to about a 1 nucleotide increase in apparent chain length (50). Here
we studied the capping reaction of Mce1 using stalled transcription complexes
containing RNA transcripts labeled internally with 32P-CMP during a stepwise
transcription-walk down the template (Figure 2).
We found that A22 , C30 , and U46 TECs catalyzed near-quantitative
addition of a cap guanylate to their nascent RNAs in a reaction that depended on
prior incubation with Mce1 and the provision of GTP (Figure 2B). However, the
nascent 14-mer RNA in the U14 TECs was refractory to guanylylation (Figure
2B), even though Mce1 is present in the U14 transcription complexes (Figure
1C). These data show that capping of HIV mRNA within paused elongation
complexes can occur during a defined interval between the synthesis of 14-mer
and 22-mer nascent transcripts. We infer that the 5' end of the U14 transcript is
inaccessible to the active site(s) of Mce1 because it is sequestered within the
nascent RNA binding pocket of Poll!. Thus , the window for capping on paused
TECs reflects a steric constraint on the minimum substrate size.
HIV-1 mRNA transcripts can be capped by the mammalian capping enzyme
traveling with the early transcription elongation complexes
To probe the window for cap formation , we asked whether Mce1 that was
recruited to stalled U 14 TECs is available to cap the nascent RNA at a later
stage during a stepwise transcription walk (Figure 2C). The size heterogeneity of
the RNAs contained in U14 TECs , being either 12 , 13 , or 14 nucleotides (Figure
, lanes 1 and 2), reflects the capacity of Pol II to initiate at any of the three G
residues at +1 to +3 of the transcription unit (the degree of heterogeneity varies
from one experiment to another). We incubated stalled U14 TECs with or without
purified Mce1 , removed the unbound Mce1 by washing, and allowed Pol II to
elongate to +30C. Whereas the original RNAs in the U14 complex were not
capped in response to Mce1 , they were capped nearly quantitatively by the time
Pol II had extended the chain to 30 nucleotides. Thus , the capping enzyme binds
to the TEC before the 5' end is extruded from the polymerase and remains
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poised during subsequent elongation steps to cap the nascent chain after it is
extruded from the polymerase.
Capping enzyme association with Pol II elongation complexes does not
require RNA
Our finding that Mce1 can load onto the U14 TECs , at a stage when the
nascent mRNA is not exposed to cap addition , suggested that the recruitment of
Mce1 to the Pol II elongation complexes may be RNA independent. To address
this question directly, we first treated A22 TECs with RNase A to remove the
segment of the nascent RNA that had been extruded from Pol II and then
examined the binding of Mce1 to the digested A22 TECs (designated A22' in
Figure 3). RNase A converted the 32P-labeled A22 transcript into a discrete
product of -15 nucleotides (Figure 3B). After washing to remove RNase A , the
A22' TECs remained competent to elongate the digested RNA during a
subsequent walk to +26G (Figure 3B). This result verifies that the RNase
digestion removed only the 5' end of the A22 RNA and left the 3' OH end of the
RNA intact at the polymerase active site. Neither the digested 15-mer RNA in the
A22' TEC nor the 19-mer RNA in the G26' TEC could be capped in vitro by
Mce1 , because the 5' OH generated by RNase A cleavage cannot serve as a
substrate for RNA guanylyltransferase (Figure 3B). Nonetheless , Mce1 bound to
the RNase-digested A22' TEC as well as it did to the intact A22 TEC , as gauged
by Western blotting of the TECs released from the beads by Pvull digestion of
the template (Figure 3C). Based on these results , we conclude that Mce1
association with Pol II elongation complexes does not require a direct interaction
between Mce1 and nascent RNA.
CTD phosphorylation Is required for capping enzyme association with Poll!
at the HIV-1 L TR promoter
Mce1 is likely to interact with the Pol II elongation complex through direct
protein-protein contacts. Mce1 binds in vitro to the phosphorylated Pol II CTD
but not to the unphosphorylated CTD; the CTD interaction is mediated by the C-
terminal guanylyltransferase domain of Mce1. Binding of Mce1 to a CTD peptide
phosphorylated at position Ser5 stimulates Mce1 guanylyltransferase activity
(93). To determine whether CTD phosphorylation is required for recruitment of
Mce1 to the HIV L TR promoter, we prepared PICs containing either the
hypophosphorylated IIA or the phosphorylated 110 forms of Pol II by incubating
the PICs with or without dATP (which serves as a substrate for the TFIIH-
associated CTD kinase , but not for RNA synthesis by Pol II) (Figure 3D). The
PICs were then incubated with purified Mce1 and washed to remove unbound
protein. The PICs were released from the beads by digestion with BspEI , and
their associated polypeptides were resolved by electrophoresis through a 5%
polyacrylamide gel containing SDS. Western blotting with Pol II antibody showed
that the PICs not exposed to dA TP contained only the IIA form , whereas
inclusion of dATP elicited its conversion to the 110 form (Figure 3E). Mce1 was
associated exclusively with PICs that had undergone CTD phosphorylation in the
presence of dATP (Figure 3E). We conclude that Pol II CTD phosphorylation is
necessary for recruitment of mammalian capping enzyme to the transcription
machinery at the HIV L TR promoter.
Mce1 release from the Pol II complex during transcription elongation
requires a factor present in nuclear extract
To determine the fate of Mce1 after cap guanylylation , TECs stalled at
+22A with capped nascent transcripts were prepared and then incubated with or
without nuclear extract (Figure 4A). After washing to remove unbound proteins
the NE-treated and control TECs were chased for 10 min to the end of the
template. TECs were released by restriction enzyme digestion , and the
associated proteins were detected by immunoblotting. RNA transcript analysis
showed that the stalled A22 TECs with capped nascent RNAs had elongated to
produce an -168 nucleotide transcript (Figure 4B). Most of the Mce1 that had
been associated with the arrested A22 TECs remained bound to the transcription
complexes after elongation to the 3' end of the template (Figure 4C). However
the transient exposure of the A22 TECs to nuclear extract resulted in the release
of the majority of the Mce1 from the transcription complex (Figure 4C). We
conclude that Mce1 can dissociate from Pol II during later stages of transcription
elongation and that nuclear extract contains a factor (or factors) that stimulate
this dissociation step.
Cap methyltransferase Hcm1 associates stably with the transcription
complex and methylates the caps of nascent mRNAs
The enzyme RNA (guanine-N7) methyltransferase (referred to hereafter
as cap methyltransferase) catalyzes the transfer of a methyl group from AdoMet
to the GpppRNA terminus to produce m7GpppRNA and AdoHcy. To determine
when the cap structure of nascent HIV-1 transcripts becomes methylated , we
incubated stalled A22 TECs with purified Mce1 and (a- P)GTP so that the
nascent A22 RNA will be 5' cap labeled with 32P-GMP. After removing the
unbound protein and free (a- P)GTP by washing with transcription buffer, the
cap- labeled A22 TECs were incubated with purified human cap
methyltransferase (Hcm1) for short periods of time. After washing away the
unbound Hcm1 , the A22 TECs were walked stepwise down the template by
incubation with different sets of three NTPs. Stalled TECs were released from the
beads by restriction enzyme digestion. At this point , the released transcription
complexes were incubated in the presence of AdoMet , and the labeled RNAs
were recovered by phenol extraction and ethanol precipitation. An electrophoretic
analysis of the labeled RNAs recovered from A22 , U46 , and C61 TECs and
complexes chased to near the 3' end of the template is shown in Figure 5B. To
analyze the cap structures present on the nascent transcripts , the isolated RNAs
were digested to cap dinucleotides with nuclease S1 and then analyzed by
polyethyleneimine-cellulose thin layer chromatography, which resolves the
GpppG cap from the methylated cap m7GpppG (Figure 5C). The TLC analysis
shows that the caps found in A22 complexes that had not been exposed to
exogenous Hcm1 were exclusively unmethylated , but that transient exposure to
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Hcm1 resulted in stable binding of the cap methyltransferase to the A22 TEC
such that 25% of the caps were methylated during a subsequent incubation of
the A22 TECs with AdoMet (Figures 5C and 5D). The effciency of cap
methylation increased steadily as the elongation complex progressed down the
template , implying that (i) access of Hcm1 to the 5' GpppRNA end may increase
as more RNA is extruded from the polymerase or (ii) other protein factors that
impede such access may dissociate from the 5' end as the polymerase
elongates. By the time Pol II had approached the 3' margin of the 168 nucleotide
transcription unit, nearly 90% of the caps could be methylated by Hcm1
associated with the TEC (Figures 5C and 5D). Cap methylation by Hcm1
depended on the inclusion of AdoMet in the reaction mixture (data not shown).
The binding of Hcm1 to template-engaged Pol II was gauged by
incubating polliA PICs , polliO PICs , and TECs with HA-tagged Hcm1 , followed
by washing to remove unbound protein , release of the Pol II complexes by
restriction endonuclease digestion , and probing their protein content by Western
blotting with antibodies against Pol 1\ and the HA-tag of HA-Hcm1 (Figure 5E).
We found that the cap methyltransferase is excluded from the PIC containing Pol
IIA , but present at similar levels (relative to Pol II) in PICs containing polliO and
in TECs paused at promoter proximal (U14 , U22 , U46) and promoter distal
(+168) positions on the template. That the methyltransferase remains physically
associated with the elongating polymerase complex confirms the functional
analysis of cap methylation by TECs paused at proximal and distal template
, '
1;'
, . ; , ' '
sites. An instructive finding was that transient exposure of the U46 TECs to
nuclear extract after they had been incubated with Hcm1 did not diminish the
amount of Hcm1 present in TECs that were subsequently chased to the end of
the template (Figure 5E , lane 6). Thus , Hcm1 is not susceptible to dissociation by
the factor(s) in the nuclear extract that triggers release of Mce1 during elongation
(compare Figures 4C and 5E ).
Tat stimulates the capping of nascent HIV-1 RNA
Although our experiments show that short nascent Pol II transcripts (on
the order of 22 nucleotides) can be capped and methylated , such results reflect
the action of the mammalian capping enzymes on arrested polymerase
elongation complexes , where there is no kinetic competition between ongoing
elongation and capping. The unimpeded rate of elongation by RNA polymerases
(-20 nucleotides/s) is faster than the rate of the overall RNA capping reaction
(94). Thus , it is not clear when (or how efficiently) capping would occur during
reactions in which elongation is ongoing. To address this issue for transcription
directed by the HIV-1 L TR promoter , we analyzed the abundance of capped
RNAs via "Capture" affinity chromatography with immobilized elF4E (Figure 6A)
(54).
TECs containing internally CMP- labeled nascent RNAs were stalled at
position +14U and then incubated with purified Mce1. As shown above , Mce1
can associate with TECs at this stage , but cannot cap the nascent transcript. The
U14 TECs were then chased by the addition of 2 M concentration of all four
NTPs for 90 s. The labeled nascent RNAs were isolated and then reacted with
Hcm1 and AdoMet in order to methylate any RNAs that had been guanylylated
by Mce1 during the chase phase. The m7G-capped nascent transcripts were
isolated by elF4E affinity chromatography, and the bound material (" ) was
analyzed by denaturing PAGE in parallel with a sample of the unfractionated
input nascent RNA population (" ) and the supernatant phase containing
uncapped RNA (li ). The specificity and efficiency of this assay is demonstrated
in Figure 6B (lanes 2-6), whereby CMP labeled RNAs in A22 TECs that were
guanylylated by Mce1 (compare lanes 2 and 3 and note the mobility shift
resulting from cap guanylylation) and split into two portions , one of which was
treated with Hcm1 and AdoMet. Whereas -:5% of the unmethylated GpppRNA
was retained on the elF4E affinity column , the input Hcm1-treated RNA was
retained nearly quantitatively (95% bound) (lane 4 versus lane 6).
In contrast to the high effciency of cap guanylylation observed for arrested
TECs (nearly 100%), we found that when U14 TECs were chased for 90 s
(yielding a heterogeneous population of transcripts from -19 to 70 nucleotides 
length), only 25% of the nascent chains had 5' GpppN caps that could be
converted into m7G caps by Hcm1 and thus bind to elF4E (Figures 6B and 6C).
This result raised an important question of whether additional factors might be
required to more tightly couple capping of HIV mRNAs to early transcription
elongation.
Previously, we showed that the HIV Tat protein , which activates gene
expression from the H IV-1 L TR at the early elongation phase of the transcription
1 -
cycle , interacts directly with Mce1 in vitro and stimulates the activity of both the
RNA triphosphatase and RNA guanylyltransferase components (27). We also
found that Tat stimulated the capping of isolated HIV TAR mRNA , which is
inefficiently guanylylated by Mce1. To analyze the effect of Tat on mRNA capping
during HIV-1 transcription elongation , we loaded Mce1 on stalled U14 TECs and
included recombinant Tat during the chase phase. More than 80% of the nascent
RNAs chased in the presence of Tat were bound to the elF4E beads after
reaction with Hcm1 (Figures 6B , lane 11 , and 6C). The size distribution of the
capped RNA population was indistinguishable from that of the input RNA. Thus
Tat significantly increased the effciency of cotranscriptional capping.
Tat is composed of two major functional domains: an N-terminal
transactivation domain (amino acids 1-48) that interacts with the cyclin T1
subunit of P- TEFb , and a C-terminal domain (amino acids 49-86) that mediates
RNA binding and nuclear localization. Two truncated versions of Tat- Tat2/36
and Tat48-which are deleted for the transactivation domain and RNA binding
domain , respectively, were tested for their effects on cotranscriptional cap
formation. Tat48 did not significantly enhance cap guanylylation (29% of nascent
RNAs "captured") compared to the basal level of 25% in the absence of Tat.
However , Tat2/36 did stimulate capping to an extent of 52% (Figures 6B and
6C). We showed previously that Mce1 binds in vitro to either wild-type Tat or
I ...
Tat2/36 (but not to Tat48) and that the interactions with Tat or Tat2/36 stimulate
the Mce1 guanylyltransferase activity (27). Thus , the ability of Tat to stimulate
capping of nascent RNA during transcription elongation correlates with its
capacity to bind and activate the isolated mammalian capping enzyme.
Interaction of Tat and mammalian capping enzyme 
in vivo
Direct association of Tat and Mce1 has been demonstrated by protein-
affinity chromatography in vitro (27). To analyze the interaction of Tat and Mce1
in vivo , we contransfected human HL3T1 cells with plasm ids expressing GFP-
Mce1 and HA-Tat fusion proteins. Immune precipitates of cell Iysates were
prepared using anti-GFP antibodies and then probed by Western blotting as
shown in Figure 7. IP with anti-GFP antibody coprecipitated HA-Tat from cells
that had been transfected to produce GFP fused to either full- length Mce1 or to
the guanylyltransferase domain Mce1 (211-597), but not from cells producing
GFP alone. Similar results were obtained when the IP step was performed using
anti-Mce1 antibody (data not shown). Control immunoblots of the unfractionated
Iysates confirmed that each of the expected proteins was produced in the
transfected cells (Figure 7). We conclude that Tat can interact with mammalian
capping enzyme in vivo in mammalian cells.
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DISCUSSION
Freeze-frame analysis of cap formation and capping enzyme recruitment
during transcription by human Pol"
Here we investigated how capping and methylation of HIV pre-mRNAs is
coupled to Pol II elongation under both static and dynamic conditions. The static
or "freeze-frame" approach entails arresting RNA polymerase stepwise at
discrete template positions and then querying whether nascent chains within the
arrested TECs can be modified when purified capping enzymes are added (81).
Because the 5' end of the substrate RNA is a "sitting target" within the arrested
TECs , the freeze-frame analysis focuses on the steric constraints on access of
the 5' RNA end to the active site(s) of the various cap-forming enzymes. We
found that cotranscriptional cap guanylylation of HIV pre-mRNA occurred with
virtually 100% efficiency on nascent RNAs 22 nucleotides long, whereas RNAs
14 nucleotides long could not be capped , implying that the 5' end of the growing
RNA is accessible to the active site of Mce1 only after a critical chain length is
extruded from Pol II. RNase footprinting showed that Pol II protects a 
nucleotide RNA segment extending back from the 3' growing point of the chain.
Our findings about the timing of cap formation under static conditions agree with
earlier studies showing that: (i) 6- to 17 -mer nascent RNAs synthesized in vitro
by Pol II from the adenovirus major late promoter were uncapped (41) and (ii)
nascent RNA within TECs stalled in vivo at promoter-proximal positions on the
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Drosophila heat shock genes were capped only after attaining a minimal chain
length of 20 nucleotides (184). The efficiency of capping of Hsp70 nascent
transcripts increased within a narrow window from 50% for 20-mer RNAs to
nearly 100% for 30-mer RNAs.
To our knowledge , there have been no prior studies comparing the timing of the
cap guanylylation and guanine-N7 methylation steps during transcription
elongation. The analysis of nascent heat shock transcripts within arrested TECs
relied on removal of the cap with tobacco acid pyrophosphatase and did not
discriminate GpppRNA and m7GpppRNA caps (184). Whereas it is obvious that
guanylylation is a prerequisite for methylation , it was not clear if the two reactions
occur in rapid succession during elongation. Here we demonstrated a distinct lag
between guanylylation and methylation. Mce1 readily guanylylated the 22-
nucleotide nascent HIV RNA , but only 25% of the caps were methylated by
Hcm 1. The extent of cap methylation increased to 65% as the TEC was walked
stepwise to +46 and to 85% by the time Pol II reached -+168. Conceivably,
Hcm1 may require the extrusion of a longer 5' segment of RNA from the
polymerase than does Mce1 , or the Hcm1 may be impeded by (or compete with)
another factor that interacts with the 5' cap guanylate (Mce1 itself may be such a
competing factor).
Mce1 and Hcm1 bind stably to the TEC prior to the extrusion of the 5' end
of the nascent RNA out of the RNA polymerase. Indeed , Mce1 binding to the
TEC is unaffected by RNase digestion of any 5' RNA segment that is extruded.
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Mce1 and Hcm1 can be recruited to the Pol II complex even prior to the initiation
of chain elongation , provided that CTD phosphorylation has already occurred.
Neither Mce1 nor Hcm1 binds to PICs containing Pol liA. Thus CTD
phosphorylation is required (and perhaps sufficient) for recruitment of both
components of the mammalian capping apparatus.
A key finding is that both Mce1 and Hcm1 remain bound to the Pol II TEC
even after the cap guanylylation and N7 methylation reactions have been
executed. Transient exposure of TECs to nuclear extract stimulated the
dissociation of Mce1 from the TEC during a subsequent chase down the
template , but Hcm1 was refractory to dissociation by nuclear extract and traveled
with the TEC to the end of the template (near +168). We infer the existence of
factor(s) in the extract that trigger the release and recycling of Mce1 after it
modifies the 5' RNA end. Our findings concerning the dynamic association of
mammalian capping enzymes with the TEC in a reconstituted in vitro
elongation/processing system echo recent in vivo findings in S. cere visiae , where
physical association of the triphosphatase and guanylyltransferase enzymes with
actively transcribed genes is maximal at the 5' end of the transcription unit and
decays incrementally toward the 3' end of the gene whereas the cap
methyltransferase remains on the template DNA across the full length of the
gene (128 , 199). Our in vitro experiments show that dissociation of the
guanylyltransferase is an active process that depends on a factor extrinsic to the
TEC. Candidates for such a role include: (i) phosphatases and kinases that
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remodel the CTD phosphorylation array and thereby affect CTD interaction with
Mce1 (29 , 88 , 93) or (ii) factors that interact with Mce1 and regulate its affinity for
the CTD. Although it remains unclear why the cap methyltransferase would travel
with the yeast and human Pol II TECs after the cap is methylated, it is worth
considering that this enzyme might play additional roles in transcription or mRNA
maturation.
Cap formation during continuous Poll! elongation
The freeze-frame view of capping enlightens us with respect to the earliest
step at which capping enzymes can associate with template-engaged Pol II and
the window in elongation during which the 5' modifications can first be executed
by mammalian capping enzymes. But this analysis does not address whether
capping actually occurs at these early stages when Pol II elongation is ongoing
or whether cotranscriptional capping is subject to regulation by trans-acting
factors. The present study provides answers to both of these key questions.
The timing of cap guanylylation under dynamic transcription conditions is
determined by a kinetic balance between the rate of Mce1 binding to the TEC
the rates of the serial triphosphatase and guanylyltransferase reactions , the rate
of polymerase movement , and the rate of premature dissociation of Mce1 from
the TEC. Our experimental strategy entailed preloading Mce1 on TECs prior to
extrusion of the 5' end and then gauging the overall efficiency of guanylylation
during a brief chase in the presence of all four NTPs. Because we showed that
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Mce1 remains bound and travels with the TEC under these reaction conditions
the experiment focuses exclusively on the kinetic balance between cap formation
and polymerase movement. The instructive finding was that capping of nascent
HIV transcripts under dynamic conditions was much less efficient (25% overall)
than capping in the context of an arrested Pol II TEC (nearly 100%).
The inherently low efficiency of cotranscriptional capping of nascent H 
mRNA under dynamic conditions provides a rationale for the elongation
checkpoint that regulates HIV gene expression. We hypothesize that
DSIF/NELF-induced arrest of Pol II at promoter-proximal sites on the HIV
transcription unit expands the kinetic window during which Mce1 can bind to the
TEC and catalyze cap guanylylation (in essence providing a "sitting target" for
the capping enzyme so that short nascent chains can be more efficiently
capped). The cap promotes downstream mRNA processing steps , especially the
splicing of the 5' proximal intron , and it protects mRNA from exonucleolytic
decay. If Pol II commits prematurely to traversing the entire transcription unit
without the benefit of a cap, it runs a risk of failing to excise the first intron in a
timely fashion , or perhaps at all , a process that would yield a nonfunctional or
misfunctional transcript. Accelerated 5' to 3' decay of unguanylated nascent
RNAs would also result in a wasteful round of transcription.
Tat stimulates cotranscriptional capping of HIV mRNA
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Our earlier findings that Tat binds directly to Mce1 in vitro and stimulates
its triphosphatase and guanylyltransferase activity raised the prospect that Tat
may regulate cap formation during HIV transcription. Here we showed that
recombinant Tat protein stimulates cotranscriptional cap guanylylation during
ongoing Pol II elongation. Whereas only 25% of the nascent HIV mRNAs were
capped during a chase in the absence of Tat , more than 80% were guanylylated
in the presence of Tat. Thus , our results provide an instance in which the
efficiency of cotranscriptional capping is demonstrated to be regulated by a 
trans-
acting factor.
A highly instructive point about the Tat-mediated stimulation of HIV RNA
guanylylation is that it applies to nascent RNAs ranging from 19 to 70 nucleotides
in length (Figure 6). The majority of the transcripts whose capping is enhanced
by Tat are shorter than the 45 nucleotides of nascent 5' RNA that would be
required to form the minimal TAR secondary structure. Thus , we conclude that
the salutary effect of Tat on cotranscriptional capping precedes , and 
independent of, its interaction with TAR. The C-terminal domain of Tat that
suffices for binding and stimulation of isolated Mce1 and for stimulation of
cotranscriptional capping includes the segment required for Tat binding to TAR.
Thus , it is sensible that Tat stimulation of capping is temporally unlinked from
TAR binding, given the likelihood that the two binding events (to Mce1 or TAR)
are mutually exclusive for a given molecule of Tat protein. A second key point
about the Tat effect on capping is that it occurs on TECs that have already been
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loaded with Mce1 , Le. , the effect is directly on cap formation rather than on the
recruitment of Mce1 to the TECs.
Because Tat binds directly to Mce1 in solution , it is conceivable that Tat
T--. joins the TEC at a stage prior to TAR formation , using Mce1 as a bridge.
Alternatively, Tat may interact with the TEC via a parallel pathway that is
independent of Mce1. By applying the freeze-frame approach to gauge the
association of Tat with Poll! TECs on the HIV transcription unit, we have found
that Tat is not present in PICs , but is present in U14 TECs formed in the absence
of Mce1 (274). Thus , Tat requires neither TAR nor capping enzyme to bind to the
Pol II complex. Nonetheless , it is likely that the functional status of Tat and its
macromolecular interactions are subject to change as Mce1 and TAR are
elaborated as components of the TEC.
A revised view of Tat function in HIV transcription
A dominant paradigm for Tat upregulation of HIV gene expression at the
level of transcription elongation revolves around the ability of the Tat-TAR
complex to bind P- TEFb , stimulate its phosphorylation of the CTD and Spt5 , and
thereby override the elongation arrest elicited by DSIF and NELF. Here we show
that Tat plays a TAR- independent role in stimulating cotranscriptional capping of
nascent HIV mRNAs. This function rationalizes elongation arrest and restart as a
means to ensure a temporal window for efficient cap formation. In this revised
regulatory axis , Tat elicits a stimulation of capping (in concert perhaps with Spt5
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and CTD-P04) and triggers the release from elongation arrest in concert with P-
TEFb.
;",
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Figure 1. Mammalian capping enzyme is not a component of PICs but can
associate with TECs on the HIV- 1 transcription unit. (A) RNA sequence of the
early transcribed region (+1 to +70) in the HIV-1 promoter. TAR RNA secondary
j .
structure and various positions of transcription arrest are shown. (B) PICs were
prepared by incubating an immobilized DNA template containing the HIV- 1 L TR
promoter with HeLa nuclear extract. TECs were formed by stepwise transcription.
PICs and stalled TECs were incubated with purified Mce1; then , unbound
proteins were removed by washing with buffer. To isolate PICs , DNA was
cleaved at the indicated BspE1 restriction site. For isolating TECs , RNA Pol II
complexes were released from the beads by cleavage at the indicated Pvull
restriction site. (C) Protein contents of PICs (lanes 2 and 3) or TECs stalled at
U14 (lanes 4 and 5) and C30 (lanes 6 and 7) were resolved by SDS-PAGE
followed by immunoblottng with antibodies against RNA Pol II and Mce1.
Complexes were isolated without (lanes 2 , 4 , and 6) and with Mce1
supplementation (lanes 3 , 5 and 7). Lane 1 contains 10% of the nuclear extract
used in the PIC assembly reaction.
109
G G
30-C
22 - A 
C G
C G
A U -4614-UA
U A
G U
U A
C G
U G
CU A
- G CACUGCUUAAGC 
...... . 
GUGUGG61 168
145
BspE1
Stepwise Transcription
. -
+ Mce1
RE Digestion
PIC U14 C30
Mce1
Poll!
Mce1
110
Figure 2. HIV-1 mRNA capping during transcription elongation. (A) 32
CMP- Iabeled TECs stalled at different positions on the template were prepared
by stepwise transcription and then incubated with or without Mce1. After
removing the unbound Mce1 by washing with transcription buffer , the TECs were
incubated with or without 50 M GTP in reaction mixtures (20 
I) containing 50
mM Tris-HCI , pH 8. , 5 mM DTT , and 2. 5 mM MgCh. (B) PAGE analysis of
radiolabeled RNAs isolated from U14 (lanes 1-4), A22 (lanes 5-8), C30 (lanes
12), or U46 (lanes 13-16) TECs after reaction with Mce1 and GTP as
indicated above the lanes. Capped and uncapped species are indicated by
arrows. Lane M contains radiolabeled 18- , 33- , and 43-mer DNA oligonucleotide
size markers. (C and D) Stalled 32P-CMP- labeled U14 TECs were incubated
with (lane 2) or without Mce1 (lane 1), washed , and then walked to +30C (lanes 3
and 4). Labeled RNAs recovered from the U14 , and C30 TECs were analyzed by
PAGE.
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Figure 3. Mce1 binding to Pol II transcription complexes requires CTD
phosphorylation but does not require nascent RNA. (A) Stalled A22 TECs
were treated with 1 0 g of RNase A for 5 min at 30 C to digest the extruded 5'
end of the RNA (A22' ) and then walked to position +26G (G26'). (8) PAGE
analysis of radiolabeled RNAs isolated from TECs at U14 (lanes 1 and 2), at A22
before (lanes 3 and 4) and after (lanes 7 and 8) RNase A treatment , and after
walking from +22A to +26G without (lanes 5 and 6) or after (lanes 9 and 10)
RNase treatment. The A22 and A22' TECs had been incubated with or without
Mce1 prior to walking to +26G as indicated above the lanes. (C) A22 and A22'
(RNase treated) TECs that were incubated with or without Mce1 were isolated
and probed by Western blottng for Pol II and Mce1. PICs were analyzed in
parallel as controls (lanes 1 and 2). (D) PICs were prepared as described in
Figure 1. Incubation of the PICs with dATP converted Pollia to Pollio by the
action of the TFIIH-associated CTD kinase. (E) PICs that had been incubated
with or without Mce1 were released by BspE1 digestion and the protein contents
were resolved by 5% SDS-PAGE and probed by Western blotting for the Pol 
largest subunit and Mce1.
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Figure 4. Dissociation of Mce1 from the transcription complex during
elongation is stimulated by a factor in nuclear extract. (A) Stalled A22 TECs
were incubated for 10 min in a capping reaction mixture containing 20 pmol of
Mce1 , 50 J.M GTP , 50 mM Tris-HCI , pH 8. , 5 mM DTT , and 2. 5 mM MgCI2.
After washing to remove Mce1 and GTP , the TECs were incubated with or
without nuclear extract (NE; 20 J.1). After removing the unbound proteins by
washing with transcription buffer, all four NTPs were added to chase the TECs to
the +168 position. (B) PAGE analysis of radiolabeled RNAs isolated from the A22
TECs and TECs chased to the end of the template after exposure to Mce1 and
nuclear extract as indicated. (C) The presence of Poll! and Mce1 in the A22 and
chased TECs was probed by Western blotting. PICs were analyzed in parallel as
controls.
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Figure 5. Hcm1 associates with transcription elongation complexes and
methylates the 5' Cap of nascent RNAs. (A) Stalled A22 TECs were 5' P-cap
labeled by Mce1 , washed , and then incubated with Hcm1. After washing to
remove unbound Hcm1 , TECs were walked to distal template positions , released
from the beads , and then incubated in methylation reaction mixtures containing
50 mM Tris-HCI (pH 8. 0), 5 mM DTT , and 50 I-M AdoMet. (B) Radiolabeled
RNAs isolated from the stalled TECs were analyzed by PAGE. (C) The cap
structures of the RNAs isolated from the indicated TECs were analyzed by 
nuclease digestion followed by polyethyleneimine-cellulose TLC (lanes 5-9). The
chromatographic origin (lane 2) and the positions of e PIGTP (lane 1) and 32
labeled cap dinucleotide GpppG (lane 3) or m7GpppG (lane 4) markers prepared
by in vitro guanylylation and methylation of isolated 17 -mer RNA using Mce1 and
Hcm1 are indicated on the left. (D) The extent of cap methylation of the nascent
cap- labeled RNAs by the indicated TECs was quantitated by scanning the TLC
plate with a phosphorimager. (E) PICs (lanes 1 and 2) and stalled U 14 TECs
(lane 3) were incubated with 20 pmol of HA-tagged Hcm1 for 10 min at 30
The U14 TECs were walked to A22 (lane 4) or U46 (lane 5). Nuclear extract was
added to TECs stalled at U46 , washed to remove unbound proteins , and the
TECs were chased to +168 (lane 6). The presence of Pol II and HA-Hcm1 in the
PICs and TECs was probed by Western blotting.
.. + Hcm1
.. Stepwise transcription
.. RE Cleavage
.. 
AdoMet
CD .. 
C' .. CD 0
C( :: 0
1 2 3 4
168
117
Tecs
. 32p cap N N
abeled RNACJ 
+ . + + + + 
Hcm1
- + + 
(Q 
.. CD 
GpppG--
origin
GpppG
100
g 60
i 40
A22(-) A22 C30 U46 168
Stalled TECs
a: 
Poll!
HA-Hcm1
118
Figure 6. Tat stimulates cotranscriptional capping by Mce1. (A) Nascent
RNAs were labeled internally with CMP during stepwise transcription. TECs
stalled at U14 were incubated with Mce1. After washing to removing unbound
Mce1 , TECs were chased for 90s in the absence or presence of the Tat proteins
(10 pmol) as indicated above the lanes in (B). RNAs isolated from TECs were
incubated with Hcm1 as described in Figure 5. m7G-capped RNAs were isolated
by elF4E affinity chromatography. (B) PAGE analysis of the input RNA (I), the
RNAs bound by the G8T-eIF4E fusion proteins (B), and the uncapped RNAs in
the supernatant phase (8). To evaluate the specificity and efficiency of the
capture assay, G-capped transcripts were isolated from stalled A22 TECs treated
with Mce1 and analyzed by elF4E affinity chromatography (lanes 3 and 4) in
parallel with m7G-capped transcripts isolated from stalled A22 TECs treated with
Mce1 and Hcm1 plus AdoMet (lanes 5 and 6). Other samples are as follows:
transcripts isolated from stalled U14 and A22 TECs (lanes 1 and 2); transcripts
isolated from U14 TECs after a chase with 4 NTPs in the absence (lanes 7-9) or
presence of Tat (lanes 10-12), Tat2/36 (lanes 13-15), or Tat48 (lanes 16-18).
(C) The percent of the input RNA sample that bound to elF4E was quantitated by
scanning the gel in (B) with a phosphorimager.
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Figure 7. Interaction of Tat and Mce1 in vivo. HL3T1 cells were transfected
with plasmids expressing HA-Tat and either GFP or the indicated GFP-Mce1
fusion proteins. Cells were lysed with RIPA buffer at 48 hr posttransfection. (I)
The cell Iysates were immunoprecipitated (IP) with anti-GFP antibody, the
precipitates were analyzed by SDS-PAGE , and the gel contents were probed by
Western blotting (WB) with anti-HA antibody. (II-IV) Unfractionated lysate (60 -
of protein) was resolved by SDS-PAGE and probed by Western blotting using
antibodies against HA (II), Mce1 (III), and GFP (IV). The identities of the
immunoreactive polypeptides are indicated by arrowheads on the right. The
asterisk (*) in (III) indicates the endogenous untagged Mce1 polypeptide.
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CHAPTER IV
HUMAN TRANSCRIPTION ELONGATION FACTOR
J _
(CDK9/CYCLINT1): A NEW THERAPEUTIC TARGET FOR
AIDS AND CANCER?
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ABSTRACT
Regulation of mRNA transcription plays a central role in mammalian cell
growth and development. A large number of genes in human and other
eukaryotic cells , as well as their viruses , are specifically regulated at the level of
transcription elongation. P-TEFb , a positive elongation factor composed of two
subunits , CDK9 and Cyclin T1 (CycT1), allows the transition to productive
elongation , producing longer mRNAs. Replication of human immunodeficiency
virus type 1 (HIV- 1) requires Tat protein , which activates elongation of RNA
polymerase II transcription at the HIV-1 promoter by interacting with human
CycT1 (hCycT1). The trans-activation domain of Tat binds directly to the hCycT1
subunit of P- TEFb and induces loop sequence-specific binding of P- TEFb onto
nascent HIV-1 trans-activation responsive (TAR) RNA. Using RNA interference
to specifically degrade mRNA for hCycT1 or CDK9 , we show here that down
regulation of P- TEFb expression in HeLa cells achieved without causing major
toxic or lethal effects and can control Tat transactivation and HIV replication in
host cells. In addition , we have used high-density oligonucleotide arrays to
determine the effect of P-TEFb knockdown on global gene expression. Of 44 928
human genes analyzed , 25 were down-regulated and known or likely to be
involved in controllng and mediating cell proliferation and differentiation. Our
results provide new insight into P- TEFb function , its potent role in early
embryonic development and strong evidence that P- TEFb is a new target for
developing AIDS and cancer therapies.
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INTRODUCTION
Regulation of mRNA transcription plays a central role in mammalian cell
growth and development. A large number of genes in human and other
eukaryotic cells , as well as their viruses , are specifically regulated at the level of
transcription elongation. Among these genes are several protooncogenes (c-
myc, c-myb, c-fos) , the gene for adenosine deaminase , a collection of stress
response genes , and HIV-1 and HIV-2. During elongation , RNA polymerase II
(RNA pol II) can pause , get arrested , pass through terminator sequences , or
terminate transcription. Recent studies have uncovered that shortly after
initiation , RNA pol II faces a barrier of negative transcription elongation factors
(N-TEF) and enters abortive elongation (181). Positive transcription elongation
factors (P-TEF) lower the barrier of N-TEF and help RNA pol II escape from this
transition phase , which could lead to premature termination of transcription (181).
A positive elongation factor, P-TEFb , which is composed of two subunits (CDK9
and Cyclin T1 (71)) allows the transition to productive elongation , producing
longer mRNA transcripts (181).
One elegant example of transcription elongation control is the mechanism
of HIV-1 gene expression (reviewed in 43 , 108 , 233). HIV-1 encodes a small
regulatory protein , Tat, which is required for efficient transcription of viral genes.
Tat enhances the processivity of RNA pol II elongation complexes that initiate in
the HIV long terminal repeat (L TR) region. Tat activates transcription by binding
....
to a highly structured RNA element, trans-activation responsive (TAR) RNA
/ 1
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which is located at the 5' -end of nascent viral transcripts (183). Tat functions
through TAR RNA to control an early transcription elongation step that is
sensitive to protein kinase inhibitors and requires the carboxyl-terminal domain
(CTD) of the large subunit of RNA pol II (108). Tat interacts with the human
Cyclin T1 (hCycT1) subunit of P-TEFb and recruits the kinase complex to the pol
II elongation complex (43 , 181 233 252).
Recruitment of P-TEFb to TAR RNA has been proposed to be both
necessary and sufficient to activate transcription elongation from the HIV- 1 L TR
promoter (16). Neither hCycT1 nor the P-TEFb complex bind TAR RNA in the
absence of Tat, indicating that binding to RNA is highly co operative for both Tat
and P-TEFb (70 , 252). Tat appears to contact residues in the carboxy-terminal
boundary of hCycT1 ' s cyclin domain that are not critical for binding of hCycT1 to
CDK9 (16 , 68 , 71 , 104 , 255 , 276). Mutagenesis studies have shown that the
hCycT1 sequence containing amino acids 1-272 is sufficient to form complexes
with Tat-TAR , CDK9 , and to activate transcription by Tat (16 , 104 255
276). Human Cyclin T1 residues 250-262 represent the Tat-TAR RNA
recognition motif (TRM)(71). TRM is required but not sufficient to form the
hCycT1-Tat-TAR RNA ternary complex. N-terminal residues in the cyclin box are
also necessary. We have recently identified the sequence and structural
determinants for high affinity hCycT1-Tat-TAR RNA ternary complex formation
(188). Our results show that hCycT1 and Tat binding to TAR RNA is highly
cooperative , with a capacity of 85% , Hill coefficient of 2.7 and a dissociation
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constant (Ko) of 2.45 nM (188). In another study, we showed that residues 252-
260 of hCycT1 interact with one side of the TAR RNA loop and enhance
interaction of Tat residue K50 with the other side of the loop (189). Our results
show that TAR RNA provides a scaffold for two protein partners to bind and
assemble a regulatory switch in HIV replication.
The pol II CTD, Spt5 and Tat are intimately connected to the regulation of HIV
gene expression. Human Spt5 and its binding partner hSpt4 comprise the
transcription elongation regulatory factor DSIF (DRB sensitivity inducing
factor)(242). DSIF binds to pol II and , in concert with NELF (negative elongation
factor), represses elongation at promoter-proximal positions in the transcription
unit (186 , 261). Escape from the repressive effect of DSIF/NELF requires the
action of P-TEFb , a DRB-sensitive protein kinase that phosphorylates both the
pol II CTD and the Spt5 subunit of DSIF (103 123 178 243). In previous studies
we have analyzed the in vitro interactions of the CDK9 and hCycT1 subunits of
TEFb and the HIV Tat protein with pol II at discrete functional stages of
transcription from the HIV- 1 L TR promoter. We found that P-TEFb is a
component of the pol II preinitiation complex (PIC) and that it travels with the
transcription elongation complex (TEC) as it moves along the HIV transcription
unit unit (179). In contrast , DSIF and NELF are not present in the PIC , but
associate with the TEC at promoter proximal positions and then travel with the
TECs down the template (178). Our current model for understanding HIV-1 gene
regulation is depicted in Figure 1A.
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To understand the cellular functions of P-TEFb and to test the notion that
HIV infectivity can be modulated by targeting host proteins such as P-TEFb
without causing major toxic or lethal effects , we used RNA interference (RNAi) to
specifically degrade mRNA for hCycT1 or CDK9. RNAi is a remarkably efficient
process whereby double-stranded RNA (dsRNA) induces the sequence-specific
degradation of homologous mRNA in animals and plant cells (99 , 206). In
mammalian cells , RNAi can be triggered by 21-nucleotide (nt) duplexes of small
interfering RNA (siRNA)(28 , 55). Our results show that specific down-regulation
of P- TEFb expression in human cells can be achieved without causing major
toxic or lethal effects and can be used to control Tat transactivation and HIV
replication in host cells. To determine the effect of P-TEFb knockdown on global
gene expression , we used high-density oligonucleotide arrays to analyze the
expression of 44 928 human genes. We observed down-regulation of genes that
are known or likely to be involved in controlling and mediating cell proliferation
and differentiation. The data presented in this chapter provide new insight into P-
TEFb function and its role in early embryonic development and offer strong
evidence that P- TEFb is a new target for developing AIDS and cancer therapies.
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MATERIALS AND METHODS
siRNA preparation. 21-nt ds RNAs were chemically synthesized as 2'
bis(acetoxyethoxy)-methyl ether-protected oligos by Dharmacon (Lafayette , CO).
Synthetic oligonucleotides were deprotected , annealed and purified according to
the manufacturer s recommendation. Successful duplex formation was confirmed
by 20% non-denaturing polyacrylamide gel electrophoresis (PAGE). All siRNAs
were stored in DEPC (0. 1 % diethyl pyrocarbonate)-treated water at -
Sequences of siRNA duplexes were designed according to the manufacturer
recommendation and subjected to a BLAST search against the NCBI EST library
to ensure that they targeted only the desired genes. siRNA sequences used in
our experiments were: hCycT1 ds (5' UCCCUUCCUGAUACUAGAAdTdT-
hCycT1 mm (5' UCCCUUCCGUAUACUAGAAdTdT-
CDK9 ds (5' CCAAGCUUCCCCCUAUAAdTdT-
CDK9 mm (5' CCAAGCU CCCCUAUAAdTdT-
CDK7 ds (5' UUGGUCUCCUUGAUGCUUUdTdT-
Tat ds (5' GAACGUAGACAGCGCAGAdTdT-
GFP ds (5' GCAGCACGACUUCUUCAAGdTdT- ); and
RFP ds (5' GUGGGAGCGCGUGAUGAACdTdT-
Underlined residues represent the mismatched sequence to their targets.
Culture and transfection of cells. HeLa cells were maintained at 37 C in
Dulbecco s modified Eagle s medium (DMEM , Invitrogen) supplemented with
10% fetal bovine serum (FBS), 100 unitlml penicillin and 100 J.g/ml streptomycin
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(Invitrogen). Magi ( ultinucleate g,ctivation of galactosidase indicator) cells
harboring the endogenous HIV L TR- gal gene were maintained at 37 C in
DMEM , supplemented with 10% FBS , 0.2 mg/ml Geneticin (G418) and 0. 1 mg/ml
hygromycin B (Roche Molecular Biochemicals). Cells were regularly passaged at
sub-confluence and plated at 70% confluency 16 h before transfection.
Lipofectamine (Invitrogen)-mediated transient cotransfections of reporter
plasm ids and siRNAs were performed in duplicate 6-well plates (Falcon) as
described by the manufacturer for adherent cell lines. A standard transfection
mixture containing 100 nM siRNA and 1 0 llipofectamine in 1 ml serum-reduced
OPTI-MEM (Invitrogen) was added to each well. Cells were incubated in
transfection mixture for 6 h and further cultured in antibiotic-free DMEM. For
Western blot analysis at various time intervals , the transfected cells were washed
twice with phosphate buffered saline (PBS , Invitrogen), flash frozen in liquid
nitrogen , and stored at - C for analysis. For in vivo assays of Tat-mediated
transactivation at 48 h post transfection , Magi cells were subjected to gal
staining directly or flash frozen in liquid nitrogen and stored at - C for 
galactosidase assay as described below.
Western blotting. Cells treated with siRNA were harvested as described
above and lysed in ice-cold reporter lysis buffer (Promega) containing protease
inhibitor (complete, EDTA-free, 1 tablet/10 ml buffer, Roche Molecular
Biochemicals). After clearing the resulting Iysates by centrifugation , protein in
clear Iysates was quantified by Dc protein assay kit (Bio- Rad). Proteins in 60 
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of total cell lysate were resolved by 10% SDS-PAGE , transferred onto a
polyvinylidene difluoride membrane (PVDF , Bio-Rad), and immuno-blotted withJ;:
antibodies against hCycT1 and CDK9 (Santa Cruz). Protein content was
visualized with a BM Chemiluminescence Blotting Kit (Roche Molecular
Biochemicals). The blots were exposed to x-ray film (Kodak MR-1) for various
times (30 s to 5 min).
RT-PCR for amplification of hCycT1 and CDK9 mRNA. Total cellular
mRNA was prepared from HeLa cells with or without hCycT1/CDK9 siRNA
treatment using a Qiagen RNA mini kit , followed by an oligotex mRNA mini kit
(Qiagen). RT-PCR was performed using a SuperScript One-Step RT-PCR kit
with platinum Taq (Invitrogen) and 40 cycles of amplification. Each RT-PCR
reaction included 100 ng total cellular mRNA , gene-specific primer sets for
hCycT1 and CDK9 amplification (0.5 J-M for each primer), 200 J-M dNTP , 1.2 mM
MgS04 and 1 U of RT/platinum Taq mix. Primer sets for hCycT1 produced 2178
bp products , while CDK9 primer sets produced 1116 bp products. RT -PCR
products were resolved in 1 % agarose gel and viewed by ethidium bromide
staining.
Plasm ids harboring the HIV- 1 Tat sequence. pTat-RFP plasmids were
constructed by fusing the DNA sequence of HIV-1 Tat with DNA sequences of
DsRed1- , harboring coral (Oiscosoma spp. derived red fluorescent protein
(RFP), per the manufacturer s recommendation (Clontech). Cytomegalovirus
promoter control drove the expression of Tat-RFP fusion proteins , which were
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easily visualized in living cells by fluorescence microscopy (Zeiss). Expression 
Tat-RFP fusion proteins was also quantified by directly exciting the RPF
fluorophore in clear ceillysates and measuring fluorescence , as described below.
galactosidase staining of cells. Magi cells were transfected with Tat-
containing plasmids in the absence or presence of siRNAs. At 48h post
transfection , cells were washed twice with PBS and fixed 5 min in fixative (1 %
formaldehyde and 0.2% glutaraldehyde in PBS) at room temperature. After
washing twice with PBS , cells were covered with staining solution (PBS
containing 4 mM potassium ferrocyanide , 4mM potassium ferricyanide , 2 mM
MgCb and 0.4 mg/ml X-gal (PromegaD and incubated at 37 C for exactly 50 min.
Plates were washed twice with PBS. Cell counts represent number of gal
positive (blue) cells per 1 OO-power field.
Galactosidase enzyme assay. Magi cells were transfected with Tat-
containing plasmids in the absence or presence of siRNAs. At 48 h post
transfection , cells were harvested and clear cell Iysates were prepared and
quantified as described above. Total cell lysate (120 f.g) in reporter lysis buffer
(150 f.1) was subjected to standard galactosidase assay by adding 150 f.1 2X 
galactosidase assay buffer (Promega) and incubating at 37 C for 30 min. The
reactions were stopped by adding 500 f.1 1 M sodium carbonate and briefly
vortexing. Absorbance was read immediately at 420nm. The same amount of cell
lysate was subjected to fluorescence measurements on a PTI (Photon
Technology International) fluorescence spectrophotometer, with slit widths set at
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4 nm for both excitation and emission wavelengths. All experiments were carried
out at room temperature. Fluorescence of Tat-RFP in the cell lysate was
detected by exciting at 568 nm and recording the emission spectrum from 588
nm to 650 nm; the spectrum peak at 583 nm represents the maximum
fluorescence intensity of Tat-RFP. Tat transactivation was determined by
calculating the ratio of galactosidase activity (absorbance at 420 nm) of the
pTat-RFP transfected cells to that of cells without pTat-RFP plasmid treatment.
The inhibitory effect of siRNA treatment was determined by normalizing Tat-
transactivation activity to the amount of Tat-RFP protein (represented by RFP
fluorescence intensity) in the presence and absence of siRNA.
In vivo fluorescence analysis. pEGFP-C1 reporter plasmids (1 /lg) and
siRNA (100 nM) were cotransfected into HeLa cells by lipofectamine as
described above , except that cells were cultured on 35 mm plates with glass
bottoms (MatTek Corporation , Ashland MA) instead of standard 6-well plates.
Fluorescence in living cells was visualized 50 h post transfection by conventional
fluorescence microscopy (Zeiss). For GFP fluorescence detection , FITC filter
was used.
GeneChipCI experiments. HeLa cells were transfected with
hCycT1/CDK9 ds siRNA. For comparison , cells treated with non related ds siRNA
(RFP ds) were used as control. At 48 h post transcription , total cellular mRNA
was prepared from HeLa cells with or without hCycT1/CDK9 ds siRNA treatment
using a Qiagen RNA mini kit followed by oligotex mRNA mini kit. Double-
-- ---_. -_.
133
stranded cDNAs were synthesized from 2 f.g total mRNA using the Superscript
Choice System for cDNA synthesis (Invitrogen) with the T7-(dT)24 primer
following the manufacturer s recommendations. cDNAs were cleaned up by
-r. phase lock gel (PLG) (Brinkman Instrument)-phenollchloroform extraction and
concentrated by ethanol precipitation. Biotin- labeled cRNA was synthesized from
cDNA by in vitro transcription using the Bioarray HighYield RNA transcript
Labeling Kit (Affmetrix) following vendor s recommendation. In vitro transcription
products were cleaned up using RNeasy spin columns (Qiagen) and fragmented
into 35-200 base units by metal- induced hydrolysis in fragmentation buffer
(40mM Tris-acetate , pH 8. , 100mM KOAc , 30mM MgOAc). Fragmented cRNA
was then subjected to Affymetrix Human Genome U133A and U133B
GeneChipCI sets in hybridization buffer (100mM MES , 1M NaCI , 20mM EDTA
01 % Tween-20). All hybridization , washing, staining and scanning procedures
were performed in the UMASS Medical School Genomics Core Facility following
the manufacturer s protocols. GeneChipCI images were analyzed with Affymetrix
Microarray Suite V5. 0 and Affmetrix Data Mining Tool V3.0. The HG-U133
GeneChipCI includes HG-133A and HG-133B sets of arrays containing 22 283
and 22 645 genes , respectively. Each gene was represented by a probe set
containing 11 probe pairs. 100 human maintenance genes on both arrays serve
as a tool to normalize and scale the data prior to making comparisons. Signal
intensities of all probe sets were scaled to a target value of 150. Results of
Detection Call , Change Call and Signal Log Ratio were obtained by applying the
Ii:.
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default parameters to statistical algorithms for both absolute and comparison
analyses. For comparison analysis , data from cells treated with nonrelated ds
siRNA (RFP ds) were used as baseline array. Each probe pair in a probe set is
. .
considered as having a potential vote in determining whether the measured
transcript is detected (Present) or not detected (Absent). The Detection algorithm
uses probe pair intensities to generate a Detection p-value and assign a Present
Marginal or Absent call. Only probe pairs in the baseline array assigned a
Present call were considered for further analysis. The comparison analysis
compares the difference values of each probe pair in the baseline array to its
matching probe pair on the experiment array. A Change p-value is calculated
indicating an increase , decrease or no change in gene expression. The Signal
Log Ratio (base on 2) estimates the magnitude and direction of change of a
transcript when two arrays are compared. Log ratio larger than 1 indicating more
than 2 fold up-regulation while log ratio smaller than 1 indicating more than 2 fold
down-regulation.
Magi infectivity assay. HeLa-CD4- TR/ gal indicator (Magi) cells (124)
were plated in 24-well plates (7. 5x10 cells per well) and transfected with siRNAs
as previously described (105). siRNA (60 pmol) was transfected into cells using
oligofectamine (2\.1 , Invitrogen) for 3 h in serum-free DMEM (GIBCO). Cells were
rinsed twice and top- layered in 500 \.I of DMEM-10% FBS. Sixteen hours after
transfection , cells were trypsinized and seeded in 96-well microtiter plates (4x10
: . c
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cells per well), incubated 3 h and infected. HIV-1 virions (normalized to RT
activity in cpm) were added in doubling dilutions to duplicate wells. Thirty-six
hours post infection , cells were harvested to quantify galactosidase activity.
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RESULTS AND DISCUSSION
Specific knockdown of P- TEFb expression by siRNA in HeLa cells
We used RNAi to inhibit hCycT1 and CDK9 expression in cultured human
(HeLa) cell lines. The short interfering RNA (siRNA) sequence targeting hCycT1
was from position 351 to 371 relative to the start codon , and the CDK9 siRNA
sequence was from position 258 to 278 relative to the start codon. Using
lipofectamine , we transfected HeLa cells with hCycT1 or CDK9 siRNA duplex
targeting either hCycT1 or CDK9. To analyze RNAi effects , we prepared Iysates
from siRNA duplex-treated cells at various times after transfection. Western blot
experiments were carried out (Figure 1 B) using anti-hCycT1 and anti-CDK9
antibodies. Analysis of immunoblotting experiments reveals that the siRNA
targeting hCycT1 inhibited hCycT1 expression (Figure 1 B , lanes 8- , upper
panel). siRNA targeting CDK9 was similarly specific against CDK9 expression
(Figure 1 B , lanes 15- , lower panel). This RNAi effect depended on the
presence of a 21-nt duplex siRNA harboring a sequence complementary to the
target mRNA, but not on the antisense strand siRNA (data not shown) nor on an
irrelevant control siRNA, which targeted a coral 
(Oiscosoma spp. derived red
fluorescent protein (RFP) (Figure 1B , lanes 1-7). As a specificity control , cells
were also transfected with mutant siRNAs (mismatched siRNA) of hCycT1 or
CDK9 , which have two nucleotide mismatches between the target mRNA and the
antisense strand of siRNA at the putative cleavage site of the mRNA. Mutant
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siRNAs showed no interference activity (Figure 1 B , lanes 22-28 and 29-35),
indicating the specificity of the RNAi effect.
Kinetics of P- TEFb mRNA interference in HeLa cells
RNA interference is a highly efficient process because a few dsRNA
molecules are sufficient to inactivate a continuously transcribed target mRNA for
long periods of time. Experiments have shown in plants and worms (38 , 47 , 78)
that this inactivation can spread throughout the organism and is often heritable to
the next generation. Mutations in genes encoding proteins related to RNA-
dependent RNA polymerase (RdRP) affect RNAi-type processes in Neurospora
Caenorhabdits elegans and plants (38 , 47 , 136 , 160 217), and the involvement
of RdRP in amplifying RNAi has been postulated (136).
Western blot experiments (Figure 1 B) using anti-hCycT1 and anti-CDK9
antibodies also revealed the kinetics of gene suppression and persistence of
. I
RNAi in HeLa cells. Although RNAi can suppress expression of hCycT1 and
CDK9 proteins up to 66 h post transfection , maximum activities were observed at
42-54 h , and inhibition by siRNAs did not persist. After reaching maximal activity
at 42-54 h post transfection , RNA interference started to decrease at 54 h , with
protein amount showing gradual recovery to normal levels between 66 to 90 h (3
to 4 days) post transfection (Figure 2). Similar phenomena were demonstrated in
293T cells , a human T lymphocyte cell line (data not shown). The recovery of
target gene expression indicates that RNAi by exogenous siRNA duplexes does
not last forever in mammalian cells. These findings suggest that the amplification
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system driven by RdRP in plants and nematodes may not exist or has very little
effect on siRNA-mediated gene silencing in mammalian cells.
Another intriguing finding revealed by this Western analysis is that treating
cells with hCycT1 siRNA also down-regulated the level of CDK9 protein. The
kinetics of CDK9 knockdown by hCycT1 siRNA shows a pattern similar to
hCycT1 knockdown (Figure 1 B , lanes 8- , lower panel). No homologous
sequence has been found between the CDK9 mRNA and hCycT1 siRNA used in
this assay, suggesting that CDK9 knockdown by hCycT1 siRNA was not due to
cleavage of CDK9 mRNA by the RNAi pathway. Two possibilities could explain
this unexpected down-regulation. First hCycT1 knockdown may affect the
stability of CDK9 , the kinase component of the P-TEFb complex. Second , since
P- TEFb is a positive transcription factor , it is possible that the P- TEFb complex is
required for transcription of the CDK9 gene. Thus , the down-regulation of
hCycT1 by hCycT1 siRNA would also down-regulate intracellular CDK9 levels.
Specific down-regulation of P- TEFb by siRNA at the mRNA level and
stabilty of CDK9
To determine the specificity of P-TEFb knockdown by siRNA at the mRNA
level and to distinguish the two hypotheses proposed above , we performed RT-
PCR to reveal the effect of siRNA on the level of mRNA involved in P- TEFb
expression. As shown in Figure 1 C , transfection of cells with siRNA duplex
targeting hCycT1 (hCycT1 ds) significantly reduced hCycT1 expression (Figure
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, lanes 1- , upper panel), but had no effect on CDK9 mRNA (Figure 1C , lanes
, lower panel). On the other hand , transfection of cells with siRNA duplex
targeted to CDK9 (CDK9 ds) significantly interfered with the expression of CDK9
but not hCycT1 (Figure 1 C , lanes 8-14). The siRNA duplex started to cause an
RNAi effect as early as 6-18 h post transfection and gradually increased with
time , peaking at 30 h , and decreased between 54-66 h. The time-dependent
effect of siRNA indicates that siRNAs need to be processed or assembled into an
active complex with cellular factors for effective RNA interference. A time lag was
also seen between the degradation of target mRNA (starting at 6 h post siRNA
transfection , as shown by semi-quantitative RT-PCR in Figure 1C) and the half-
life of the existing protein expressed by the target gene , because protein levels
didn t show any down-regulation until 18-30 h post siRNA transfection (Figure
1 B). Combined with Western blot analysis (Figure 1 B), semi-quantitative RT-PCR
(Figure 1C) not only confirms the specific knockdown of P-TEFb by siRNA at the
mRNA level , but also suggests that forming a complex with hCycT1 is a
prerequisite for maintaining the stability of CDK9 proteins in living cells. Thus
hCycT1 siRNA down-regulated hCycT1 levels by the RNAi pathway, while down-
regulating CDK9 levels by promoting its degradation without affecting its gene
expression at the mRNA level.
hCycT1 and CDK9 knockdown can be achieved without causing major toxic
or lethal effects
140
To analyze cell viability in vivo under siRNA treatment , pEGFP-
'--
reporter plasmid (harboring enhanced green fluorescent protein (GFP)) and
siRNAs were cotransfected into HeLa cells using lipofectamine. Reporter gene
(GFP) expression , driven by cytomegalovirus (CMV) immediate early promoter
was monitored in living cells (Figure 3A , upper panels). Cellular morphology and
density were monitored by phase contrast microscopy (Figure 3A , lower panels).
GFP expression was not affected by hCycT1 or CDK9 knockdown (Figure 3A
compare panels a-c). Cells with P-TEFb knockdown had normal shape and
growth rate. At 50 h post transfection , cell density reached -90% to 100%
confluency (Figure 3A, compare panels e-
g).
For comparison , we transfected cells with siRNA targeting CDK7 , a well-
characterized kinase required for TFIIH , an essential transcription factor , to
phosphorylate the CTD of RNA pol II at the step of promoter clearance during
initiation of transcription. Kin28 , a protein in Saccharomyces cerevisiae that is
equivalent to CDK7 in mammals , is an essential gene product that
phosphorylates Ser5 of the CTD YSPTSPS repeat region (128 , 191 , 199) and is
required to recruit the mRNA capping enzyme to the transcription machinery (31
152 , 153 , 269). CDK7 is a bifunctional enzyme in larger eukaryotes , promoting
both CDK activation and transcription (86). Reduction of CDK7 levels by RNAi
led to a lower reporter (GFP) expression and an arrest in cellular growth (Figure
, panel d). CDK7 knockdown cells were smaller than control cells and showed
blebbing (Figure 3A , panel h).
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We also analyzed cellular viability under various siRNA treatments. At
various times after transfection , cell viability was assessed by trypan blue
exclusion (see Experimental Procedures). Over a 66 h time course experiment
the rate of cell death in P-TEFb (hCycT1 or CDK9) knockdown cells was
comparable to that in control cells with unrelated siRNA treatment , while CDK7
knockdown cells showed a significant increase in cell death (Figure 3B). These
results indicate that transient P-TEFb knockdown can be achieved without
causing major toxic or lethal effects to human cells , while a much more stringent
threshold for CDK7 is required to maintain cell viability and growth.
hCycT1 and CDK9 RNAi inhibit HIV-1 Tat transactivation in human cells
A dominant paradigm for Tat up-regulation of HIV gene expression at the
level of transcription elongation revolves around the ability of the Tat-TAR RNA
complex to bind P- TEFb and stimulate phosphorylation of the CTD and Spt5
thereby overriding the elongation arrest elicited by DSIF and NELF (178 , 181).
To test whether siRNAs that targeted sequence elements of P-TEFb would
specifically block Tat transactivation , we cotransfected Magi cells with the Tat
expression construct pTat-RFP and hCycT1 or CDK9 ds siRNA or as controls
antisense RNA strands or mutant siRNAs. Magi , a HeLa cell line harboring a
single copy of persistently transfected HIV-1 L TR- galactosidase gene , is
programmed to express the CD4 receptor and the CCR5 coreceptor for HIV-
(124). We confirmed that the HIV- 1 Tat-RFP fusion protein was expressed under
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control of the CMV early promoter by Western blot , using anti-RFP antibody
(data not shown).
Tat-RFP strongly enhanced gene expression , which is under control of the
HIV- 1 L TR promoter in transfected Magi cells. Tat transactivation was
determined by calculating the ratio of gal activity in pTat-RFP transfected cells
to the activity in cells without pTat-RFP treatment. Inhibitory activity was
determined by normalizing Tat-transactivation activity to the amount of Tat-RFP
protein (represented by RFP fluorescence intensity as described in Experimental
Procedures) in the presence and absence of siRNA. Under standard
experimental conditions , Tat-RFP enhanced gene transactivation 20- to 25-fold
(Figure 4C , lane 1). This activation was strongly inhibited by cotransfecting host
Magi cells with the specific ds siRNAs targeting hCycT1 and CDK9 (Figure 4C
lanes 4 and 5), but notwith antisense (as) RNA strands (Figure 4C , lanes 2 and
3), mutant (mm) siRNAs (Figure 4C , lanes 6 and 7), or an unrelated control
siRNA (Figure 4C , lane 8). Specific RNA interference with hCycT1 and CDK9
expression in Magi cells was demonstrated by Western blot analysis (Figure 4A
lanes 3 and 4), and the inhibition of Tat transactivation correlated well with the
knockdown of hCycT1 and CDK9 protein levels by the hCycT1 and CDK9
siRNAs (compare Figure 4C , lanes 4 and 5 to Figure 4A , lanes 3 and 4). As
shown in Figure 4B , syncytia formation and L TR activation (represented by cells
with blue gal staining) were reduced in hCycT1 ds siRNA-treated cells (Figure
, compare panels d to hand b to f). From these results , we conclude that
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siRNA targeting P-TEFb can inhibit Tat-transactivation in human cells without
causing major toxic or lethal effects.
hCycT1 and CDK9 RNAi inhibit HIV-1 infectivity
Can we inhibit HIV replication by targeting the human P-TEFb complex?
To investigate this question , we transfected HeLa-CD4- TR/ gal (Magi) cells
with homologous and mismatched siRNAs directed against hCycT1 or CDK9 and
16 h later infected the Magi cells with NL-GFP , an infectious molecular clone of
HIV-1. HIV-1 Tat-mediated transactivation of the L TR led to gal production that
was quantified 36 h post- infection. As shown in Figure 5 , ds siRNA directed
against hCycT1 or CDK9 inhibited viral infectivity. Doubling dilutions of the
inoculums are consistent with an 8-fold decrease in viral infectivity. Control
experiments using siRNA duplexes containing mismatched sequences (see
Experimental Procedures) and an unrelated ds siRNA against the RFP sequence
showed no antiviral activities. Consistent with publised studies (105), siRNA
targeting GFP-Nef and Tat led to an 8-fold decrease in viral infectivity. No
significant toxicity or cell death was observed during these experiments. These
results demonstrate that HIV infectivity can be modulated by siRNAs targeting
CycT1 or CDK9 , both components of P-TEFb.
Genomewide analysis of gene expression in P- TEFb knockdown HeLa cells
. ,
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To investigate the effects of P-TEFb knockdown on global gene
expression , we isolated total mRNA from HeLa cells treated with and without
siRNA directed against hCycT1 or CDK9 at 48h post transfection and analyzed
the expression of various genes using the GeneChip(I Human Genome U 133
(HG-U133) from Affmetrix. The HG-U133 includes HG- 133A and HG- 133B sets
of arrays containing 22 283 and 22 645 genes , respectively. Each gene was
represented by a probe set containing 11 probe pairs. Another 100 human
maintenance genes on both arrays serve as a tool to normalize and scale the
data prior to making comparisons. For comparison analysis , data from cells
treated with nonrelated ds siRNA (RFP ds) were used as baseline. The
comparison analysis compares the difference values of each probe pair in the
baseline array to its matching probe pair on the experiment array. A Change 
value is calculated indicating an increase , decrease or no change in gene
expression. The Signal Log Ratio (base on 2) estimates the magnitude and
direction of change of a transcript when two arrays are compared. Log ratio larger
than 1 indicating more than 2 fold up-regulation while log ratio smaller than 1
indicating more than 2 fold down regulation (see Material and Methods for detail).
Genomewide analysis of the gene expression profile of P- TEFb
knockdown cells revealed that 202 genes out of 44 928 were down-regulated. A
complete list of down- and up-regulated genes with names and accession
numbers is listed in Appendix (see Appendix Table 1). Of those 202 genes , 53
are known and were classified according to their function or protein product
I I
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activity (Figure 6A). It is widely accepted that P-TEFb is a positive transcription
factor during RNA pol II elongation. Down-regulated genes in the P-TEFb
knockdown background are presumably those required by P-TEFb for normal
levels of expression , especially at the transcription elongation level.
p- TEFb regulates gene involved in controllng and mediating cell
proliferation and differentiation
Broadly speaking, about 50% (25 out of 53) of the down-regulated genes
are known or likely to be involved in controlling and mediating cell proliferation
and differentiation. These genes can be further divided into three classes (Figure
, I - III). The first class (Figure 6A, I) includes genes directly linked to cellular
proliferation and differentiation. Most of these genes belong to the protein
tyrosine kinase (PTK) superfamily. PTKs catalyze phosphate transfer from A TP
to tyrosine residues on protein substrates , activating numerous signaling
pathways leading to cell proliferation , differentiation , migration , or metabolic
changes and playing a prominent role in the control of a variety of cellular
processes during embryonic development (96). Two classes of PTKs are
affected by P-TEFb knockdown: transmembrane receptor protein tyrosine
kinases (RTKs) and non-receptor tyrosine kinases (NRTKs). AXL receptor
tyrosine kinase (AXL) , discoidin domain receptor 1 (DDR1), epidermal growth
factor receptor (EGFR) and fibroblast growth factor receptor (FGFR) belong to
the RTKs , while cell adhesion kinase (CAK) belongs to the NRTKs. AXL , DDR1
? . :/::
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and EGFR are required for the epithelial-mesenchymal transition during
embryonic development , which allows multicellular organisms to get past the
blastula stage (234).
Transforming growth factor beta (TGF-beta), also down-regulated by P-
TEFb knockdown (Figure 6A, I), binds to another membrane receptor family with
diverse functions during embryonic development and adult tissue homeostasis
, 149). The genes for pre-T/NK cell-associated proteins (fasciculation and
elongation protein zeta 2) are preferentially expressed in early stages of human
T/NK cells and brain , suggesting that they playa role in early development (102
254). Brain-derived neurotrophic factor (BDNF) has been implicated in activity-
dependent plasticity of neuronal function and network arrangement (259).
A second class of genes affected by P- TEFb knockdown is functionally
linked to the cell membrane and extracellular matrix (Figure 6A , II). Junction
plakoglobulin (JUP) cooperates with beta-catenin and promotes epithelial growth
and morphogenesis (87). Moesin (MSN), a plasma membrane protein associated
with the underlying cytoskeleton , determines cell shape and participates in
adhesion , motility and signal transduction pathways (19). This class of genes is
also required for embryonic development , especially for angiogenesis and
neuronal development. For example , integrin functions in epithelial cell
organization and synaptogenesis during development of the CNS (100 , 156).
Epithelial membrane protein 1 (EMP1), which is highly expressed by immature
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neurons in the embryonic stage , functions in neuronal differentiation and neurite
. .
r=:
outgrowth (257).
A third class of genes is involved in signal transduction (Figure 6A, III), the
events downstream of membrane receptor activation. The inositol 1,4,
triphosphate receptor (ITPR1) responds to G-protein-coupled receptor activation
(115), while mitogen-activated protein kinase 6 (MAPK6) propagates cell
proliferation/differentiation signals from receptor tyrosine kinase activation (96
115). Non-receptor type protein tyrosine phosphatase regulates phosphotyrosine
signalling events during complex ectodermal-mesenchymal interactions that
regulate mammalian limb development (4 , 196). Protein phosphatase 
(PPP1 CB) regulates the phosphorylation status of anti-apoptotic and pro-
apoptotic proteins and their cellular activity in the apoptosis cascade (127). Dual
specificity phosphatase 2 (DUSP2) participates in the regulation of intracellular
signal transduction mediated by MAP kinases (266).
There is cross talk among these three gene classes (Figure 6A , I , II , and
III). For example , collagen (type III , alpha 1), an extracellular matrix membrane
protein can be a direct ligand for tyrosine kinase receptors (class I) and integrin
(class 11)(209). Coordinated regulation of PTK (class I) and protein phosphatase
(class II) also acts at different steps in a common signal transduction process
(11). Non-receptor type protein tyrosine phosphatase (class III) positively
regulates BDNF-promoted (class I) survival of ventral mesencephalic
dopaminergic neurons (229). FGFR (class I), EMP1 (class II), pre-T/NKcell-
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associated protein (fasciculation and elongation protein zeta 2; class I) and
integrin (class II) all participate in neuronal development. Nedasin (S form , class
X), which is predominantly expressed in the brain , plays a role in the formation
1== and structural changes of synapses during neuronal development by modifying
clustering of neurotransmitter receptors at synaptic sites (130). Down-regulation
of the genes coding for these last five proteins by P-TEFb knockdown indicates
an important role for P- TEFb during neuronal development.
From the expression profile of these three classes of genes , we conclude
that P-TEFb regulates expression of genes involved in controllng and mediating
cell proliferation and differentiation. We suggested that P-TEFb is essential for
embryonic gene expression and development, while knockdown of its subunits
(hCycT1 and CDK9) may not cause major toxic or lethal effects at the adult
stage. Although P-TEFb knockdown or knockout has never been explored in
mammalian embryonic tissue , it has been proposed that the P- TEFb complex is
required for global gene expression during embryonic development of C. elegans
(208). Knockdown of CDK9 or CycT1 siRNA in C. elegans embryos inhibits
transcription of embryonic genes , including the MAP kinase pathway and cell
cycle-related genes (208).
The role of P- TEFb in human cancers
An intriguing finding is that genes linked to embryonic development and
showing down-regulation in P-TEFb knockdown cells (as described above) also
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participate in tumorogenesis and metastasis. Dysfunction of protein tyrosine
kinases (Figure 6A , I) or aberrations in key components of the signaling
pathways they activate can lead to severe pathologies such as cancer, diabetes
and cardiovascular disease. For example , overexpression of EGFR (Figure 6A , I)
has been implicated in mammary carcinomas , squamous carcinomas and
glioblastomas (197). AXL , another receptor tyrosine kinase (Figure 6A , I), was
originally identified with oncogenic potential and transforming activity in myeloid
leukemia cells (20). Elevated TGF-beta levels can contribute to tumor
progression and metastasis (149). Lysyl oxidase (LOX class II), an extracellular
matrix remodeling enzyme , is up-regulated in prostatic tumor, cutaneous and
uveal cell lines (126). Down-regulating these genes by P-TEFb knockdown could
become a new therapeutic strategy for inhibiting tumorogenesis and metastasis.
Genes involved in mediating progression through the cell cycle and as
checkpoints in cancer were regulated by P-TEFb (Figure 6A , IV). Cyclin G1 is the
downstream target of the P53 pathway and plays a role in G2/M arrest , damage
recovery and growth promotion after cellular stress (125). Cyclin D , a cell-cycle
requlatory protein essential for G1/S transition , has been identified as a potential
transforming gene in lymphoma (159). Misregulation of the activity of its partner
CDK4/6 , by overexpression of Cyclin D leads to hyperproliferative defects and
tumor progression (169). Several marker genes in cancer cells (class V) are also
regulated by P-TEFb. For example , breast cancer-specific protein 1 (BCSG1) is
overexpressed in advanced , infiltrating breast cancer and colorectal tumors
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(140). Another example is soluble urokinase plasminogen activator receptor
(SUPAR), which is present in high concentrations in cystic fluid form ovarian
cancer , tumor tissue of primary breast cancer , and gynecological cancer (190
244). Although the functions of these marker genes are still unknown , their high
correlation with cancer has been used for prognosis in cancer therapy. The
down-regulation of cyclin D and cancer marker genes by P- TEFb knockdown
offer more encouraging evidence to support our proposal that P- TEFb could
become a new and potent target for cancer therapy.
Another strong line of evidence in support of P- TEFb's role in cellular
proliferation comes from clinical studies. Flavopiridol (L86-8275 , HMR1275) is a
cyclin-dependent kinase (CDK) inhibitor being tested in clinical trials as a
potential anti-cancer drug (117 , 205) but its target and the mechanism for its
antiproliferative effects are unknown. Recent evidence indicates that flavopiridol
inactivates P-TEFb and inhibits HIV-1 transcription (25 , 26). Based on our results
showing that P-TEFb knockdown in human cells down-regulates genes involved
in controlling proliferation and differentiation , we propose that the antiproliferative
effects of flavopiridol are due to P-TEFb inhibition.
Links between P- TEFb and stress responses
Another interesting group of genes down-regulated by P-TEFb are those
involved in responding to stress or oxidant-mediated regulation (Figure 6A , VII).
There are three known major redox signaling systems in eukaryotic cells , namely
L",
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glutathione/glutathione reductase , thioredoxin/thioredoxin reductase and
glutaredoxin (GLRX , thioltransferase)(180). SH3 domain-binding glutamine-rich
like protein (SH3BGRL3) also belongs to the thioredoxin family. Glutathione S-
transferase M4 (GSTM4) is involved in detoxifying reactive electrophiles , such as
drug or foreign compounds, by catalyzing their reaction with glutathione
(GSH)(42). Oxidant-mediated regulation by GSH systems plays a direct role in
cellular signaling through thiol-disulfide exchange reactions with membrane-
bound receptor proteins , transcription factors , and regulatory proteins in the cell
(42). During stress responses , redox regulation has an important function in
biological events such as DNA synthesis , enzyme activation , gene expression
and cell cycle regulation. Down-regulation of genes involved in these events by
p- TEFb knockdown in cells indicates an important role for P- TEFb in stress
responses , especially oxidant-mediated regulation of cell proliferation. Moreover
glutathione (GSH) has been linked to multi-drug resistance (42), promising
evidence for P- TEFb as a therapeutic target in cancer research.
Unlike the covalent modifications in redox regulation described above , the
BAG family of modulating proteins (Figure 6A, VII) functions through alterations
in conformation and influences signal transduction through non-covalent post-
translational modifications (230). The BAG family molecular chaperone regulator-
2 (BAG-2) belongs to this family, which contains an evolutionarily conserved
BAG domain" that allows its members to interact with and regulate the Hsp 70
(heat shock protein 70) family of molecular chaperones (230). Like Hsp 70 , BAG-
, .
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family proteins have been reported to mediate the physiological stress signaling
pathway that regulates cell division , death , migration and differentiation (230). p-
TEFb has been shown to be recruited to heat shock loci in Drosophila
melongaster and to co- localize with Hsp 70 and Hsp 90 upon heat shock stress
(138). Down-regulation of the BAG-2 gene in P-TEFb knockdown cells indicates
an important role for P-TEFb in regulating Hsp70 molecular chaperones in
human cells. CDK9 itself has been proposed to form complexes with Hsp 70 and
Hsp90/cdc37 , thereby involving this chaperone-dependent pathway in the
stablization/folding of CDK9 as well as the assembly of an active CDK9/CycT1
complex (167).
Role of P- TEFb in Metabolism and Biosynthesis
Several genes involved in metabolism and biosynthesis are also regulated
by P-TEFb (Figure 6A, IX). Human iron-sulfur protein or ferredoxin (FDX1)
serves as an electron transport intermediary for mitochondrial cytochrome P450
involved in steroid , vitamin D , and bile acid metabolism (135). Low-density
lipoprotein receptor-related protein 5 (LRP5) contains conserved modules
characteristic of the low-density lipoprotein (LDL) receptor family, genetically
associated with Type 1 diabetes (61). Because alterations in LRP5 expression
may be responsible for susceptibility to diabetes , LRP5 may therefore be a
potential target for therapeutic intervention. The vacuolar (H+)-ATPases (or V-
A TPases) function in the acidification of intracellular compartments in eukaryotic
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cells. Eukaryotic translation elongation factor 1 , alpha 2 isoform (EEF1A2), a key
factor in protein synthesis , has been shown to have oncogenic properties: it
I -
enhances focus formation , allows anchorage- independent growth and decreases
doubling time of fibroblasts (2). EEF1A2 is amplified in 25% of primary ovarian
tumors , its expression makes NIH3T3 fibroblasts tumorogenic and it increases
the growth rate of ovarian carcinoma cells (2).
Role of P- TEFb in Cell Cycle Regulation
Also affected by P-TEFb knockdown were genes involved in cell cycle
regulation (Figure 6A, VI), which in turn controls proliferation and differentiation.
The retinoblastoma (RB) protein regulates both the cell cycle and tissue-specific
transcription by modulating the activity of its associated factors (143). Efforts to
identify such cellular targets have led to the isolation of two novel proteins , RB-
associated protein (RBP21) and RB- and p300-binding protein EID-1 (an E1A-
like inhibitor of differentiation)(143). Although its cellular function is still unclear
RBP21 is widely expressed in various human tissues and cancer cell lines. EID-
is a potent inhibitor of differentiation , an activity that has been linked to its ability
to inhibit p300 (and the highly related molecule , CREB-binding protein , or CBP)
acetylation of histones (158). EID- , which is rapidly degraded by the
proteasome as cells exit the cell cycle , may act at a nodal point that couples exit
from the cell cycle to transcriptional activation of genes required for differentiation
(158). Regulation of EID-1 expression by P-TEFb knockdown provides evidence
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that P-TEFb is also involved in cell cycle regulation , especially RB- linked
regulation of proliferation and differentiation.
Up-regulated genes
Four major classes of up-regulated genes were observed , including those
involved in signal transduction (Figure 6B , I), transcription regulation (Figure 6B
II), cell cycle regulation (Figure 6B , IV) and metabolism and biosynthesis (Figure
, VI). This up-regulation may not be a direct effect of P-TEFb knockdown but
rather a secondary or correlated effect , to which the cell responds by
overexpressing certain genes to compensate the loss of function of genes
modulated by P-TEFb. The up-regulation of genes involved in signal
transduction , transcription and cell cycle regulation (Figure 6B , I , II , and IV)
suggests that these genes could complement cellular functions in P-TEFb
knockdown cells or playa role in overcoming effects of down-regulated genes.
An interesting correlation was observed between up-regulation and the functions
of two classes genes i.e. , transcription regulation and
metabolism/biosynthesis (Figure 6B , III and VI). Translation regulator gene eIF-
which controls a signaling pathway to activate genes involved in amino acid
biosynthesis (85) was up-regulated.
CONCLUSIONS
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Our results raise new and intriguing questions for P-TEFb function and its
role in regulating gene expression. First , is P-TEFb required for cellular viability?
Recent evidence indicates that P- TEFb is essential for transcription in C. elegans
embryos (208). P-TEFb may also be essential during mammalian embryonic
development to control transcription elongation and ensure fidelity of mRNA
production. This requirement for P- TEFb could explain why it has been difficult to
create P-TEFb knockout mice. At later stages in the life cycle , knockdown of P-
TEFb may be achieved without causing major toxic or lethal effects. Second
does P-TEFb regulate expression of genes involved in proliferation and cancer?
Our results support this notion because ds siRNA directed against hCycT1 or
CDK9 lowered levels of proliferation and cancer genes , indicating that expression
of these genes is regulated by P- TEFb and negative elongation factors. It is
tempting to postulate that HIV has evolved a mechanism of gene expression
similar to the expression of genes involved in human cancers. Identifying how
these genes and signaling pathways are regulated by P- TEFb function presents
a significant and exciting future challenge.
.w,
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Figure 1. Specific down-regulation of P-TEFb expression by RNAi. (A)
Model for HIV Tat transactivation involving the human P- TEFb
(CyclinT1/CDK9) complex. Human RNA pol II initiates transcription from HIV
promoter DNA, and TFIIH kinase assists in promoter clearance steps. TFIIH
leaves the elongation complex when 30-36 nt mRNA is transcribed. Elongation is
inefficient in the absence of Tat protein. Tat recruits the P-TEFb kinase complex
to TAR RNA by contacting he RNA and CycT1 components of the complex.
CDK9 kinase then phosphorylates RNA pol II and Spt5 , a component of negative
elongation factor (N-TEF) in the elongation complex , which leads to processive
transcription elongation. (B) Analysis of specific hCycT1 and CDK9 RNAi
activities by Western blotting. HeLa cells were transfected with double-
stranded (ds) siRNAs targeting RFP (control , lanes 1-7), hCycT1 (lanes 8-14), or
CDK9 (lanes 15-21). Cells were also transfected with mutant siRNAs (hCycT1
mismatch (lanes 22-28) or CDK9 mismatch (lanes 29-35)) having 2 nucleotide
mismatches between the target mRNA and the antisense strand of siRNA at the
hypothetical cleavage site of the mRNA. Cells were harvested at various times
post transfection , their protein content resolved on 10% SDS-PAGE , transferred
onto PVDF membranes , and immunoblotted with antibodies against hCycT1 and
CDK9. (C) Analysis of specific hCycT1 and CDK9 RNAi activities by RT-
PCR. HeLa cells were transfected with hCycT1 ds siRNA (lanes 1-7) and CDK9
ds siRNA (lanes 8-14), harvested at various times after transfection and mRNAs
extracted. One-step RT-PCR was performed , setting the specific primer for
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hCycT1 and CDK9 amplification (see Experimental Procedure for details). RT-
r=-
PCR products were resolved in 1 % agarose gel and viewed by ethidium bromide
staining.
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Figure 2. Kinetics of hCycT1 and CDK9 silencing by siRNA. ds siRNAs were
transfected into HeLa cells as described in Experimental Procedures. Cells were
harvested at various times and protein contents were resolved on 10% SDS-
PAGE , transferred onto PVDF membranes , and immunoblotted with antibodies
against hCycT1 and CDK9. Western Blotting of hCycT1 and CDK9 over a 90-
hour time course are shown.
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Figure 3. P- TEFb down-regulation can be achieved without causing major
toxic or lethal effects to HeLa cells. (A) Analysis of cell viability by in vivo
fluorescence analysis. HeLa cells were cotransfected by lipofectamine with
pEGFP-C1 reporter (GFP) plasmid and siRNAs (see Experimental Procedures).
Four siRNA duplexes , including a control duplex targeting RFP (panels a and e)
and three duplexes targeting hCycT1 (panels b and f), CDK9 (panels c and g),
and CDK7 (panels d and h), were used in these experiments. Reporter gene
expression was monitored at 50 h post transfection by fluorescence imaging in
living cells (upper panels). Cellular shape and density were recorded by phase
contrast microscopy (lower panels). (B) Analysis of cell viability by counting
trypan blue-stained cells. HeLa cells were cotransfected by lipofectamine with
pEGFP-C1 reporter (GFP) plasmid and siRNAs (see Experimental Procedures).
Four siRNA duplexes , including a control unrelated duplex (light blue) and three
duplexes targeting hCycT1 (green), CDK9 (dark blue), and CDK7 (red), were
used in these experiments. At various times after transfection , cells floating in
the medium were collected and counted in the presence of 0.2% trypan blue (see
Experimental Procedures). Cells that took up dye (stained blue) were not viable.
(A)
siRNA
Q) t/
t/ as
as ,:
J: C
a. 0
(B)
Control ds
450000
400000
Q) 350000
-g 
300000
250000
..
200000
150000
:i 100000
50000
hCycT1 ds
siRNA
CDK9 ds
:.1'
siRNA
.""'
Control ds
-hCycT1 ds
-CDK9 ds
-CDK7 ds
18h 30h 42h
,-." ,,,..,,, 
;,r
54h 66h
162
CDK7 ds
Hours Post Transfection
. .. .
163
Figure 4. hCycT1 and CDK9 duplex siRNAs inhibit HIV-1 Tat transactivation
in Magi cells. (A) Analysis of hCycT1 and CDK9 RNAi activities in Magi cells
by Western blotting. Magi cells were co-transfected with pTat-RFP plasmid
and various siRNAs. Cells were harvested at 48 h post transfection
, resolved on
10% SDS-PAGE , transferred onto PVDF membranes , and immunoblotted with
antibodies against hCycT1 (upper panel) and CDK9 (lower panel). RNAi activities
in Magi cells treated with antisense (as) strands of hCycT1 and CDK9 siRNAs
are shown in lanes 1 and 2 , while those of cells treated with ds siRNA targeting
hCycT1 and CDK9 are shown in lanes 3 and 4. RNAi activities in cells treated
with mutant hCycT1 siRNA (hCycT1 mm) or mutant CDK9 siRNA (CDK9 mm)
are shown in panels 5 and 6. GFP ds siRNA was used as an unrelated control
(lane 7), while Tat ds RNAi was used to target mRNA encoding Tat (lane 8). (B)
Photomicograph of p-gal stained Magi cells. Magi cells were either
untransfected (panels a , c , e and g) or transfected (panels b , d , f and h) with
pTat-RFP in the presence of mismatched hCycT1 siRNA (mm) (panels band 
or hCycT1 ds siRNA (panels d and h). Syncytia formation and L TR activation
(represented by blue p-gal-staining cells) were reduced in the hCycT1 ds siRNA-
treated cells (panels d and h). (C) Effect of P- TEFb knockdown by RNAi on
Tat transactivation in Magi cells. Twenty-four hours after pre-treating Magi
cells with siRNA , they were cotransfected with pTat-RFP plasmid and various
siRNAs. Cells were harvested 48h post pTat-RFP transfection , and activity of p-
galactosidase in clear ceillysates was measured (see Experimental Procedures).
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Tat transactivation was determined by the ratio of galactosidase activity in
pTat-RFP-transfected cells to that of cells without pTat-RFP treatment. Inhibitory
1 ..
activity was determined by normalizing Tat transactivation activity to the amount
of Tat RFP protein (see Experimental Procedures) in the presence or absence of
siRNA treatment. Tat-RFP transfection (mock) is shown in lane 1. Magi cells
were cotransfected with ds siRNAs targeting hCycT1 and CDK9 (lanes 4 and 5),
with antisense (as) RNA strands (lanes 2 and 3), or mutant (mm) siRNAs (lanes
6 and 7). GFP ds siRNA was used as an unrelated control siRNA (lane 8), while
Tat ds siRNA , targeting the mRNA encoding Tat sequence , was used as a
positive control (lane 9). MeanS:l SD of two experiments are shown.
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Figure 5. Small interfering RNAs targeting Cyclin T1 or CDK9 modulate HIV-
1 infectivity. HeLa-CD4- TR/ galactosidase (Magi) cells were transfected with
homologous (ds , lanes 3 and 4) and mismatched (mm , lanes 5 and 6) siRNAs
directed against CycT1 or CDK9. Cells were also mock transfected without
siRNA (lane 2) or transfected with an unrelated ds siRNA against the RFP
sequence (lane 7). Sixteen hours later, cells were infected with NL-GFP , an
infectious molecular clone of HIV-1. Cells infected with virus and not treated with
oligofectamine are shown in lane 1. HIV-1 Tat-mediated transactivation of the
L TR led to gal production , which was quantified 36 h post-infection. Cells
treated with ds siRNA targeting GFP-Nef (lane 8) and targeting the mRNA
encoding Tat sequence (lane 9) served as positive controls. Serial double
dilutions of the viral inoculum (in cpm of RT activity) are consistent with 8-fold
decreases in viral infectivity.
siRNA
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Figure 6. Genomewide analysis of gene expression in P- TEFb knockdown
HeLa cells. HeLa cells were treated with and without ds siRNA directed against
hCycT1 or CDK9 , and total mRNA was isolated. Total mRNA was used to
synthesize ds cDNAs , from which biotin- labeled cRNA was synthesized and
fragmented. Fragmented cRNA was then subjected to high-density
oligonucleotide microarray hybridization (GeneChip(8) using Human Genome
U133 from Affymetrix (see Experimental Procedures). Of the 44 928 genes
expressed , 90 are displayed by class , based on their putative functions. Each
row represents one gene. Column 1 indicates hCycT1 ds siRNA treatment and
column 2 indicates CDK9 ds siRNA treatment. The down- (A) and up- (B)
regulated genes are represented by green and red , respectively. The brightness
of each color reflects the magnitude of the gene expression level (Signal Log
Ratio). See Experimental Procedure for details of analysis.
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CHAPTER V
RNA INTERFERENCE IN HUMAN CELLS: BASIC
STRUCTURAL AND FUNCTIONAL FEATURES OF
SMALL INTERFERING RNA
. o
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ABSTRACT
We investigated the mechanism of RNA interference (RNAi) in human
cells. Here we demonstrate that the status of the 5' hydroxyl terminus of the
antisense strand of a siRNA determines RNAi activity, while a 3' terminus block is
tolerated in vivo. 5' hydroxyl termini of antisense strands isolated from human
cells were phosphorylated , and 3' end biotin groups were not efficiently removed.
We found no requirement for a perfect A-form helix in siRNA for interference
effects , but an A-form structure was required for antisense-target RNA duplexes.
Strikingly, crosslin king of the siRNA duplex by psoralen did not completely block
RNA interference , indicating that complete unwinding of the siRNA helix is not
necessary for RNAi activity in vivo. These results suggest that RNA amplification
by RNA-dependent RNA polymerase is not essential for RNAi in human cells.
, "
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INTRODUCTION
RNAi interference (RNAi) is the process whereby double-stranded RNA
(dsRNA) induces the sequence-specific degradation of homologous mRNA.
Although RNAi was first discovered in Caenorhabditis elegans (62), similar
phenomena had been reported in plants (posttranscriptional gene silencing
(PTGS)) and in Neurospora crassa (quelling) (reviewed in 84 , 206). It has
become clear that dsRNA- induced silencing phenomena are present in
evolutionarily diverse organisms , e. , nematodes , plants , fungi, and
trypanosomes (8 , 122 , 150 206 215 238 248). Biochemical studies
in Drosophila embryo Iysates and S2 cell extracts have begun to unravel the
mechanisms by which RNAi works (15 239 271).
RNAi is initiated by an A TP-dependent , processive cleavage of dsRNA
into 21 to 23 nucleotide (nt) short interfering RNAs (siRNAs) (82 , 83 , 271) by the
enzyme Dicer, a member of the RNase III family of dsRNA-specific
endonucleases (15). These native siRNA duplexes containing 5' phosphate and
3' hydroxyl termini are then incorporated into a protein complex called RNA-
induced silencing complex (RISC) (83). ATP-dependent unwinding of the siRNA
duplex generates an active complex , RISC* (the asterisk indicates the active
conformation of the complex) (166). Guided by the antisense strand of siRNA
RISC* recognizes and cleaves the corresponding mRNA (57 , 166).
Recently, Tuschl and colleagues (55) have demonstrated that RNAi can
be induced in numerous mammalian cell lines by introducing synthetic 21 nt
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siRNAs. By virtue of their small size , these siRNAs avoid provoking an interferon
response that activates the protein kinase PKR (219). Functional anatomy
studies of synthetic siRNA in Drosophila cell Iysates have demonstrated that
each siRNA duplex cleaves its target RNA at a single site (58). The 5' end of the
guide siRNA sets the ruler for defining the position of target RNA cleavage (58).
5' phosphorylation of the antisense strand is required for effective RNA
interference in vitro (166). Mutation studies have shown that a single mutation
within the center of a siRNA duplex discriminates between mismatched targets
(58). These experiments showed a more stringent requirement for the antisense
strand of the trigger dsRNA as compared to the sense strand (78 , 171).
However , none of these phenomena have been demonstrated in vivo especially
in mammalian systems.
A particularly fascinating aspect of RNAi is its extraordinary efficiency. It
has been estimated that in Drosophila embryos , -35 molecules of dsRNA can
silence a target mRNA thought to be present at ::1000 copies per cell (118).
Conversion of the long trigger dsRNA into many 21 to 23 nt siRNA fragments
would , itself, provide some degree of amplification. Another plausible explanation
for the potency of interference is that the RISC* is a multiple-turnover enzyme
which can catalytically perform the targeting and cleavage activity. The
involvement of RNA-dependent RNA polymerase (RdRP) in the amplification
process has recently been postulated since genetic screening has identified the
gene for RdRP as a requirement for gene silencing in plants , fungi , and worms
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(36 , 160 215). A random degradative PCR model has been suggested (136
164 , 215), in which siRNA serves as the primer for the RdRP reaction. The
siRNA-primed RdRP converts target mRNA into dsRNA , which can serve as
Dicer substrates , initiating the RdRP chain reaction. The polarity of the RdRP
reaction limits the synthesis of secondary siRNAs to the region upstream of the
trigger sequence. Certain structural features of siRNA, including the 3' hydroxyl
group and 5' phosphate group, are critical for the RdRP reaction and RNA
ligation (136 , 215). A number of apparent constraints on the role of Rd RP activity
in RNAi , however, severely limit models in which RdRP carries out a multiround
replication of a double-stranded trigger. Experiments using siRNA with two
differentially modified strands (171 , 264) have shown a more stringent
requirement for the antisense strand of the original trigger as compared to the
sense strand. Multiround replication of a double-stranded trigger by RdRP would
result in loss of memory of the difference between the original two strands and
thus be incompatible with the observed effects of strand-specific modification.
Although RdRP activity has been reported in Drosophila embryo Iysates (136), a
homolog of RdRP has not been identified in available mammalian genomic
sequences.
A number of basic questions remain to be answered regarding RNA
interference in human cells. (1) What is the kinetics of RNAi? (2) Is 5' 
required for kinase activity and is it phosphorylated in vivo? (3) Is 3' OH required
for RNA-dependent RNA polymerase- like activity? (4) Is an A-form helix of
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dsRNA required for RNAi? If yes , at which stage during the pathway? (5) Is
complete unwinding of the dsRNA helix necessary to cause RNAi effects? This
chapter addresses these issues.
'! .
176
MATERIALS AND METHODS
siRNA preparation. Twenty-one nucleotide RNAs were chemically
synthesized as 2' bis(acetoxyethoxy)-methyl ether-protected oligos by
I . Dharmacon (Lafayette , CO). Synthetic oligonucleotides were deprotected
annealed , and purified as described by the manufacturer. Successful duplex
formation was confirmed by 20% nondenaturing polyacrylamide gel
electrophoresis (PAGE). All siRNAs were stored in DEPC (0. 1 % diethyl
pyrocarbonate)-treated water at - C. The sequences of GFP or RFP target-
specific siRNA duplexes were designed according to the manufacturer
recommendation and subjected to a BLAST search against the human genome
sequence to ensure that no endogenous genes of the genome were targeted.
Culture and transfection of cells. HeLa cells were maintained at 3rC 
Dulbecco s modified Eagle s medium (DMEM , Invitrogen) supplemented with
10% fetal bovine serum (FBS), 100 units/ml penicillin , and 100 
/-g/
streptomycin (Invitrogen). Cells were regularly passaged at subconfluence and
plated 16 h before transfection at 70% confluency. Lipofectamine (Invitrogen)-
mediated transient cotransfections of reporter plasmids and siRNAs were
performed in duplicate 6-well plates as described by the manufacturer for
adherent cell lines. A transfection mixture containing 0.66 /-g pEGFP-C1 and
33 /-g pDsRed1-N1 reporter plasm ids (Clontech), 50 nM siRNA, and 10 /-1
lipofectamine in 1 ml serum-reduced OPTI-MEM (Invitrogen) was added to each
well. Cells were incubated in transfection mixture for 6 h and further cultured in
.. ,
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antibiotic-free DMEM. Cells were treated under the same conditions without
siRNA for mock experiments. At various time intervals , the transfected cells were
washed twice with phosphate-buffered saline (PBS, Invitrogen), flash frozen in
liquid nitrogen , and stored at - C for reporter gene assays.
In vivo fluorescence analysis. pEGFP- , pDsRed1-N1 reporter
plasmids and 50 nM siRNA were cotransfected into HeLa cells by lipofectamine
as described above except that cells were cultured on 35 mm plates with glass
bottoms (MatTek Corporation , Ashland , MA) instead of standard 6-well plates.
Fluorescence in living cells was visualized 48 hr posttransfection by conventional
fluorescence microscopy (Zeiss). For GFP and RFP fluorescence detection
FITC and CY3 filters were used , respectively.
Dual fluorescence reporter gene assays. pEGFP- , pDsRed1-
reporter plasmids and 50 nM siRNA were cotransfected into HeLa cells. EGFP-
C1 encoded enhanced green fluorescence protein (GFP), while DsRed1-
encoded red fluorescence protein (RFP). Cells were harvested as described
above and lysed in ice-cold reporter lysis buffer (Promega) containing protease
inhibitor (complete, EDTA-free, 1 tablet/10 ml buffer, Roche Molecular
Biochemicals). After clearing the resulting Iysates by centrifugation , protein in the
clear lysate was quantified by Dc protein assay kit (Bio-Rad). One hundred
twenty micrograms of total cell lysate in 160 III reporter lysis buffer was
measured by fluorescence spectroscopy (Photon Technology International). The
slit widths were set at 4 nm for both excitation and emission. All experiments
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were carried out at room temperature. Fluorescence of GFP in cell Iysates was
detected by exciting at 488 nm and recording from 498-650 nm. The spectrum
peak at 507 nm represents the fluorescence intensity of GFP. Fluorescence of
RFP in the same cell Iysates was detected by exciting at 568 nm and recording
from 588-650 nm; the spectrum peak at 583 nm represents the fluorescence
intensity of RFP. The fluorescence intensity ratio of target (GFP) to control (RFP)
fluorophore was determined in the presence of siRNA duplex and normalized to
that observed in the presence of antisense strand siRNA. Normalized ratios less
than 1. 0 indicate specific interference.
Western blotting. Cell Iysates were prepared from siRNA-treated cells
and analyzed as described above. Proteins in 30 g of total cell lysate were
resolved by 10% SDS-PAGE , transferred onto a polyvinylidene difluoride
membrane (PVDF membrane, Bio-Rad), and immunoblotted with antibodies
against EGFP and DsRed1-N1 (Clontech). For loading control , the same
membrane was also blotted with anti-actin actibody (Santa Cruz). Protein content
was visualized with a BMChemiluminescence Blotting Kit (Roche Molecular
Biochemicals). The blots were exposed to X-ray film (Kodak MR- 1) for various
times (between 30 sand 5 min).
Psoralen photocrosslink of siRNA duplex. Forty micrograms of siRNA
duplex was incubated with 132 M of a psoralen derivative , 4' hydroxymethyl-
trimethylpsoralen (HMT) in 200 I DEPC-treated water at 30 C for 30 min.
Mixtures of siRNA duplex and HMT were exposed to UV 360 nm at 4 C for 20
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min , then denatured by mixing with 400 JlI formamide/formaldehyde (12. 5:4.
RNA loading buffer and heating at 95 C for 15 min. Crosslinked siRNA duplex
and noncrosslinked siRNA were resolved by 20% PAGE containing 7 M urea in
Tris-borate-EDTA. Crosslinked siRNA duplexes appeared as a population with
retarded electrophoretic mobility compared to the noncrosslinked species. RNAs
were cut from the gel and purified by C18 reverse-phase column chromatography
(Waters). Purified crosslinked dsRNA and noncrosslinked dsRNA were used in
dual fluorescence reporter assays as described above , except that all procedures
were performed in the dark to avoid light effects on psoralen. To ensure that the
crosslink depended on the presence of psoralen , part of the UV 360 nm treated
mixture was also subjected to UV 254 nm at 4 C for 20 min. Photoreverse-
crosslinked siRNA migrated in 20% polyacrylamide-7 M urea gels with similar
mobility to the siRNA duplex without HMT treatment.
Biotin pull-out assay for siRNA isolation from human cells. Antisense
strands of the siRNA duplex were chemically synthesized and biotin-conjugated
at the 3' end (Dharmacon , Lafayette , CO). Synthetic oligonucleotides were
deprotected and annealed with the unmodified sense strand RNA to form duplex
siRNA (ss/as3' Biotin). HeLa cells , which had been plated at 70% confluency in
100 mm dishes , were cotransfected with duplex siRNA (-600 pmole) and EGFP-
C1 plasmid (1 Jlg) by a lipofectamine-mediated method as described above. At
various times , the transfected cells were washed twice with PBS (Invitrogen) and
flash frozen in liquid nitrogen. Low molecular weight RNA was isolated from the
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cells using a Qiagen RNAIDNA Mini Kit. Biotinylated siRNA was pulled out by
incubating purified RNA with streptavidin-magnetic beads (60 j.l) in TE buffer (10
mM Tris-HCI (pH 8. 0), 1 mM EDTA) containing 1 M NaCI at room temperature for
3 hr. The beads were washed four times with 200 j.l TE buffer , resuspended in
100 j.l TE buffer, and split into two equal aliquots. To one aliquot (50 j.l), we
added 50 units of shrimp alkaline phosphatase (SAP , Roche Molecular
Biochemicals) in 1X SAP buffer and incubated at 3rC for 1 hr. The SAP reaction
was then stopped by heating at 65 C for 15 min and washed four times with 200
j.l TE buffer. The other aliquot was not treated with SAP. Aliquots of beads with
or without SAP treatment were incubated with 30 units T4 polynucleotide kinase
(T4 PNK , Roche Molecular Biochemicals) in 30 j.l 1X PNK buffer containing 0.
mCi -32P ATP at 3rC for 1 hr. RNA products were resolved on 20%
polyacrylamide-7 M urea gels and 32P- labeled RNAs were detected by
phosphorimaging.
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RESUL TS
Dual fluorescence reporter system for RNAi analysis in mammalian cells
To explore the functional anatomy of siRNA in mammalian cells , we
established a dual fluorescence reporter system , using HeLa cells as a model
system. Two reporter plasmids were used: pEGFP-C1 and pDsRed1-
harboring enhanced green fluorescent protein (GFP) or coral (Oiscosoma spp.
derived red fluorescent protein (RFP), respectively. The expression of these
reporter genes was under cytomegalovirus promoter control and could be easily
visualized by fluorescence microscopy in living cells. The siRNA sequence
targeting GFP was from position 238-258 relative to the start codon , and the
RFP siRNA sequence was from position 277-297 relative to the start codon
(Figure 1A). Using lipofectamine , we cotransfected HeLa cells with pEGFP-
and pDsRed1-N1 expression plasmids and siRNA duplex , targeting either GFP
or RFP. Fluorescence imaging was used to monitor GFP and RFP expression
levels. As shown in Figures 1 Ba and 1 Bb , mock treatment (without siRNA)
allowed efficient expression of both GFP and RFP in living cells. Transfection of
cells with siRNA duplex targeting GFP (GFP ds) significantly reduced GFP
expression (Figure 1 Bc) but had no effect on RFP expression (Figure 1 Bd)
compared with mock-treated cells (Figures 1 Ba and 1 Bb). On the other hand
transfection of cells with siRNA duplex targeted to RFP (RFP ds) significantly
interfered with the expression of RFP but not GFP (Figures 1 Be and 1 Bf).
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To quantify RNAi effects , we prepared Iysates from siRNA duplex-treated
cells at 42 hr posttransfection. GFP and RFP fluorescence in clear Iysates was
measured on a fluorescence spectrophotometer. The peak at 507 nm (Figure 1 C
left panel) represents the fluorescence intensity of GFP , and the peak at 583 nm
(Figure 1 C , right panel) represents the fluorescence intensity of RFP. GFP
fluorescence intensity of GFP ds-treated cells (Figure 1 C , left panel , green line)
was only 5% of mock-treated (black line) or RFP ds-treated cells (cyan line). In
contrast to GFP fluorescence , RFP fluorescence intensity (Figure 1 C , right panel)
significantly decreased only in cells treated with RFP ds (red line), indicating the
specificity of the RNAi effect.
To confirm these findings on RNAi effects in living mammalian cells , we
carried out Western blotting experiments (Figure 2) using anti-GFP and anti-RFP
antibodies. Analysis of immunoblots revealed that the siRNA targeting GFP
inhibited only GFP expression without affecting RFP levels (Figure 2A , lanes
14); siRNA targeting RFP was similarly specific against RFP expression
(Figure 2B , lanes 9-14). This RNA interference effect depended on the presence
of 21 nucleotide duplex siRNA but not of the antisense strand siRNA (Figures 2A
and 2B , compare right and left panels). These results demonstrate that we have
established a reliable and quantitative system for studying specific RNA
interference in HeLa cells.
Kinetics of RNA interference in HeLa cells
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One of the many intriguing features of gene silencing by RNA interference
is its unusually high efficiency-a few dsRNA molecules suffice to inactivate a
continuously transcribed target mRNA for long periods of time. It has been
demonstrated in plants (36 , 47) and worms (78) that this inactivation can spread
throughout the organism and is often heritable to the next generation. Mutations
in genes encoding a protein related to RdRP affect RNAi-type processes in
Neurospora (QDE- 1; 36), C. elegans (EGO- 1; 217), and plants ((SGS2; 160) and
(SDE- 1; 47)). The involvement of RdRP in amplifying RNAi has been postulated
(136).
To understand the kinetics of gene suppression and persistence of RNA
interference in HeLa cells , we prepared Iysates from cells cotransfected with
GFP siRNA and dual fluorescence reporter plasmids , pEGFP-C1 and pDsRed1-
N 1. In this experiment, GFP was the target of the duplex siRNA , while RFP was
used as a control for transfection efficiency and specificity of RNA interference.
Emission spectra of GFP in ceillysates at various times after transfection (Figure
3) show that siRNA duplex caused an RNA interference effect as early as 6 hr
posttransfection. This effect gradually increased with time , peaking at 42 hr , then
started to decrease at 66 hr (Figure 3 , green lines). As a control experiment , GFP
expression in the presence of antisense strand was also monitored and showed
no RNAi effects (Figure 3 , blue lines). Thus , RNA interference can last for at
least 66 hr in HeLa cells (Figure 3 , green lines).
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To quantify the kinetics of RNA interference , we measured the
fluorescence intensity ratio of target (GFP) to control (RFP) fluorophore in the
presence of siRNA duplex (ds) and normalized it to the ratio observed in the
presence of antisense strand siRNA (as). Normalized ratios less than 1. 0 indicate
specific interference. As shown in Figure 1 D , at 6 hr posttransfection GFP duplex
siRNA (green bars) inhibits 60% of GFP expression compared to antisense
strand siRNA (blue bars). RNA interference reached its maximum (92%
inhibition) at 42 hr posttransfection; only 8% of normal GFP expression was
observed in duplex siRNA-treated cells. These results show that RNA
interference can suppress target protein expression up to 66 hr, although
maximum activities were observed at 42-54 hr posttransfection.
Free 5' OH groups on the antisense strand of the siRNA duplex are required
for RNA interference in vivo
Synthetic 21 nucleotide siRNA duplexes with 5' hydroxyl termini and 3'
overhang have been shown to specifically suppress expression of endogenous
and heterologous genes in Drosophila extracts (57) and mammalian cell lines
(55). Nonetheless , native siRNA, processed by Dicer cleavage of dsRNA
contains 5' phosphate ends (57). It has been demonstrated in vitro that
Drosophila embryo Iysates contain a potent kinase activity that phosphorylates
the 5' hydroxyl termini of synthetic siRNAs (166). The 5' phosphate is required on
the siRNA strand that guides target cleavage in RNA interference (166).
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To examine the importance of 5' termini of siRNA in RNA interference in
human cells , we modified synthetic siRNAs targeting GFP by using an amino
group with a 3-carbon linker (5' N3 , Figure 4A) to block their 5' termini. Synthetic
siRNAs with this modification lacked a hydroxyl group to be phosphorylated by
kinases in vivo. This modification could also block access to siRNA by cellular
factors that might require recognizing the 5' OH termini. We annealed unmodified
siRNA strands with 5' modified strands , producing siRNA duplexes with 
modification at only the sense strand (5' N3ss/as), at only the antisense strand
(ss/5' N3as), or at both strands (5' N3ss/5' N3as) (Figure 4B). RNAi effects of
these siRNA duplexes were analyzed in our dual fluorescence reporter system
as described in Figure 1. 5' modification of the sense strand had no effect on
RNAi activity (Figures 5b and 5c), whereas 5' modification of the antisense strand
completely abolished the RNAi effect (Figures 5d and 5e; Figures 6A and 6B
upper panels). HeLa cells transfected with antisense strand (as) siRNA as control
showed no RNAi activity (Figure 5a). These results demonstrate that the 5' OH in
the antisense strand of the siRNA duplex is an important determinant of RNAi
activity in human cells.
Blocking the 3' nd oef siRNAs has little effect on RNA interference in vivo
To determine the effect of 3' OH groups on RNAi activity, we synthesized
siRNA duplexes containing a 3' end blocked with 3' puromycin (3' Pmn , Figure
4A) or biotin instead of 3' OH groups on the overhang deoxythymidine (Figure
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4B). These 3' end modifications would block any processing of the siRNA duplex
that required a free 3' hydroxyl group. We prepared three combinations of siRNA
duplexes containing 3' puromycin: 3' blocked at only the sense strand (ss3'
Pmn/as), at only the antisense strand (ss/as3' Pmn), or at both strands (ss3'
Pmn/as3' Pmn) (Figure 4B). We also prepared a siRNA duplex containing biotin
at the 3' end of antisense strand (ss/as3' Biotin). The RNAi activities of these
siRNA duplexes were analyzed in our dual fluorescence reporter system. Results
of these experiments indicate that a 3' block at either the sense or antisense
strand of siRNA duplex had little effect on its RNA interference activity (Figures
5f-5i; Figures 6A and 6B , middle panels). Furthermore , biotin pull-out
experiments showed that the 3' end biotin groups on the antisense strand were
not effciently removed during RNAi activities in HeLa cells (Figure 7 , see below).
Modifications could be introduced in the 3' overhangs without affecting siRNA
efficacy, suggesting that RNA interference in mammalian cells does not occur
through the recently reported RdRP-dependent degradative PCR mechanism
(Lipardi et aI. , 2001; Sijen et aI. , 2001), which requires a free 3' hydroxyl group.
Form helix of siRNA is absolutely required for effective RNA interference
in vivo
Synthetic and native siRNAs , generated from ATP-dependent cleavage of
double-strand RNA , have been proposed to act as "guide RNAs" that target an
associated nuclease complex , the RISC (RNA-induced silencing complex), to the
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corresponding mRNA through strand complementarity (83 , 166). How are these
siRNA duplexes recognized and incorporated into the RISC protein complex?
siRNA duplexes are readily characterized by their A-form helix , which can be
distinguished from the structures of B-form helix DNA and single-stranded RNA
in the cell. A single mismatch between a target mRNA and its guide strand siRNA
completely prevents target RNA cleavage in Drosophila embryo Iysates (58).
Although the mechanism of target recognition has not been experimentally
demonstrated , this finding indicates that recognition requires exact
complementarity between the guide strand and target mRNA.
These observations raise two fundamental questions regarding RNAi
effects in vivo. (1) Is an A-form RNA helix required in the siRNA structure? (2) Is
an A-form helix recognized by proteins after the antisense strand of siRNA
duplex is hybridized with the target mRNA? To address these questions , we
designed three siRNA duplexes containing internal bulge structures in the RNA
helices (Figure 4B). The A-form RNA helix has a deep, narrow major groove and
a shallow, wide minor groove. More than one nucleotide bulge has been shown
to distort RNA helical structures , widening the major groove and enhancing
accessibility to its functional groups (162 , 250 , 251) . We decided to use 2 nt
bulges to generate distorted A-form helices in siRNAs. We synthesized mutant
siRNA by introducing two extra nucleotides into the sense or antisense strand of
siRNA duplexes. Combining these mutant siRNA strands with original siRNA
sequences produced three siRNA duplexes with an internal bulge at only the
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sense strand (ss-bulge/as), at only the antisense strand (ss/as-bulge), or at both
strands (ss-bulge/as-bulge) (Figure 4B). This design of bulge-containing siRNAs
could dissect the requirement for the A-form helix at two different steps of RNA
interference: (1) siRNA recognition by RISC and (2) RISC targeting of mRNA via
the guiding siRNA. siRNA duplexes with an internal bulge at only the sense
strand (ss-bulge/as) caused a structural change in the siRNA duplex (an
imperfect A-form) without affecting the complementarity between target mRNA
and the antisense strand , which acts as the guiding strand in the RNA
interference pathway. RNA interference by these siRNA duplexes was analyzed
and quantified in our dual fluorescence reporter system as described above.
Surprisingly, the siRNA duplex containing a bulge in its sense strand
retained most of its RNA interference activity (compare Figures 5b and 5j;
Figures 6A and 6B , lower panels , green line and bars), indicating that an A-form
siRNA helix is not essential for effective RNA interference in vivo. However
bulges in the antisense strand or both strands of duplex siRNA completely
abolished RNA interference ability (Figures 5k and 51; Figures 6A and 6B , lower
panels , dark and light blue line and bars), indicating that effective RNA
interference in vivo absolutely requires A-form helix formation between target
mRNA and its guiding antisense strand.
5' OH groups on the antisense strand of the siRNA duplex are
phosphorylated in vivo
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To analyze the phosphorylation status of the 5' termini of siRNA and to
probe the participation of siRNA 3' termini in the RNA interference pathway in
vivo, we transfected HeLa cells with 21 nt RNAs containing biotin at the 3'
terminal of the antisense strand (ss/as3' Biotin) and isolated the biotinylated
siRNA at various times after transfection (see Experimental Procedures). In brief
streptavidin magnetic beads were used to pull out biotinylated siRNAs from
transfected cells , washed to remove unbound RNA, and split into two aliquots.
One aliquot was dephosphorylated with shrimp alkaline phosphatase (SAP), and
the RNA 5' ends were labeled with 32P by T4 polynucleotide kinase (PNK)
reaction. The other aliquot was subjected to 5' end radiolabeling with
polynucleotide kinase without prior dephosphorylation reaction with SAP. RNA
was resolved on 20% polyacrylamide-7 M urea gels and visualized by
phosphorimager analysis. Cells without siRNA treatment showed no detectable
signal after biotin pull-out assay (Figure 7 , lane 4), indicating the absence of
nonspecific RNA-bead interactions. Efficient 5' end radiolabeling was observed
only when RNA was pretreated with phosphatase (compare lanes 5-9 and
10-14), indicating that the 5' termini of siRNA did not contain free OH groups in
vivo. Although phosphorylating with SAP and quenching the phosphatase
reaction by heating resulted in some RNA degradation , the efficiency of the
kinase reaction after SAP treatment is obvious. These results indicate that 5' OH
groups are phosphorylated in vivo for RNAi activities.
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These experiments demonstrate three key findings. First, biotinylated-
siRNA can be isolated from HeLa cells at 6 to 54 hr posttransfection (Figure 7
lanes 5-9). The amount of isolated siRNA decreased in a time-dependent
manner , indicating the degradation of siRNA in vivo. Our dual fluorescence
assays showed that RNA interference mediated by 3' end biotinylated siRNA was
as effective as unmodified siRNA (Figures 5f and 5b; Figures 6A and 6B , middle
panel). RNA interference is seen as early as 6 hr post-siRNA transfection and
can be maintained for 42 hr posttransfection. Our ability to isolate biotin-RNA
from cells after RNA interference had been initiated indicates that biotin was not
removed from the RNA and rules out the possibility of siRNA 3' OH termini
involvement in the RNA interference pathway in human cells.
Second , in this biotin pull-out assay, only siRNA with 5' OH ends can be
32P- labeled by T4 PNK. As shown in Figure 7 , the siRNA without SAP treatment
was not efficiently labeled by T4 PNK (e. , compare lane 10 to lane 5 and lane
11 to lane 6), indicating that the 5' termini of siRNA did not contain free 
groups in vivo. These 5' terminal groups can be removed by alkaline
phosphatase treatment for subsequent radiolabeling (Figure 7 , lanes 5-9),
indicating that the 5' termini of the siRNA had been phosphorylated in vivo.
Third , only the antisense strand is recovered by biotin pull-out assays.
siRNA duplexes were 5' end labeled with 32P by T4 PNK, heat denatured (10
min at 95 C), and analyzed on a polyacrylamide-7 M urea denaturing gel. As
shown in Figure 7 (lane 3), two single-stranded RNA species corresponding to
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the sense and biotinylated-antisense strands were observed , indicating that the
siRNA duplexes were fully denatured under these conditions. Denatured siRNA
duplexes contained approximately equal molar amounts of the sense and the
antisense strands of RNA (Figure 7 , lane 3). The cells were transfected with
duplex siRNA, but the major products of the isolated siRNA (Figure 7 , lanes 5-
by biotin pull-out assay exhibited electrophoretic moblities identical to the
antisense strand (lane 3), indicating that only biotinylated antisense strands were
being recovered. These results suggest that RISC melts the duplex siRNA and
separates the antisense from the sense strand during RNA interference in vivo.
Complete unwinding of siRNA duplex is not necessary for RNA
interference pathway in vivo
ATP-dependent unwinding of the siRNA duplex in the RISC has been
proposed to activate the complex to generate RISC* , which is competent to
mediate RNAi (166). Although unwinding of siRNA in Drosophila embryo Iysates
has been demonstrated in the presence of A TP , the efficiency of unwinding
seems low since only 5% of unwound siRNA was detected (166).
To examine whether or not the siRNA duplex in human cells is completely
unwound , we performed RNA interference experiments with siRNA duplexes
covalently crosslinked by psoralen photochemistry. Psoralens are bifunctional
furocoumarins that intercalate between the base pairs of double-stranded nucleic
acids and can photoreact with pyrimidine bases to form monoadducts and
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crosslinks (for review see 34). The structure of the psoralen derivative , 4'
(hydroxymethyl)- trimethylpsoralen (HMT) used in this study is shown in
Figure 8A. Psoralen crosslinking involves two successive photochemical
reactions that take place at the 3,4 or 4' 5' double bonds of psoralen (34). Upon
long-wave UV irradiation (320-400 nm), the intercalated psoralen can photoreact
with adjacent pyrimidine bases to form either furan-side or pyrone-side
monoadducts , which are linked to only one strand of the helix (34). By absorbing
a second photon , the furan-side monoadducts can be driven into diadducts
which are covalently linked to both strands of the helix (89 , 111). Psoralen
crosslink formation occurs only when psoralen adds to adjacent and opposite
pyrimidine bases in the double helix. The reaction is primarily with uracil in native
RNAs, but reactions with cytidine have also been reported (137 , 235, 237).
Based on psoralen photoreactivity, three possible psoralen crosslink sites in the
GFP siRNA duplex are shown in Figure 88. Note that there is no chance for all
three sites to be crosslinked in one RNA.
Unlike the noncrosslinked ds siRNA , the two strands of the crosslinked
siRNA duplex could not separate from each other under denaturing conditions so
that the crosslinked siRNA duplex showed characteristically retarded mobility in
polyacryalmide gel electrophoresis (PAGE) containing 7 M urea (Figure 8C).
Crosslinking efficiency depended on the psoralen concentration (Figure 8C
lanes 2 and 3). To further verify the presence of crosslinks in the RNA helix and
rule out the possibility of only monoadduct formation , the psoralen crosslinks
,,-
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were irradiated with short wave UV (254 nm), which showed photoreversal of the
crosslinked bonds (Figure 8C
, lane 4). The crosslinked siRNA duplex (Figure 8C
lane 3 , upper band) was excised from the gel and purified. As control , the
noncrosslinked siRNA that was irradiated with long wave UV (360 nm) (Figure
, lane 3 , lower band) was also purified by the same method. The structures of
the purified noncrosslinked and psoralen crosslinked siRNA duplexes were
confirmed by PAGE containing 7 M urea (Figure 8C , lanes 5 and 6).
Fluorescence imaging of living cells treated with crosslinked siRNA duplex
showed that the siRNA duplex s inability to separate on PAGE did not completely
abolish its RNA interference activity (Figure 8D
, ds-XL). Quantitative analysis of
GFP fluorescence intensity indicated that crosslinked siRNA retained 30% of its
RNAi activity (Figure 8E , blue line). These results demonstrate that a complete
unwinding of the siRNA duplex is not required for gene 
silencing in vivo (see
Discussion).
There is a possibility that the psoralen crosslink of RNA can be
photoreversed during transfection
, repaired or removed by some unknown
mechanism inside the cells
, which might cause the partial RNA interference
effect in vivo observed in Figures 8D and 8E. To rule out this possibility, we
carried out a psoralen crosslinking experiment with siRNA duplex containing
biotin at the 3' end of the antisense strand. The crosslinked duplex (ss/as3'
Biotin-XL) was isolated and purified as described above and transfected into
HeLa cells by lipofectamine. Biotinylated siRNA was isolated from the cells 30 hr
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posttransfection by biotin pull-out assay, SAP treated , and 32P- labeled by T4
PNK as described above. The biotinylated siRNA was still crosslinked (Figure 9
lane 7) at 30 hr posttransfection. When UV irradiated (254 nm), this higher
molecular weight siRNA species was converted into two RNA species
corresponding to sense and antisense strands (Figure 9 , lane 8), indicating the
reversibility of the psoralen crosslink. These results show that crosslinked siRNA
duplexes can enter the RNAi pathway.
195
DISCUSSION
By using a quantitative dual fluorescence-based system , we have
dissected the kinetics and a number of important parameters involved in the
RNAi pathway in cultured human cells. Our results highlight the role of free 5' end
hydroxyl groups and the requirement of an A-form helical structure between the
antisense strand and the target mRNA. We also found that a complete unwinding
of the siRNA helix is not necessary to cause RNAi effects in vivo.
The time-dependent effect of siRNA may reflect a time lag between target
mRNA degradation and the half- life of the existing protein expressed from the
target gene. This time dependence may also indicate that the siRNAs need to be
processed or assembled into an active complex with cellular factors for effective
RNA interference.
Although RNA interference lasted at least 66 hr in HeLa cells , quantitative
analysis indicated that inhibition by siRNAs did not persist. After reaching
maximal activity at 42 hr posttransfection , RNA interference started to decrease
at 54 hr, with only 70% inhibition activity at 66 hr. We also found that 5%-10%
protein expressed from the genes targeted by siRNA remained at 42 hr
posttransfection , but protein amount showed gradual recovery to normal levels
between 66 to 90 hr (3 to 4 days) posttransfection (Y. L.C. and T.M.
unpublished data). The recovery of target gene expression also indicates that
RNA interference by exogenous siRNA duplex does not exist forever 
mammalian cells. These findings suggest that the proposed amplification system
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driven by RdRP and present in plants and nematodes may not exist or has very
little effect on siRNA-mediated gene silencing in mammalian cells.
Recent studies have shown that synthetic siRNAs containing 5' OH termini
can successfully induce RNAi effects in Drosophila embryo Iysates (58 , 166) and
cultured mammalian cells (55). A model involving a 5' end kinase activity
necessary for RNA interference has been proposed (166). To our knowledge
however, there is no evidence that the 5' end hydroxyl is required for in vivo
interference activity. Our results show that replacing the 5' OH , a kinase target
site , with amino groups inhibited RNAi activity. Further isolation of siRNA by
biotin pull-out experiments revealed that prior phosphatase activity was required
for in vitro 5' end radiolabeling by a polynucleotide kinase. Taken together , these
results provide strong evidence for the requirement of 5' end kinase activity for
RNA interference effects in vivo.
What about a free 3' end for RNAi effects in vivo? An RNA-directed RNA
polymerase (RdRP) chain reaction , primed by siRNA , has recently been
proposed to amplify the interference effects of a small amount of trigger RNA
(reviewed in 164). Lipardi et al. (2001) have shown siRNA-primed RNA synthesis
in Drosophila embryo Iysates and suggested that RNAi in Drosophila involves an
RdRP where siRNA primes the conversion of target RNA to dsRNA. Further
evidence of RdRP involvement in the RNAi pathway in C. elegans has been
provided in studies (215) showing target RNA-templated synthesis of new
dsRNA. These studies highlight the importance of a 3' hydroxyl in priming
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subsequent RdRP reactions. An RdRP homolog has not yet been identified in the
human genome , suggesting the presence of a separate enzyme that can carry
out primer-dependent replication of an RNA template. Our results demonstrate
that blocking the 3' position did not significantly affect RNAi activity of siRNA in
human cells. Results of our kinetic experiments show that the interference effect
lasted only -4 days , indicating the absence of an amplification mechanism in
human cells. In addition , our biotin pull-out experiments show that the 3' end
biotin groups on the antisense strand were not efficiently removed during RNAi
activities in HeLa cells. Based on these studies , we suggest a model where RNA
amplification by RNA-dependent RNA polymerase is not essential for RNA
interference in mammalian cell lines.
It is interesting to note that we found no requirement for a perfect A-form
helix in siRNA for interference effects in HeLa cells , but an A-form structure was
required for antisense-target RNA duplexes. These results suggest an RNAi
mechanism where RISC formation does not involve perfect RNA helix
recognition , but RISC* assembly requires an A-form helical structure.
The most intriguing results were obtained by crosslinking siRNAs and
testing their interference activities in HeLa cells. Psoralen crosslinked siRNA
duplexes retained 30% of RNA interference activity. This result can be explained
by psoralen photocrosslinking chemistry. There are three possible sites in the
GFP siRNA duplex where psoralen can crosslink , yet the crosslinking reaction is
not efficient enough to create multiple crosslinks in a single given siRNA duplex
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(34 , 235). Thus , in the purified crosslinked siRNA duplex population , about one-
third had crosslinking at the site near the 5' end of the antisense strand , about
one-third had crosslin king in the middle region , and the rest had crosslin king near
the 3' end of the antisense strand.
We already showed that accessibility to the 5' termini of the antisense
strand is required for efficient RNA interference in vivo. 5' phosphorylation of the
antisense strand is also required for RNA interference in vitro (166). The
cleavage site on target mRNA has been shown to be determined by the 5' end
position of the target-recognizing siRNA (58). Based on these findings , we
suggest that unwinding of the siRNA duplex would start from the 5' end of the
antisense strand , which sets the ruler for target mRNA cleavage. If crosslinking
occurred near the 5' end of the antisense strand , it would completely prohibit the
unwinding of the siRNA duplex and block access to the 5' termini of the antisense
strand , which would completely abolish the RNAi effect. If crosslinking occurred
in the middle of the siRNA duplex , near the cleavage site of mRNA, we suggest
that , although the siRNA duplex could still undergo some unwinding, this
crosslink might interfere with the pairing between target mRNA and the guiding
siRNA, thus also blocking the RNAi effect. If crosslinking occurred near the 3'
end of the antisense strand , the duplex RNA could unwind , not completely but
sufficient for the antisense strand to hybridize to the target mRNA. We have
already shown that blocking either the 3' end of the antisense strand or the 5' end
of the sense strand has no significant effect on its RNAi activity. It would thus be
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reasonable to believe that a siRNA duplex with crosslinking near the 3' end of the
antisense strand may stil be competent in RNA interference. This hypothesis
also explains the remaining 30% RNAi activity in the psoralen-crosslinked siRNA
duplex.
These results suggest a possible model for the RNAi pathway in human
cells. An RNA-protein complex containing siRNA (RISC) is assembled without
the requirement for an A-form RNA helix and/or a free 3' OH. The 5' OH of the
siRNA duplex is phophorylated by a kinase. During activation of RISC to RISC*
a 5'3' helicase unwinds the RNA duplex to allow hybridization between the
antisense strand of siRNA and the target RNA. The requirement of a perfect A-
form helix at this stage strongly suggests that another protein (or protein
complex) binds this RNA duplex , either in a structural role and/or assisting in the
cleavage of mRNA. A complete unwinding of the siRNA duplex is not required for
this process , nor can this interference activity be amplified via the 3' end.
However, unwinding of the duplex up to the cleavage site may be necessary so
that the antisense strand can form an A-form helix with the target strand for
further protein interactions. These results also argue against the involvement of
RNA amplification mechanism(s) for RNA interference in human cells.
In summary, our results provide new insight into the mechanism of RNAi
in mammalian cells , and these results could guide the design of siRNA structures
useful in probing biological questions and in functional genomic studies.
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Figure 1. Dual fluorescence reporter assay system for RNAi analysis in
HeLa cells. (A) Graphical representation of dsRNAs used for targeting GFP
mRNA and RFP mRNA. GFP and RFP were encoded by the pEGFP-C1 and
pDsRed1-N1 reporter plasmid , respectively. siRNAs were synthesized with 2 nt
deoxythymidine overhangs at the 3' end. The position of the first nucleotide of the
mRNA target site is indicated relative to the start codon of GFP mRNA or RFP
mRNA. The sequence of the antisense strand of siRNA is exactly complementary
to the mRNA target site. (B) Fluorescence images showing specific RNA
interference effects in living HeLa cells. Fluorescence in living cells was
visualized by fluorescence microscopy at 48 hr posttransfection. (a) and (b),
images of mock-treated cells (no siRNA added); (c) and (d), images of GFP
siRNA-treated cells; (e) and (f), images of RFP siRNA-treated cells. (C)
Quantitative analysis of RNAi effects in HeLa cells. Fluorescence emission
spectra of GFP and RFP in total ceillysates were detected by exciting at 488 and
568 nm , respectively. (D) Kinetics of RNAi effects in HeLa cells. Ratios of
normalized GFP to RFP fluorescence intensity over a 66 hr time course. The
fluorescence intensity ratio of target (GFP) to control (RFP) protein was
determined in the presence of double-strand (ds) RNA (green bars) and
normalized to the ratio observed in the presence of antisense strand (as) RNA
(blue bars). Normalized ratios less than 1.0 indicate specific RNA interference.
Maximal RNAi effect occurred at 42 hr posttransfection.
Poly A
AAGUGGGAGCGCGUGAUGAAC277 297
Sense strand (55) 5 ' GUGGGAGCGCGUGAUGAACdTdT
Antisense strand (as) dTdTCACCCUCGCGCACUACUUG 5
GFP ds siRNA Sense strand (55)Antisense strand (as)
GFP mRNA target site sequence
GFP mRNA m7GpppG
RFP mRNA m7GpppG
RFP mRNA target site sequence
RFP ds siRNA
MOCK
201
' GCAGCACGACUUCUUCAAGdTdT
dTdTCGUCGUGCUGAAGAAGUUC 5
AAGCAGCACGACUUCUUCAAG238 258
/ --
OlY A
GFP ds RFP ds
GFP
RFP
''' ...
siRNA
Mock
RFP d.
GFP dB
...
65.
Wavelength (om)
, 8
Hours Post Trsnsfectlon
,..
'50
siRNA
Mock
RFP dB
GFP dB
Wavelength (om)
GFP as
GFP ds
202
Figure 2. Analysis of specific RNAi activities by western blotting. Antisense
and double-strand RNA are indicated as as and ds , respectively. GFP as ((A), left
panel), GFP ds ((A), right panel), RFP as ((B), left panel), or RFP ds ((B), right
panel) were cotransfected with pEGFP-C 1 and pDsRed 1-N 1 reporter plasm ids
into HeLa cells. Cells were harvested at various times , resolved on 10% SDS-
PAGE , transferred onto PVDF membranes , and immunoblotted with antibodies
against EGFP and DsRed1-N1. The membrane was stripped and reprobed with
anti-actin antibody to check for equal loading of total proteins.
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Figure 3. Expression of GFP in HeLa cells treated with antisense or double-
stranded siRNA targeting GFP. Transfected cells were harvested at various
times after transfection and total cell Iysates were analyzed by fluorescence
spectroscopy. Fluorescence emission spectra of GFP and RFP were detected by
exciting at 488 and 568 nm , respectively.
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Figure 4. Modification of GFP siRNA duplexes. (A) Structure of 5' N3 (amino
group with 3-carbon linker, red) and 3' Pmn (puromycin , blue) modifications. (B)
Classification and nomenclature of the modified siRNAs. Sense (top row , purple)
and antisense (bottom row , black) strands of siRNA species are shown with their
N3 (red) and 3' Pmn or biotin (blue) modifications. A dinucleotide internal
bulge structure (green) was introduced in sense , antisense , or duplex RNAs.
207
- Amino modification = N3
, /
Y NH2
MeO
- Puromycin = Pmn
aae0- 
.,/ 
GFP siRNA
ds (W GCAGCACGACUUCUUCAAGdTdT
dTdTCGUCGUGCUGAAGAGUUC
N3 - GCAGCACGACUUCUUCAAGdTdT
.N3sslas dTdTCGUCGUGCUGAAGAGUUC
GCAGCACGACUUCUUCAAGdTdT
ssl5' -N3as dTdTCGUCGUGCUGAAGAGUUC - N3
N3 - GCAGCACGACUUCUUCAAGdTdT
.N3ssl5' N3as dTdTCGUCGUGCUGAAGAGUUC - N3
GCAGCACGACUUCUUCAAGdTdT - Pmn
ss3' Pmnlas dTdTCGUCGUGCUGAAGAAGUUC
GCAGCACGACUUCUUCAAGdTdT
ssas3' .pmn Pmn. dTdTCGUCGUGCUGAAGAAGUUC
ss3' .Pmnlas3' .pmn GCAGCACGACUUCUUCAAGdTdT - PmnPmn - dTdTCGUCGUGCUGAAGAAGUUC
ssas3' -Biotin GCAGCACGACUUCUUCAAGdTdTBiotin - dTdTCGUCGUGCUGAAGAGUUC
ss-bulge/as GCAGCACGA CUUCUUCAAGdTdTdTdTCGUCGUGCU GAAGAGUUC
sslas-bulge
GCAGCACGA CUUCUUCAAGdTdT
dTdTCGUCGUGCU GAAGAGUUC
ss-bulge/as-bulge GCAGCACGA CUUCUUCAAGdTdTdTdTCGUCGUGCU GAAGAAGUUC
208
Figure 5. Fluorescence images showing RNA interference effects in living
HeLa cells transfected with modified siRNA duplexes. HeLa cells were
cotransfected by lipofectamine with pEGFP- , pDsRed1-N1 reporter plasmids
and siRNA with a 5' modification (c-e) , 3' modification (f- i) , or internal bulge U-I).
Fluorescence in living cells was visualized at 48 hr posttransfection. GFP
fluorescence (left panels) and phase contrast images (right panels) are shown.
RNA used in each experiment is indicated on the left of each pair of panels.
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Figure 6. Quantitative analysis of RNAi effects in HeLa cells transfected
with modified siRNAs. pEGFP-C1 (as reporter), pDsRed1-N1 (as control)
plasmids and 50 nM siRNA were cotransfected into HeLa cells by lipofectamine.
Cells were harvested at various times after transfection. Fluorescence emission
spectra of GFP and RFP in total ceillysates were detected by exciting at 488 and
568 nm , respectively. (A) GFP emission spectra of modified siRNA-treated cells.
Emission spectra of GFP in Iysates from cells transfected with 5'-modified GFP
siRNAs (upper panel), 3' -modified GFP siRNAs (middle panel), and bulge-
containing GFP siRNAs (lower panel). For comparison , results from antisense-
(as , red line) and unmodified duplex siRNA- (ds , black line) treated cells are
included in each panel. (B) Ratios of normalized GFP to RFP fluorescence
intensity in Iysates from modified siRNA-treated HeLa cells over 66 hr. The
fluorescence intensity ratio of target (GFP) to control (RFP) fluorophore was
determined in the presence of 5' -modified GFP siRNAs (upper panel), 3'-modified
GFP siRNAs (middle panel), and bulge-containing GFP siRNAs (lower panel)
and normalized to the ratio observed in the presence of antisense strand siRNA.
Normalized ratios less than 1.0 indicate specific RNA interference effects. For
comparison , results from antisense RNA and duplex siRNA-treated cells are
included in each panel (as , orange bars; ds , yellow bars).
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Figure 7. Isolation of 5' end phosphorylated and 3' end biotinylated siRNA
from HeLa cells. HeLa cells were cotransfected with biotinylated GFP duplex
siRNA (ss/as3' Biotin) and pEGFP-C1 plasmid as described in the Experimental
Procedures. The siRNA was isolated by pull-out assay and subjected to
phosphatase and kinase reactions (see Experimental Procedures). In brief
streptavidin magnetic beads were used to pull out biotinylated siRNAs from
transfected cells , washed to remove unbound RNA , and split into two aliquots.
One aliquot was dephosphorylated with shrimp alkaline phosphatase (SAP), and
the RNA 5' ends were labeled with 32P by T4 polynucleotide kinase (PNK)
reaction. The other aliquot was not dephosphorylated. RNA was resolved on
20% polyacrylamide-7 M Urea gels and visualized by phosphorimager analysis.
Lanes 1-3 (marker lanes) contain 5' end-labeled RNA: lane 1 , sense strand (ss);
lane 2 , 3' biotinylated antisense strand (as3' Biotin); lane 3 , heat denatured (10
min at 95 C) siRNA duplex (ss/as3' Biotin). Lanes 5- , isolated biotinylated
siRNA with SAP treatment (lanes 5-9) or without (lanes 10-14). Lane 4 , RNA
isolated as above from HeLa cells without siRNA transfection.
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Figure 8. RNA interference activities of covalently photocrosslinked duplex
RNA in HeLa cells. (A) Structure of a psoralen derivative , 4' hydroxymethyl-
trimethylpsoralen (HMT), used to crosslink the duplex RNA. (B)
Photocrosslinking sites in GFP siRNA. Three preferred sites for psoralen addition
to a duplex RNA are shown by cyan letters with red bars indicating the C-
crosslinks formed by UV irradiation in the presence of HMT. (C) Psoralen
photocrosslinking of siRNA duplexes. Mixtures of siRNA duplex and psoralen
were exposed to UV 360 nm and denatured. Crosslinked and noncrosslinked
siRNAs were resolved on 20% PAGE containing 7 M urea (lanes 2 and 3). UV-
irradiated RNA bands were excised from the gel and purified. Purified crosslinked
dsRNA (ds-XL) and noncrosslinked dsRNA (ds ) are shown in lanes 6 and 5
respectively. To confirm the nature and purity of the crosslink , a portion of the
360 nm UV- irradiated sample (lane 3) was UV irradiated at 254 nm.
Photoreversal of psoralen crosslinked siRNA resulted in products with similar
electrophoretic mobility to the siRNA duplex without HMT treatment (lane 4). (D)
Fluorescence images showing RNA interference effects of psoralen
photocrosslinked siRNAs in living HeLa cells. Purified crosslinked ds siRNA (ds-
, bottom panels) was cotransfected with reporter pEGFP-C1 and control
pDsRed1-N1 plasmids into HeLa cells for dual fluorescence reporter assays.
Fluorescence (left panels) and phase contrast (right panels) images of living cells
were taken 48 hr posttransfection. For comparison , images from noncrosslinked
ds siRNA (ds , middle panels) and antisense siRNA (as , top panels) are also
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shown. (E) GFP emission spectra of psoralen photocrosslinked siRNA duplex-
treated cells. Cell Iysates were prepared from HeLa cells treated with antisense
siRNA (as), unmodified UV- irradiated duplex siRNA (ds ), and crosslinked ds
siRNA (ds-XL) and analyzed by fluorescence spectroscopy. Fluorescence
emission spectra of GFP and RFP were detected by exciting at 488 and 568 nm
respectively. GFP emission spectra are shown normalized to RFP expression.
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Figure 9. Isolation of psoralen-crosslinked siRNA from human cells. siRNA
duplexes were conjugated with 3' biotin (ss/as3' Biotin), psoralen crosslinked
and purified as described in Figure 6 and in the Experimental Procedures. HeLa
cells were cotransfected by lipofectamine with crosslinked siRNA (ss/as3' Biotin-
XL) and pEGFP-C1 plasmid , and siRNAs were isolated by biotin pull-out assay at
30 hr posttransfection as described in the Experimental Procedures. In brief
streptavidin-magnetic beads with biotinylated siRNA were subjected to
phosphatase treatment and 5' end labeled with 32P. RNA was resolved on 20%
polyacrylamide-7 M urea gels and visualized by phosphorimager analysis. Lane
RNA from HeLa cells without siRNA transfection. Lane 2 , 32P- labeled
noncrosslinked siRNA duplex (ss/as3' Biotin). Lane 3 , 32P- labeled 3' biotinylated
antisense strand siRNA (as3' Biotin). Lane 4 , 32P- labeled sense strand RNA
(ss). Lane 5 , 32P- labeled crosslinked siRNA duplex (ss/as3' Biotin-XL). Lanes 7
and 8 , siRNA isolated from HeLa cells treated with crosslinked siRNA duplex
(ss/as3' Biotin-XL). Lanes 6 and 8 , UV irradiation (254 nm) of crosslinked siRNA
to photoreverse the psoralen crosslinks.
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APPENDIX
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Table 1. Genomewide analysis of gene expression in P- TEFb knockdown
HeLa cells. Total mRNA from HeLa cells treated with and without siRNA directed
against hCycT1 (Cyclin T i1) or CDK9 (CDK9 i1) at 48h post transfection and the
expression of various genes were analyzed by using the GeneChip(I Human
Genome U133 (HG-U133) from Affmetrix. For comparison analysis , data from
cells treated with nonrelated ds siRNA (RFP ds) were used as baseline. A
Change p-value is calculated indicating an increase (I), decrease (D) or no
change in gene expression. The Signal Log Ratio (base on 2) estimates the
magnitude and direction of change of a transcript when two arrays are compared.
A complete list of down- and up-regulated genes with names and accession
numbers is shown here.
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Table 1.
ID# CyclinT.. CDK9.. Description
Signal Change Signal Change
ratio ratio
230465 -4. D Consensus includes gb:AI806674/FEA=EST
/DB XREF=gi:5393240
IDB - XRE F =estwf35d02.
ICLONE=IMAGE:2357571/UG=Hs. 121898 ESTs
204379 D gb:NM 000142.2/DEF=Homo sapiens fibroblast
growth factor receptor 3 (achondroplasia
thanatophoric dwarfsm) (FGFR3), transcript
variant 1 , mRNA. IFEA=mRNA IGEN=FGFR3
IPROD=fibroblast growth factor receptor 3
isoform 1 precursor IDB XREF=gi:13112046
IUG=Hs. 1420 fibroblast growth factor receptor 3
(achondroplasia, thanatophoric dwarfsm)
IFL= b:NM 000142. b:M58051.
234986
229256
225710
203650
226625
203153 2.49 D gb:NM 001548. 1/DEF=Homo sapiens interferon-
induced protein with tetratricopeptide repeats 
(IFIT1), mRNA. IFEA=mRNA IGEN=IFIT1
IPROD=interferon- induced protein
withtetratricopeptide repeats 1
IDB XREF=gi:4504584/UG=Hs.20315 interferon-
induced protein with tetratricopeptide repeats 
IFL= b:M24594. b:NM 001548.
201940 1.4
201324 D gb:NM 001423. 1/DEF=Homo sapiens epithelial
membrane protein 1 (EMP1), mRNA.
IFEA=mRNA IGEN=EMP1/PROD=epithelial
membrane protein 1 IDB XREF=gi:4503558
IUG=Hs. 79368 epithelial membrane protein 
IFL= b:U77085. b:U43916. b:NM 001423.
224893
204731
204396
203646 D gb:NM 004109.2/DEF=Homo sapiens ferredoxin
1 (FDX1), nuclear gene encoding mitochondrial
protein , mRNA. IFEA=mRNA IGEN=FDX1
IPROD=ferredoxin 1 precursor
/DB XREF=gi:13677224/UG=Hs.744 ferredoxin 1
IFL=gb:NM 0041 09.2 gb:J03548. 1 gb:M 18003.
b:M34788.
35148 D Cluster Incl. AC005954:Homo sapiens
chromosome 19 , cosmid R28784/cds=(0,2858)
Igb=AC005954/gi=3851201/ug=Hs.25527
Ilen=2859
222692
225847 _
247
200600 D gb:NM 002444. 1/DEF=Homo sapiens moesin
(MSN), mRNA. /FEA=mRNA /GEN=MSN
/PROD=moesin /DB XREF=gi:4505256
/UG=Hs. 170328 moesin /FL=gb:M69066.
b:NM 002444.
238417 _
214121
225479 1.45
201941
225032
202686 D gb:NM 021913. 1/DEF=Homo sapiens AXL
receptor tyrosine kinase (AXL), transcript variant
, mRNA. /FEA=mRNA /GEN=AXL /PROD=AXL
receptor tyrosine kinase isoform 1 precursor
/DB XREF=gi:11863122/UG=Hs.83341 AXL
rece tor rosine kinase /FL= b:NM 021913.
212993 1.4
225179
218618 D gb:NM 022763. 1/DEF=Homo sapiens
hypothetical protein FLJ23399 (FLJ23399),
mRNA. /FEA=mRNA /GEN=FLJ23399
/PROD=hypothetical protein FLJ23399
/DB XREF=gi:12232434/UG=Hs.299883
hypothetical protein FLJ23399
/FL= b:NM 022763.
224989 D Consensus includes gb:A1824013 /FEA=EST
/DB XREF=gi:5444684
/DB XREF=estwj2ge07.
ICLONE=IMAGE:2404260 IUG=Hs. 122489 Homo
sapiens cDNA FLJ13289 fis , clone
OVARC1001170
209877 _ gb:AF010126. 1/DEF=Homo sapiens breast
cancer-specific protein 1 (BCSG1) mRNA
complete cds. /FEA=mRNA /GEN=BCSG1
/PROD=BCSG1 protein IDB XREF=gi:2281473
/UG=Hs.63236 synuclein , gamma (breast cancer-
specific protein 1) /FL=gb:AF01 0126.
I Qb:AF017256. 1 Qb:NM 003087.
228745
200831
229553
205619 1.4
212731
213372
201490
207357 _
238320 Consensus includes gb:AV659198/FEA-EST
IDB XREF=gi:9880212
/DB XREF=estA V659198 /CLONE=GLCFUE07
/UG=Hs. 11367 ESTs
211162 x at
226685 1.41
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202342 D gb:NM 015271. 1/DEF=Homo sapiens tripartite
motif protein TRIM2 (KIAA0517), mRNA.
/FEA=mRNA /GEN=KIAA0517 /PROD=tripartite
motif protein TRIM2/DB XREF=gi:13446226
/UG=Hs. 12372 tripartite motif protein TRIM2
/FL= b:AF220018. b:NM 015271.
236262
226785
213012
225319
201943
232125
208867 _
225266
208051
227052
226982
212919
201389 D gb:NM 002205. 1/DEF=Homo sapiens integrin
alpha 5 (fibronectin receptor , alpha polypeptide)
(ITGA5), mRNA. /FEA=mRNA /GEN=ITGA5
/PROD=integrin alpha 5 precursor
/DB XREF=gi:4504750 /UG=Hs. 149609 integrin
alpha 5 (fibronectin receptor, alpha polypeptide)
/FL= b:NM 002205.
203231
209406 at 1 67 098 D gb'AF095192 1 /DEF=Homo sapiens BAG-family
molecular chaperone regulator-2 mRNA , complete
cds. /FEA=mRNA /PROD=BAG-family molecular
chaperone regulator-2/DB XREF=gi:4322819
/UG=Hs.55220 BCL2-associated athanogene 2
/FL=gb:AF095192. 1 gb:AL050287.
I gb:NM 004282.
201681
227112
201971 gb:NM 001690. 1/DEF=Homo sapiens ATPase
H+ transporting, lysosomal (vacuolar proton
pump), alpha polypeptide , 70kD , isoform 1
(ATP6A1), mRNA. /FEA=mRNA /GEN=ATP6A1
/PROD=ATPase , H+ transporting, lysosomal
(vacuolarproton pump), alpha polypeptide , 70kD
isoform 1/DB XREF=gi:4502304/UG=Hs.281866
ATPase, H+ transporting, lysosomal (vacuolar
proton pump), alpha polypeptide , 70kD , isoform 1
/FL=gb:L09235. 1 gb:NM 001690.
IQb:AF113129.
218196
225750 Consensus includes gb:BE966748 /FEA=EST
/DB XREF=gi:11772486
/DB XREF=est:60166124 7R 
/CLONE=IMAGE:3916235/UG=Hs. 10949 Homo
sapiens cDNA FLJ14162 fis , clone
NT2RM4002504
249
225242
241879
201149 D gb:U67195. 1/DEF=Human tissue inhibitor of
metalloproteinase-3 mRNA, complete cds.
/FEA=mRNA /PROD=tissue inhibitor of
metalioproteinase-3/DB XREF=gi:1519557
/UG=Hs.245188 tissue inhibitor of
metalloproteinase 3 (Sorsby fundus dystrophy,
pseudoinflammatory) /FL=gb:U67195.
b:U02571. b:U14394. b:NM 000362.
214895
226962
204298 D gb:NM 002317. 1/DEF=Homo sapiens Iysyl
oxidase (LOX), mRNA./FEA=mRNA /GEN=LOX
/PROD=lysyl oxidase /DB XREF=gi:4505008
/UG=Hs. 102267 Iysyl oxidase /FL=gb:M94054.
b:AF039291. b:NM 002317.
215177
232079
231550
201942 D gb:D85390. 1/DEF=Homo sapiens mRNA for
gp180-carboxypeptidase D- like enzyme , complete
cds. /FEA=mRNA /PROD=gp180-
carboxypeptidase D- like enzyme
/DB XREF=gi:3641620 /UG=Hs.5057
carboxypeptidase D /FL=gb:U65090.
b:D85390. b:NM 001304.
208712 1.49 D gb:M73554.1/DEF=Human bcl-1 mRNA
complete CDS. /FEA=mRNA /GEN=bcl-
/PROD=bcl- 1 /DB XREF= gi: 179364
/UG=Hs.82932 cyclin D1 (PRAD1: parathyroid
adenomatosis 1) /FL=gb:BC000076.
b:M73554.
227062 1.49
201409 1.48 I gb:NM 002709. 1/DEF=Homo sapiens protein
phosphatase 1 , catalytic subunit, beta isoform
(PPP1 CB), mRNA. /FEA=mRNA /GEN=PPP1 CB
/PROD=protein phosphatase 1 , catalytic subunit
betaisoform /DB XREF=gi:4506004
/UG=Hs.21537 protein phosphatase 1 , catalytic
subunit, beta isoform /FL=gb:NM 002709.
b:AF092905.
201015 1.47 D gb:NM 021991. 1/DEF=Homo sapiens junction
plakoglobin (JUP), transcript variant 2 , mRNA.
/FEA=mRNA /GEN=JUP /PROD=junction
plakoglobin , isoform 1/DB XREF=gi:12056467
/UG=Hs.2340 junction plakoglobin
/FL= b:NM 021991. b: BC000441.
224874 1.47
201617 _ 1.45 D gb:NM 004342.2/DEF-Homo sapiens caldesmon
1 (CALD1), mRNA. /FEA=mRNA /GEN=CALD1
/PROD=caldesmon 1/DB XREF=gi:11091984
/UG=Hs.325474 caldesmon 1
/FL= b:NM 004342. b:M64110.
224691 1.45
250
228418 1.44
224597 _ 1.44
206584 1.43
235198 1.43
208779 1.42 D gb:L20817. 1/DEF=Homo sapiens tyrosine protein
kinase (CAK) gene , complete cds. IFEA=mRNA
IGEN=CAK IPROD=tyrosine protein kinase
IDB XREF=gi:306474/UG=Hs.75562 discoidin
domain receptor family, member 1
IFL= b:L20817.
228220 1.42
209748 1.41
211985 1.41
239503 1.41 1 .42 D Consensus includes gb:A180301 0 IFEA=EST
IDB XREF=gi:5368482/DB XREF=esttj60c11.
ICLONE=IMAGE:2145908/UG=Hs. 126877 ESTs
224702 1.4 D Consensus includes gb:BG501219/FEA=EST
/DB XREF=gi:13462747
IDB _XRE F =est602546289F 1
ICLONE=IMAGE:4668574/UG=Hs. 10248 Homo
sa iens cDNA FLJ20167 tis , clone COL09512
228708
32502 D Cluster Incl. AL041124:DKFZp434D0316
Homo sapiens cDNA , 3 end
Iclone=DKFZp434D0316/c1one end=3
Igb=AL041124 Igi=541 0060 lug=Hs.6748
lIen=719
223571 D gb:AF329842. 1 /DEF=Homo sapiens
complement-c1 q tumor necrosis factor-related
protein (CTRP6) mRNA , complete cds.
IFEA=mRNA IGEN=CTRP6 IPROD=complement-
c1 q tumor necrosis factor-relatedprotein
IDB XREF=gi:13274530 /UG=Hs.22011 Homo
sapiens complement-c1q tumor necrosis factor-
related protein (CTRP6) mRNA, complete cds
IFL= b:AF329842.
202351
213552 1.44
211708 D gb:BC005807.1/DEF=Homo sapiens , clone
MGC:10264 , mRNA, complete cds. /FEA=mRNA
IPROD=Unknown (protein for MGC:10264)
/DB XREF= i:13543283/FL= b:BC005807.
217887 _ D gb:NM 001981. 1/DEF=Homo sapiens epidermal
growth factor receptor pathway substrate 15
(EPS15), mRNA. IFEA=mRNA /GEN=EPS15
IPROD=epidermal growth factor receptor
pathwaysubstrate 15/DB XREF=gi:4503592
IUG=Hs.79095 epidermal growth factor receptor
pathway substrate 15/FL=gb:NM 001981.
b:U07707.
219023
243495 D Consensus includes gb:AL036450 /FEA-EST
IDB XREF=gi:5406002
/DB XREF=estDKFZ 564D1062 
"-" """""" ",,,=- ,,"-
251
ICLONE=DKFZp564D1 062/UG=Hs. 1 03238 ESTs
209064 D gb:AL 136920. 1 IDEF=Homo sapiens mRNA;
cDNA DKFZp586C051 (from clone
DKFZp586C051); complete cds. IFEA=mRNA
IGEN=DKFZp586C051/PROD=hypothetical
protein IDB XREF=gi:12053334/UG=Hs. 1 09643
polyadenylate binding protein-interacting protein 1
IFL= b:AL 136920.
214975
229461
227312
225522
226390
226254 D Consensus includes gb:AI912523/FEA=EST
IDB XREF=gi:5632378
IDB XRE F =esttz25f09 .
ICLONE=IMAGE:2289641 IUG=Hs. 126914
KIM 1430 rotein
224618 1.43
226633
204855 D gb:NM 002639. 1/DEF=Homo sapiens serine (or
cysteine) proteinase inhibitor, clade B (ovalbumin),
member 5 (SERPINB5), mRNA. IFEA=mRNA
IGEN=SERPINB5/PROD=serine (or cysteine)
proteinase inhibitor, cladeB (ovalbumin), member
5 IDBjREF=gi:4505788IUG=Hs.55279 serine
(or cysteine) proteinase inhibitor, clade B
(ovalbumin), member 5/FL=gb:NM 002639.
b:U04313.
221568
208796 D gb:BC000196.1/DEF=Homo sapiens, cyclin G1
clone MGC:643, mRNA, complete cds.
IFEA=mRNA IPROD=cyclin G1
IDB XREF=gi:12652880 IUG=Hs. 79101 cyclin G1
IFL=gb:L49504. 1 gb:U47413. 1 gb:BC000196.
b:D78341. b:NM 004060.
225366
226817 _
219594
230788 D Consensus includes gb:BF059748/FEA=EST
IDB XREF=gi:10813644
IDB XREF=est7k65h01.
ICLONE=IMAGE:3480432/UG=Hs. 116346 ESTs
Highly similar to A46297 beta- 1 ,
acet I lucosamin Itransferase H.sa iens
226310
224800
1007 _ D U48705/FEATURE=mRNA
IDEFINITION=HSU48705 Human receptor
rosine kinase DDR ene , com lete cds
206315
212690
252
218706
201469
238587 _
226051 1.24
225405
201602
209380
239269
227740 D Consensus includes gb:AW173222 /FEA=EST
IDB XREF=gi:6439170
IDB XREF=estxj84g11.
/CLONE=IMAGE:2663972/UG=Hs. 127310 ESTs
225575
212488 1.22 1.4
227853 1.22
224617 _ 1.22 1.47
205905
223441 D Consensus includes gb:AK026921. 1/DEF=Homo
sapiens cDNA: FLJ23268 fis , clone COL08932
highly similar to HSA387747 Homo sapiens
mRNA for sialin. /FEA=mRNA
/DB XREF=gi:10439893/UG=Hs. 117865 solute
carrier family 17 (anionsugar transporter), member
5/FL= b:AF244577.
205552
21 0749 D gb:L 11315. 1/DEF=Homo sapiens receptor
tyrosine kinase mRNA, complete cds.
/FEA=mRNA /PROD=receptor tyrosine kinase
/DB XREF=gi:403386/UG=Hs.75562 discoidin
domain receptor family, member 
/FL= b:L11315.
235258
235125
228531
204794 D gb:NM 004418.2/DEF=Homo sapiens dual
specificity phosphatase 2 (DUSP2), mRNA.
/FEA=mRNA /GEN=DUSP2 /PROD=dual
specificity phosphatase 2
/DB XREF=gi: 12707563 /UG=Hs. 1183 dual
specificity phosphatase 2/FL=gb:NM 004418.
b:L11329.
207169
202893
209468 D gb:AB017498.1/DEF=Homo sapiens LRP5
mRNA for Lipoprotein Receptor Related Protein 5
complete cds. /FEA=mRNA /GEN=LRP5
/PROD=Lipoprotein Receptor Related Protein 5
IDB XREF=gi:3582144/UG=Hs.6347 low density
lipoprotein receptor-related protein 5
/FL=gb:AB017498. 1 gb:AF064548.
b:AF077820. b:NM 002335.
253
227685 1.48
201506
203679
206382 D gb:NM 001709. 1/DEF=Homo sapiens brain-
derived neurotrophic factor (BDNF), mRNA.
IFEA=mRNA IGEN=BDNF IPROD=brain-derived
neurotrophic factor IDB XREF=gi:4502392
IUG=Hs. 56023 brain-derived neurotrophic factor
IFL= b:NM 001709.
213623 1.46
228611
213151
213805 1.44
225571
202502
214443
223006
202067 _
205808
212589
64883 Cluster Incl. AI744083:wc36b04.x1 Homo sapiens
cDNA, 3 end Iclone=IMAGE-2317231
Iclone end=3 Igb=AI744083/gi=5112371
lu =Hs.65406/Ien=608
226671
225813
212340
229450 at
227771
204364
207147
212489
226045
221269 gb:NM 031286. 1/DEF=Homo sapiens
SH3BGRL3-like protein (SH3BGRL3), mRNA.
IFEA=mRNA IGEN=SH3BGRL3
IPROD=SH3BGRL3- like protein
IDB XREF=oi:13775197/FL=Ob:NM 031286.
228479
226115
222996 gb:BC002490. 1/DEF=Homo sapiens , hypothetical
protein , clone MGC:915, mRNA, complete cds.
IFEA=mRNA IPROD=hypothetical protein
IDB XREF=gi:12803342/UG=Hs. 15093
hypothetical protein IFL=gb:BC002490.
ab:AF151029. 1 ob:NM 016463.
203071
231716 Consensus includes gb:AF255304. 1 IDEF=Homo
sapiens membrane-associated nucleic acid
254
binding protein mRNA, complete cds.
/FEA=mRNA /PROD=membrane-associated
nucleic acid bindingprotein
/DB XREF=gi:9837126/UG=Hs. 112227
membrane-associated nucleic acid binding protein
/FL= b:AF255304.
225607 _
225912
205594
211161 D gb:AF130082. 1/DEF=Homo sapiens clone
FLC1492 PR03121 mRNA, complete cds.
/FEA=mRNA /PROD=PR03121
/DB XREF=gi:11493468/UG=Hs. 119571
collagen , type III , alpha 1 (Ehlers-Danlos
syndrome type IV , autosomal dominant)
/FL= b:AF130082.
203203
210797
215489y_
201852y_
202667 _
203325
219297
243357 _
225725
224209 D gb:AF019638. 1 /DEF=Homo sapiens nedasin s-
form mRNA, complete cds. /FEA=mRNA
/PROD=nedasin s-form /DB XREF=gi:6469319
/UG=Hs.239147 guanine deaminase
/FL= b:AF019638.
213508
229399
225192
242931 1.41
203743
205383
226711 D Consensus includes gb:BF590117 /FEA=EST
/DB XREF=gi: 11682441
IDB XREF=estnab19b11.
/CLONE=IMAGE:3266253/UG=Hs. 106131 ESTs
226312
226237 _
225950
204540 gb:NM 001958. 1/DEF=Homo sapiens eukaryotic
translation elongation factor 1 alpha 2 (EEF1A2),
mRNA. /FEA=mRNA /GEN=EEF1A2
217738
217765
229010
227082 at
220178
229075
209849
212483
218294
218542
218585
209154
231094
223039
203563
212943
218945
221802
203150 at
1.43
255
/PROD=eukaryotic translation elongation factor 
alpha2/DB XREF=gi:4503474/UG=Hs.2642
eukaryotic translation elongation factor 1 alpha 2
/FL= b:BC000432.1 b:NM 001958.
I gb:NM 021731. 1/DEF=Homo sapiens
hypothetical protein PP3501 (PP3501), mRNA.
/FEA=mRNA /GEN=PP3501 /PROD=hypothetical
protein PP3501/DB XREF=gi:11119425
/UG=Hs.301406 hypothetical protein PP3501
/FL= b:NM 021731.
I Consensus includes gb:A1754871 /FEA=EST
/DB XREF=gi:5133135
/DB XREF=estcr31 g04.
/CLONE=HBMSC cr31 04/UG=Hs. 111207 ESTs
I gb:AF029669. 1/DEF=Homo sapiens Rad51 
(RAD51 C) mRNA , complete cds. /FEA=mRNA
/GEN=RAD51 C /PROD=Rad51 C
/DB XREF=gi:2909800 /UG=Hs. 11393 RAD51
S. cerevisiae homolo C /FL= b:AF029669.
I gb:AF267865. 1 /DEF=Homo sapiens DC41
mRNA , complete cds. /FEA=mRNA /PROD=DC41
/DBjREF=gi:12006056/UG=Hs.271623
nucleoporin 50kD /FL=gb:AF267865.
b:AF107840. 1 b:NM 007172. 1 b:AF116624.
I gb:AF234997. 1/DEF=Homo sapiens glutaminase-
interacting protein 3 mRNA, complete cds.
/FEA=mRNA /PROD=glutaminase-interacting
protein 3/DB XREF=gi:12005281/UG=Hs. 12956
Tax interaction protein 1/FL=gb:AF028823.
b:NM 014604. 1 b:AF234997.
I gb:BC004144. 1/DEF=Homo sapiens , Similar to
PR01992 protein , clone MGC:1842 , mRNA
complete cds. /FEA=mRNA /PROD=Similar to
PR01992 protein /DB XREF=gi:13278734
/UG=Hs.9850 Homo sapiens cDNA: FLJ21589 fis,
clone COL06960 /FL= b:BC004144.
I gb:NM 021638. 1/DEF=Homo sapiens actin
fiament associated protein (AFAP), mRNA.
/FEA=mRNA /GEN=AFAP /PROD=actin filament
associated protein /DB XREF=gi:11056013
/UG=Hs.80306 actin fiament associated protein
/FL= b:AF188700.1 b:NM 021638.
I gb:NM 024109. 1/DEF=Homo sapiens
hypothetical protein MGC2654 (MGC2654),
mRNA. /FEA=mRNA /GEN=MGC2654
/PROD=hypothetical protein MGC2654
/DB XREF=gi:13129121/UG=Hs. 165428
hypothetical protein MGC2654
/FL= b:BC001908. 1 b:NM 024109.
256
208709 I gb:U64898. 1/DEF=Homo sapiens NRD
convertase mRNA , complete cds. IFEA=mRNA
IPROD=NRD convertase IDB XREF=gi:2897866
IUG=Hs.4099 nardilysin (N-arginine dibasic
convertase IFL= b:U64898.
228867 _ I Consensus includes gb:BE541548/FEA=EST
IDB XREF=gi:9770193
IDB XREF=est601 067822F1
ICLONE=IMAGE:3454205/UG=Hs. 123386 ESTs
225836
201292
204228
211114
201536
219204 I gb:NM 021947. 1/DEF=Homo sapiens serine
racemase (SRR), mRNA IFEA=mRNA
IGEN=SRR IPROD=serine racemase
IDB XREF=gi:11345491/UG=Hs.27335 serine
racemase IFL= b:AF169974. b:NM 021947.
224824
206364
201675 1.43 I gb:NM 003488. 1/DEF=Homo sapiens A kinase
(PRKA) anchor protein 1 (AKAP1), mRNA
IFEA=mRNA IGEN=AKAP1/PROD=A kinase
(PRKA) anchor protein 1/DB XREF=gi:4502014
IUG=Hs. 78921 A kinase (PRKA) anchor protein 
IFL= b:BC000729. b:NM 003488.
241453 I Consensus includes gb:AA912743/FEA=EST
IDB XREF=gi:3052135
IDB XREF=estoI41 d04.
ICLONE=IMAGE: 1526023/UG=Hs.126421 ESTs
Highly similar to FAK1 HUMAN FOCAL
ADHESION KINASE 1 H.sa iens
223024
202533 I gb:BC003584. 1 IDEF=Homo sapiens
dihydrofolate reductase , clone MGC:3153, mRNA
complete cds. IFEA=mRNA IPROD=dihydrofolate
reductase IDB XREF=gi: 13097773
IUG=Hs.83765 dihydrofolate reductase
IFL=gb:BC000192. 1 gb:BC003584.
b:NM 000791.
208653
218979 I gb:NM 024945. 1/DEF=Homo sapiens
hypothetical protein FLJ12888 (FLJ12888),
mRNA/FEA=mRNA IGEN=FLJ12888
IPROD=hypothetical protein FLJ12888
IDB XREF=gi:13376426/UG=Hs.284137
hypothetical protein FLJ12888
IFL= b:NM 024945.
226181
223513 I gb:AF139625. 1 IDEF=Homo sapiens centrosomal
P4. 1-associated protein (CPAP) mRNA, complete
cds. IFEA=mRNA IGEN=CPAP
IPROD=centrosomal P4. 1-associated protein
IDB XREF= i:10643591/UG=Hs.283077
257
centrosomal P4.1-associated protein;
uncharacterized bone marrow protein BM032
IFL= b:AF139625.
203740
219306 1.48
238756
228577 _
218755
219148
225456 I Consensus includes gb:AI708776 IFEA=EST
IDB XREF=gi:4998552
IDB XREF=estas35f01.
ICLONE=IMAGE:2319193/UG=Hs. 1 0130 ESTs
205063 I gb:NM 003616. 1/DEF=Homo sapiens survival of
motor neuron protein interacting protein 1 (SIP1),
mRNA. IFEA=mRNA IGEN=SIP1
IPROD=survival of motor neuron protein
interactingprotein 1/DB XREF=gi:4506960
IUG=Hs. 102456 survival of motor neuron protein
interacting protein 1 IFL=gb:AF027150.
b:NM 003616.
225549
225125 I Consensus includes gb:BF978280 IFEA=EST
IDB XREF=gi:12345495
IDB _XREF=est602148240F1
ICLONE=IMAGE:4307192/UG=Hs. 110702 Homo
sapiens mRNA; cDNA DKFZp761E212 (from
clone DKFZ 761E212
201185 I gb:NM 002775. 1 IDEF=Homo sapiens protease
serine, 11 (IGF binding) (PRSS11), mRNA.
IFEA=mRNA IGEN=PRSS11/PROD=protease
serine, 11 (IGF binding) IDB XREF=gi:4506140
IUG=Hs. 75111 protease, serine , 11 (IGF binding)
IFL= b:D87258. b:NM 002775.
211115
213761
219162
236641 I Consensus includes gb:AW183154/FEA=EST
IDB XREF=gi:6451630
IDB _XREF=estxj67b12.
ICLONE=IMAGE:2662271 IUG=Hs. 116649 ESTs
227356
225837 _
202536
225060
202399
211595 I gb:AB049944. 1 IDEF=Homo sapiens MRPS11
mRNA for mitochondrial ribosomal protein S11
complete cds. IFEA=mRNA IGEN=MRPS11
IPROD=mitochondrial ribosomal protein S11
IDB XREF= i:13620888/FL= b:AB049944.
219045
-- '- ---
258
200975 I gb:NM 00031 0. 1/DEF::Homo sapiens palmitoyl-
protein thioesterase 1 (ceroid-lipofuscinosis
neuronal 1 , infantile) (PPT1), mRNA.
IFEA::mRNA IGEN::PPT1 /PROD::palmitoyl-
protein thioesterase 1 (ceroid-lipofuscinosis
neuronal 1 , infantile) IDB XREF::gi:4506030
IUG::Hs.3873 palmitoyl-protein thioesterase 1
(ceroid-lipofuscinosis , neuronal 1 , infantile)
IFL:: b:U44772. b:NM 000310.
208931 1.48
229603
201555
202569 I gb:NM 002376. 1/DEF::Homo sapiens
MAPmicrotubule affnity-regulating kinase 3
(MARK3), mRNA. IFEA::mRNA IGEN::MARK3
IPROD::MAPmicrotubule affnity-regulating kinase
3 IDB XREF::gi:45051 02 IUG::Hs. 172766 
MAPmicrotubule affnity-regulating kinase 3
IFL:: b:M80359. b:NM 002376.
203905 I gb:NM 002582. 1/DEF::Homo sapiens poly(A)-
specific ribonuclease (deadenylation nuclease)
(PARN) , mRNA. IFEA::mRNA IGEN::PARN
IPROD::poly(A)-specific ribonuclease
(deadenylation nuclease) /D B - XRE F::g i :450561 0
IUG::Hs.43445 poly(A)-specific ribonuclease
deaden lation nuclease IFL:: b:NM 002582.
242617
227249 1.45
213007
218460
204622
207165
52164 I Cluster Incl. AA065185:zm50e09.s1 Homo
sapiens eDNA, 3 end Iclone::IMAGE-529096
/clone end::3 /gb::AA065185/gi::1559080
lu ::Hs.47008/Ien::605
203790
200639
206085 I gb:NM 001902. 1 IDEF::Homo sapiens
cystathionase (cystathionine gamma-lyase)
(CTH), mRNA. IFEA::mRNA IGEN::CTH
IPROD::cystathionase (cystathionine gamma-
lyase) IDB XREF::gi:4503124/UG::Hs. 19904
cystathionase (cystathionine gamma-lyase)
IFL:: b:NM 001902.
1.1 212651
221521 I gb:BC003186. 1/DEF::Homo sapiens, HSPC037
protein , clone MGC:673 , mRNA, complete cds.
IFEA::mRNA IPROD::HSPC037 protein
IDB XREF::gi:13112024/UG::Hs. 108196
HSPC037 protein IFL::gb:BC003186.
b:AF201939.
221931
201513
222000
201306
222103
225834
218875
207181
225195
204203
212815
222431
219502
223307 _
217127
222425
224626
201707 _
203494
208079
208808
1.44
1.4
1.47
259
I gb:NM 001227. 1/DEF=Homo sapiens caspase 7
apoptosis-related cysteine protease (CASP7),
mRNA. /FEA=mRNA /GEN=CASP7
/PROD=caspase 7 , apoptosis-related cysteine
protease /DB XREF=gi:4502580 /UG=Hs.9216
caspase 7 , apoptosis-related cysteine protease
/FL=gb:U37448. 1 gb:U40281. 1 gb:U67319.
b:U67320.1 b:NM 001227.
I gb:NM 001806. 1/DEF=Homo sapiens
CCMTenhancer binding protein (CEBP), gamma
(CEBPG), mRNA. /FEA=mRNA /GEN=CEBPG
/PROD=CCMTenhancer binding protein gamma
/DB XREF=gi:4502768 /UG=Hs.2227
CCMTenhancer binding protein (CEBP), gamma
/FL= b:NM 001806.1 b:U20240.
I gb:AL 136719.1 /DEF=Homo sapiens mRNA;
cDNA DKFZp566G0346 (from clone
DKFZp566G0346); complete cds. /FEA=mRNA
/GEN=DKFZp566G0346 /PROD=hypothetical
protein /DB XREF=gi:12052956/UG=Hs.289043
spindlin /FL=gb:AL 136719. 1 gb:AF087864.
b:AF317228.2 b:AF106682. 1 b:NM 006717.
I gb:BC002551. 1/DEF=Homo sapiens, Similar to
gene rich cluster, C8 gene , clone MGC:2577
mRNA, complete cds. /FEA=mRNA
/PROD=Similar to gene rich cluster, C8 gene
/DB XREF=gi:12803452/UG=Hs.30114 Homo
sapiens , Similar to gene rich cluster, C8 gene
clone MGC:2577 , mRNA, complete cds
/FL= b:BC002551.
I gb:NM 002857. 1/DEF=Homo sapiens
peroxisomal farnesylated protein (PXF), mRNA.
/FEA=mRNA /GEN=PXF /PROD=peroxisomal
farnesylated protein /DB XREF=gi:4506338
/UG=Hs. 168670 peroxisomal farnesylated protein
/FL=gb:BC000496. 1 gb:NM 002857.
b:AB018541.
I gb:BC000903. 1 /DEF=Homo sapiens , high-
mobilt rou nonhistone chromosomal rote in
_._--- _. -
260
, clone MGC:5234 , mRNA, complete cds.
IFEA=mRNA IPROD=high-mobility group
(nonhistone chromosomal)protein 2
IDB XREF=gi:12654170 IUG=Hs. 80684 high-
mobilty group (nonhistone chromosomal) protein
2/FL= b:BC000903. b:BC001063.
209714 I gb:AF213033.1/DEF=Homo sapiens isolate BX-
01 cyclin-dependent kinase associated protein
phosphatase mRNA, complete cds. IFEA=mRNA
IPROD=cyclin-dependent kinase associated
proteinphosphatase IDB XREF=gi: 12734643
IUG=Hs. 84113 cyclin-dependent kinase inhibitor 3
(CDK2-associated dual specificity phosphatase)
IFL=gb:AF213033. 1 gb:AF213034.
gb:AF213035. 1 gb:AF213036. 1 gb:AF213037.
gb:AF213038. 1 gb:AF213039. 1 gb:AF213040.
gb:AF213041. 1 gb:AF213042. 1 gb:AF213044.
gb:AF213046. 1 gb:AF213047. 1 gb:AF213048.
gb:AF213049. 1 gb:AF213050. 1 gb:AF213051.
gb:AF213052. 1 gb:AF213053. 1 gb:U02681.
b:L25876. b:NM 005192. b:L27711.
227157 _
218886
225649 1.49 I Consensus includes gb:AA001414/FEA=EST
IDB XREF=gi:1436899
lOB XREF=estze45d08. s 1
ICLONE=IMAGE:361935/UG=Hs. 1 00057 Homo
sa iens cDNA: FLJ22902 fis, clone KAT05581
200631 I gb:NM 003011. 1 IDEF=Homo sapiens SET
translocation (myeloid leukemia-associated)
(SET), mRNA. IFEA=mRNA IGEN=SET
IPROD=SET translocation (myeloid leukemia-
associated) IDB XREF=gi:4506890
IUG=Hs. 145279 SET translocation (myeloid
leukemia-associated) IFL=gb:U51924.
b:M93651. b:NM 003011.
201515 1.46
212297 _
213047
218602
231855
223700 I gb:AY028916.1/DEF=Homo sapiens GAJ (GAJ)
mRNA, complete cds. IFEA=mRNA IGEN=GAJ
IPROD=GAJ IDB XREF=gi:13488608
IUG=Hs.294088 Homo sapiens GAJ (GAJ)
mRNA, com lete cds IFL= b:AY028916.
222416 I gb:U76542. 1/DEF=Human pyrroline-
carboxylate synthase long form (P5CSL) mRNA
complete cds. IFEA=mRNA IGEN=P5CSL
IPROD=pyrroline-5-carboxylate synthase long
form IDB XREF=gi:4335784/UG=Hs. 114366
pyrroline-5-carboxylate synthetase (glutamate
gamma-semialdehyde synthetase)
IFL= b:U68758. b:U76542. b:NM 002860.
228812 at
261
224601
204616
218883 I gb:NM 024629. 1/DEF=Homo sapiens
hypothetical protein FLJ23468 (FLJ23468),
mRNA. /FEA=mRNA /GEN=FLJ23468
/PROD=hypothetical protein FLJ23468
/DB XREF=gi:13375855/UG=Hs.38178
hypothetical protein FLJ23468
/FL= b:NM 024629.
200629
218545
200640
217791 gb:NM 002860. 1/DEF=Homo sapiens pyrroline-
5-carboxylate synthetase (glutamate gamma-
semialdehyde synthetase) (PYCS), mRNA.
/FEA=mRNA /GEN=PYCS /PROD=pyrroline-
carboxylate synthetase (glutamategamma-
semialdehyde synthetase) /DB XREF=gi:4506348
/UG=Hs. 114366 pyrroline-5-carboxylate
synthetase (glutamate gamma-semialdehyde
synthetase) /FL=gb:U68758. 1 gb:U76542.
b:NM 002860.
201328
232235 I Consensus includes gb:AK021539. 1/DEF=Homo
sapiens cDNA FLJ11477 fis , clone
HEMBA1001746 , weakly similar to Homo sapiens
squamous cell carcinoma antigen recognized by T
cell (SART -2) mRNA. IFEA=mRNA
/DB XREF=gi:1 0432739 IUG=Hs. 124673 Homo
sapiens cDNA FLJ11477 fis, clone
HEMBA1001746 , weakly similar to Homo sapiens
squamous cell carcinoma antigen recognized by T
cell SART-2 mRNA
208654
212367 _
212444
236300
228507 _
212688
218373 I gb:NM 022476. 1/DEF=Homo sapiens
hypothetical protein FLJ13258 similar to fused
toes (FLJ13258), mRNA. /FEA=mRNA
/GEN=FLJ13258/PROD=hypothetical protein
FLJ13258 similar to fusedtoes
/DB XREF=gi:11968026/UG=Hs.288929
hypothetical protein FLJ 13258 similar to fused
toes /FL= b:NM 022476.
204962 1.4
213682 1.4
210821 1.41
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/UG=Hs. 1594 centromere protein A (17kD)
/FL= b:BC002703.
218458 1.42 I gb:NM 022471. 1/DEF=Homo sapiens
hypothetical protein FLJ 13057 similar to germ cell-
less (FLJ13057), mRNA. /FEA=mRNA
/GEN=FLJ13057 /PROD=hypothetical protein
FLJ 13057 similar to germcell-Iess
/DB XREF=gi: 11968020 /UG=Hs.243122
hypothetical protein FLJ13057 similar to germ cell-
less /FL= b:NM 022471.
40189 1.42 I Cluster Incl. M93651 :Human set gene, complete
cds /cds=(3 836) /gb=M93651/gi=338038
/u =Hs. 145279 lIen=2562
225006 1.42
217958 1.43
224560 1.43
222889 1.43 I Consensus includes gb:A1703304 /FEA=EST
/DB XREF=gi:4991204
/DB XREF=estwd82f11.
/CLONE=IMAGE:2338125/UG=Hs. 115660
hypothetical protein FLJ 1281 0
/FL= b:NM 022836.
213359 1.44
231579 1.46
228597 _ 1.46
200896 1.48 1.45
203341 1.49
213523 1.49
214949 1.49
201001 1.49
205053 I gb:NM 000946. 1/DEF=Homo sapiens primase
polypeptide 1 (49kD) (PRIM1), mRNA.
/FEA=mRNA /GEN=PRIM1/PROD=primase
polypeptide 1 (49kD) /DB XREF=gi:4506050
/UG=Hs.82741 primase , polypeptide 1 (49kD)
/FL= b:BC005266. b:NM 000946.
225865
213322
217736 I gb:NM 014413.2/DEF=Homo sapiens heme-
regulated initiation factor 2-alpha kinase (HRI),
mRNA. /FEA=mRNA /GEN=HRI/PROD=heme-
regulated initiation factor 2-alpha kinase
/DB XREF=gi:11125767 /UG=Hs.258730 heme-
regulated initiation factor 2-alpha kinase
/FL=gb:NM 014413.2 gb:AL 136563.
gb:AF147094. 1 gb:AF255050. 1 gb:AF116634.
b:AF183414.
48808 I Cluster Incl. AI144299:qb59h06.x1 Homo sapiens
cDNA, 3 end /clone=IMAGE-1704443
/clone end=3 /gb=AI144299/gi=3666108
/u =Hs. 1 06843 lIen=765
218131
220607 x at 1.43
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229700
229299
203745
203126
216484
213959
208405
212021
225343
224819
214948
222844 I gb:AF169974. 1 /DEF=Homo sapiens serine
racemase mRNA, complete cds. /FEA=mRNA
/PROD=serine racemase
/DB XREF=gi:11 034784/UG=Hs.27335 serine
racemase /FL=gb:AF169974. 1 gb:NM 021947.
225261
205417
209513 I gb:BC004331.1/DEF=Homo sapiens , Similar to
RIKEN cDNA 2610207116 gene, clone
MGC:10940 , mRNA, complete cds. /FEA=mRNA
/PROD=Simiiar to RIKEN cDNA 2610207116 gene
/DB XREF=gi:13279253/UG=Hs.47986 Homo
sapiens , Similar to RIKEN cDNA 2610207116
gene , clone MGC:10940, mRNA , complete cds
/FL=gb:BC004331.
202402 I gb:NM 001751. 1/DEF=Homo sapiens cysteinyl-
tRNA synthetase (CARS), mRNA./FEA=mRNA
/GEN=CARS /PROD=cysteinyl-tRNA synthetase
/DB XREF=gi: 1 0835050 /UG=Hs. 159604
cysteinyl-tRNA synthetase /FL=gb:NM 001751.
gb:BC002880. 1 gb:AF288206. 1 gb:AF288207.
202534
217959
224715
222843
212474
217794
226546
209512 gb:BC004331. 1/DEF=Homo sapiens, Similar to
RIKEN cDNA 2610207116 gene, clone
MGC:10940 , mRNA, complete cds. /FEA=mRNA
/PROD=Similar to RIKEN cDNA 2610207116 gene
/DB XREF=gi:13279253/UG=Hs.47986 Homo
sapiens , Similar to RIKEN cDNA 2610207116
gene , clone MGC:10940, mRNA , complete cds
/FL=gb:BC004331.
212020
218563
228992
264
213310
204634
240983
202580 I gb:NM 021953. 1/DEF=Homo sapiens forkhead
box M1 (FOXM1), mRNA./FEA=mRNA
/GEN=FOXM1/PROD=forkhead box M1
IDBJ(REF=gi:11386144/UG=Hs.239 forkhead
box M1/FL=gb:NM 021953. 1 gb:U83113.
b:L 16783.
203324
202370 I gb:NM 001755. 1/DEF=Homo sapiens core-
binding factor, beta subunit (CBFB), transcript
variant 2 , mRNA. /FEA=mRNA /GEN=CBFB
/PROD=core-binding factor, beta subunit, isoform
2/DB XREF=gi:13124872/UG=Hs. 179881 core-
bindin factor, beta subunitlFL= b:NM 001755.
221739
230251
200779 I gb:NM 001675. 1/DEF=Homo sapiens activating
transcription factor 4 (tax-responsive enhancer
element B67) (ATF4), mRNA. /FEA=mRNA
/GEN=ATF4/PROD=activating transcription factor
4/DBJ(REF=gi:4502264/UG=Hs. 181243
activating transcription factor 4 (tax-responsive
enhancer element B67) /FL=gb:M86842.
b:NM 001675.
209096
202209 2.48
216483
200749
205047 _ I gb:NM 001673. 1/DEF=Homo sapiens
asparagine synthetase (ASNS), mRNA.
/FEA=mRNA /GEN=ASNS /PROD=asparagine
synthetase IDB XREF=gi:4502258
/UG=Hs.75692 asparagine synthetase
/FL= b:M27396. b:NM 001673.
209452 I gb:AF035824.1 /DEF=Homo sapiens vesicle
soluble NSF attachment protein receptor (VTI1)
mRNA, complete cds. /FEA=mRNA /GEN=VTI1
/PROD=vesicle soluble NSF attachment protein
receptor /DB XREF=gi:2687399/UG=Hs. 169206
vesicle-associated soluble NSF attachment
protein receptor (v-SNARE; homolog of S.
cerevisiae VT11) /FL=gb:BC003142.
b:AF035824. b:AF060902. b:NM 006370.
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